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ABSTRACT
In the UK, prostate cancer is the second most commonly occurring cancer in men. 
The number o f prostate cancer incidents is expected to increase due to improved 
screening and diagnostic techniques, whilst the mortality rate continues to fall as the 
variety o f available treatments increases.
This research focuses on the commonly used brachytherapy seed OncoSeed™ Model 
6711 manufactured by GE Healthcare. Iodine-125 seeds are surgically implanted and 
left inside the prostate permanently to obtain local control o f the malignant prostate 
cancer. Prior to the surgical procedure, a treatment plan is created on a computer 
planning system. There is currently no 3-D method to verity whether the planning 
system model matches the actual delivery o f radiation dose to the prostate.
This study is presented as a typical case study o f what can be achieved using solid 
polymer dosimetry. Experimental results are presented comparing solid polymer 
dosimetry using Optical-CT with radiochromic films (RCF) and Monte Carlo 
simulations. Initial Optical-CT results have shown good agreement to Monte Carlo, 
radiochromic films and comparable to previously published data. The advantage o f 
using Optical-CT includes the ability to view and extract dose profiles o f any image 
slices within the 3-D dataset at high resolution. Combining the Optical-CT system 
with the new solid polymer dosimeter (PRESAGE't'^) enabled the 3-D dosimetry o f 
low dose-rate brachytherapy sources that was not possible with previous experimental 
methods o f dosimetry. Other brachytherapy sources were investigated including the 
successive EchoSeed™ Model 6733 and the microSelectron-HDR Ir-192 source 
manufactured by Nucletron.
The outcome to this work suggests the use o f solid polymer dosimetry using Optical- 
CT is particularly useful in true 3-D experimental verification o f the dosimetric 
characteristics o f the brachytherapy seeds and other HDR sources. Future success will 
also rely on the further optimisation o f the quality, consistency and sensitivity o f the 
solid polymer dosimeter.
Copyright © Philip Wai
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C h a p t e r  1 In t r o d u c t io n
Chapter 1 Introduction
In the UK, prostate cancer is one o f the most commonly occurring cancers in men, 
responsible for the death o f around 10,000 men every year, and it represents a fifth o f 
new cancer cases. The number o f prostate cancer incidents is expected to increase due 
to growing population age, public awareness, improved screening and diagnostic 
techniques. Recent statistics from the cancer registries show that prostate cancer has 
the second highest number o f recorded incidences and deaths after lung cancer [1]. 
However, despite the increasing number o f prostate cancer cases, the mortality rate 
continues to fall as the variety o f available treatments increases.
Chapter 2 o f the thesis provides an overview of prostate cancer and the current 
treatment available. The treatment methods include surgery, hormone therapy, and 
radiotherapy, or a combination o f treatment methods. Prostate brachytherapy, a major 
focus o f this thesis, is a type o f cancer treatment that involves the placing o f a large 
number o f millimetre-size radioactive implants (“seeds”) into cancerous regions o f the 
body in order to target tumour cells in a way that cannot be achieved using the 
external radiation beams that are the woridiorses o f modern radiotherapy. In the 
second part o f Chapter 2, this technique is described in detail.
The main goal o f this thesis is to investigate the 3-D dosimetry o f brachytherapy 
sources, using a combination o f Monte Carlo simulation validated by experimental 
measurements using the novel technique such as solid polymer dosimetry and film 
dosimetry.
Chapter 3 gives an overview o f different types o f dosimetry in common use, for 
example ion chambers, diodes, thermoluminescent dosimeters (TLD), films and gel 
dosimetry. The use o f gel dosimetry, a new method for mapping three-dimensional 
radiation dose distributions in brachytherapy is still largely unexplored (less than 10 
scientific papers world-wide). Gel dosimeti-y uses radiosensitive compounds whose 
physicochemical properties change when they are exposed to radiation dose. These 
properties may be measured in three-dimensions, via imaging techniques such as CT, 
MRI and optical computed tomography, in order to create radiation dose maps. 
Section 3.6 discusses the simulation tools that are available for performing Monte 
Carlo analysis o f the radiation patterns around brachytherapy seeds.
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Chapter 4 focuses on the commonly used brachytherapy seed Model 6711 
OncoSeed™ manufactured by Amersham Pic., now GE Healthcare. In a typical 
operation, a total o f approximately 80 to 90 1-125 seeds are surgically implanted and 
left inside the prostate permanently to deliver an average o f approximately 150 Gy in 
order to obtain local control o f the malignant prostate cancer. Prior to the surgical 
procedure, a treatment plan is conducted on a computer simulation planning system. 
There is currently no method available to verify experimentally whether the output of 
the treatment planning system matches the radiation dose that is actually delivered to 
the prostate.
Chapter 5 presents a complete study o f the Model 6711 OncoSeed™, involving: 
Monte Carlo simulation using two different code systems, MCNP and GEANT4; TLD 
dosimetry experiments using the PRESAGE™ dosimeter; Radiochromic film 
experiments using the PRESAGE™ dosimeter; and Optical-CT experiment using the 
PRESAGE™ dosimeter. Chapter 5 investigates the different methods o f dosimetry of 
the 1-125 Model 6711 OncoSeed™ introducing the adaptation o f GAFCHROMIC® 
radiochromic films (RCF) in a PRESAGE™ dosimeter phantom for 2D anisotropy 
functions analysis. The chapter also examines an interesting multi-seed implant 
scenario; looking at the dose effect o f more than one OncoSeed™. Using the different 
techniques described in earlier chapters.
Chapter 6 presents the initial dosimetric study o f the MicroSelectron-HDR Ir-192 
source manufactured by Nucletron; commonly used in oncology centres in 
conjunction with remote afterloaders.
Chapter 7 includes a detailed study o f the new 1-125 Model 6733 EchoSeed™. The 
EchoSeed™ is similar to the successful Model 6711 and has a specifically designed 
grooved surface to enhance visualization under ultrasound.
The final chapter concludes the thesis and provides some further recommendations for 
future work. A successful outcome to this work will allow us to validate the 
underpinning models and assumptions that are made by the manufacturer and 
previous published data. At present, there is no other true 3D verification o f the 
dosimetric characteristics o f the 1-125 Model 6711 OncoSeed™ and Model 6733 
EchoSeed^"^.
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Chapter 2 Prostatic Cancer & Treatment Methods
2.1 Background
The enlargement o f the prostate, the medical condition Benign Prostatic Hyperplasia, 
is a common concern for males aged 45 and above. An enlarged prostate may also be 
a sign o f Benign Pi'ostatic Cancer although not all disorders are cancer related.
The cause o f prostate cancer is unknown but may possibly link to the male hormone 
testosterone. For example, men who have their testicles removed before puberty rarely 
develop this.
2.2 The Prostate
The prostate is a circular-shaped gland about the size o f a chestnut situated at the neck 
o f the bladder enveloping the first part o f the prostatic urethra, the passageway for 
urine to pass out o f the body. Other organs close to the prostate include the rectum 
and the bladder, these are categorised as critical organs in radiotherapy planning. A 
high dose or “hot spots” at these areas may cause involuntaiy excretion and other 
unnecessary discomfort.
The prostate (See Figure 2 .1 )  is an important organ in the human reproductive system. 
Its function is to produce seminal fluid, a milky fluid used by sperm for ATP 
production. Seminal fluid is slightly acidic with a pH of 6.5 and contains citric acid, 
acid phosphatase and several proteolytic enzymes, such as prostate-specific antigen 
(PSA), pepsinogen, lysozyme, amylase, and hyaluronidase. [2 ]
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The secretion from the prostate gland enters the prostate urethra via the prostatic ducts. 
A quarter o f the semen is made up o f the prostatic secretion, which contributes to the 
motility and viability o f the sperm. The size o f the prostate slowly increases from 
birth to puberty and grows rapidly. The size remains stable between the age o f 30 to 
45. Further enlargement may occur later in life. [3]
2.3 Prostate Disorders
Reproductive system disorders in males include testicular cancer and prostate 
disorders; these are generalised as homeostatic imbalances. There are different kinds 
o f prostate disorders for example: acute prostatitis, chronic prostatitis and prostate 
cancer. As mentioned earlier, the prostate encloses the root portion o f the urethra, any 
inflammation, enlargement, tumour or infection will lead to partial blockage o f the 
bladder passage and causes obstruction to urine flow. This can become an emergency 
in the event when the patient cannot pass urine voluntarily and the bladder continues 
to fill up, this condition is called acute urinary retention (AUR). At the local hospital, 
a catheter is inserted into the urethra to drain urine directly from the bladder for 
immediate comfort.
For males in their middle age or later, chronic prostatitis is one o f the common 
infections where the prostate gland is irregularly outlined, enlarged and very tender. 
In acute prostatitis, the prostate gland is swollen and tender.
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The National Statistics Office in the UK keeps the national official record o f cancer 
incidences and mortalities. The most recent statistics from the cancer registries 
showed that prostate cancer has the second highest number o f recorded incidences and 
deaths after lung cancer. In 1999, the recorded incidences in UK for lung and prostate 
cancer were 23,708 and 21,302 respectively (Figure 2.2 top). The number of prostate 
cancer mortality was 58% lower than lung cancer: 10,062 compared to 24,433 for 
lung cancer (Figure 2.2 bottom). The incidence o f prostate cancer is expected to rise, 
as the high prostate cancer incidence counts in 1999 may reflect the result o f growing 
population age, public awareness and improved screening techniques. [4]
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2.4 Diagnosis
In diagnostic radiology, there are practical difficulties in screening the prostate gland. 
For example, looking at the diagnostic images o f CT, an experienced member o f staff 
at the radiology department would not be able to accurately distinguish the prostate 
gland from the surround tissues. For this reason, other physical tests such as digital 
rectal examination, blood test and biopsy are used in diagnosis.
The diagnosis o f prostate disorder may require a patient to fill in a questionnaire. The 
questionnaire currently used internationally is called the International Prostate 
Symptom Score (IPSS) as shown in Appendix A. The final score from the 
questionnaire will help the doctor to assess whether the patient may have an enlarged 
prostate, although the results will not give an indication o f possible prostate cancer. [5] 
The scoring system is described in Table 2.1.
The IPSS is used extensively at the Royal Surrey County Hospital, it is a simple 
screening tool to assess the significance o f the symptoms and give qualitative measure 
o f lower urinary tract symptoms (LUTS). One o f the other uses o f  the IPSS is for the 
follow-up o f patients after treatment. An average follow-up period can be up to 16 
months with questionnaires taken at 1 and 6 weeks, and later at 3, 6, 9, 12 months. 
This can be used as a guideline to monitor the improvement throughout the follow-up 
period. [6]
0-7 Symptoms are considered mild.
8-19 Symptoms are considered moderate.
20-35 Symptoms are considered severe.
Table 2.1: IPSS Scoring System
The symptoms of prostate disorders can be summarised as:
1. Emptying -  the feeling o f not completely emptying the bladder after urination
2. Frequency -  passing urine more frequent than normal, especially at night
3. Poor Stream -  weak, intermittent, difficulties and pain in passing and stopping
urine
4. Urgency -  the desire to urinate becomes more urgent
5. Bleeding -  blood found in urine or sperm
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Digital Rectal Examination
This is a physical examination o f the prostate, which involves the doctor inserting a 
gloved finger into the rectum to feel the prostate. The test is good for assessing signs 
o f advanced cancers.
Prostate Specific Antigen
This is a blood test where blood samples are taken to check for prostatic specific 
antigen (PSA). PSA is a protein produced by the prostate gland and released into the 
blood stream. A raised level o f PSA indicates benign enlargement and is usually 
higher if  cancer is present. The PSA test has an advantage o f finding an early prostate 
cancer before any noticeable symptoms. Where prostate cancer is found at an early 
stage, it can be treated as soon as possible by a surgical operation or radiotherapy. The 
PSA will be monitored regularly as an indicator o f the progress during treatment.
The results may indicate a less serious disorder such as an inflamed prostate 
(prostatitis), or an enlarge prostate as a results o f aging (Benign Prostatic Hypertrophy, 
BPH).
Transcrectai Needie Biopsy
If  the PSA level is high, a biopsy may be required. This is the removal o f a small 
tissue sample from the prostate for examination under the microscope. An ultrasonic 
probe is used to locate the prostate and guide a needle to the gland where sample cells 
can be taken. From the sample, doctors can confirm the existence o f cancer. The 
procedure is usually carried out in the out-patient clinic and last about 45 minutes 
where most men describe it as uncomfortable but not painful. Some may be admitted 
as a day case or an overnight stay for an examination under anaesthetic. The patient 
will be given antibiotics to avoid complications associated with infections. There may 
be side effect associated with the test where the patient may experience slight 
bleeding during urination.
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Flow Rate
This is a simple test used to monitor the flow o f urine. The patient pass urine into a 
funnel with sensors linked to a computer. This test will highlight any difficulties 
during urination. A full bladder is essential for this test, and patients are given water 
to consume prior to the test.
Intravenous Urogram
The spread o f cancer may affect other parts o f the urinary system, the kidney and the 
bladder. An intravenous Urogram (IVU) will confirm the existence o f any spread.
The examination takes 30 minutes to one hour where an iodine based contrast media 
will be injected into the bloodstream through a vein. As the media travels from the 
kidney to the bladder and urethra, the whole urinary system is outlined.
Some patients may show mild reaction to the dye, and may feel a warm sensation 
after injection as the dye circulates the body.
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2.5 Treatment
There are different treatment methods available to treat prostate cancer and each case 
is planned to suit the individual conditions. Not all cases are treated immediately, for 
example if the patient shows no symptoms such as difficulty or pain during urination. 
The doctor may request the patient for regular check-ups and later advice whether 
further treatment is required.
2.5.1 Watchful Waiting
For patients with mild or moderate symptoms (IPSS 0-19), no treatment is an option. 
This is highly dependant on the quality o f life particularly the influence o f the 
symptoms on the patient’s everyday life. Even though the symptoms may be moderate, 
frequent visits to the toilet at night can have considerable impact on quality o f sleep.
2.5.2 Surgery 
Trans-Urethral Resection of Prostate (TURP)
A TURP operation is a surgical procedure performed under general anaesthetic by 
utilising a cystoscope, a rod-like instrument inserted into the urethra. This will remove 
the excess prostate tissue blocking the urethra and allow uninterrupted urine flow. The 
aim o f the operation is not to remove the cancer but rather a palliative treatment. 
Though the procedure involves the removal o f prostate tissue, one o f the advantage is 
that the treatment area will not develop any visible scars or require any stitches. The 
patient will be treated as an in-patient and on average stay for about five days.
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Radical Prostatectomy
Alternatively to palliation, the doctor may recommend the patient to have a radical 
prostatectomy, where the whole prostate gland is removed. For this operation, there 
are currently two methods used:
1. Abdominal approach -  the incision for this operation is vertical, below the 
abdomen. The patient will need to stay in hospital for five to seven days.
2. Perineal approach -  the incision is made from the back o f the testicles and the 
anus. The patient will be required to stay for three to five days.
Other surgical techniques such as the use o f microwave shrinkage or laser treatment 
o f the prostate are currently under research and development and may be available in 
the future. [3]
Side Effects
The two main side effects associated with radical prostatectomy are impotence 
(unable to achieve an erection) and incontinence (leaking o f urine).
2.5.3 Radiotherapy 
External Beam
This involves a course o f high-energy photons (6 MV to 10 MV) beams to the 
prostate in order to eliminate the prostatic cancer cells. It is a localised treatment that 
aims to minimise irradiation to surrounding healthy tissues and critical organs while 
delivering the prescribed dose to the target volume. Recent technique such as 
Intensity-Modulated Radiation Therapy (IMRT) enables delivery o f high precise 
radiation doses. Radiotherapy is usually given daily, Monday to Friday, as an 
outpatient. The treatment is not usually recommended for men with less than 10 years 
life expectancy.
Side Effects
One o f the issues relating to external beam radiotherapy is the effect on the 
surrounding normal tissues adjacent to the prostate, in particular the bladder, the 
rectum and the urethra. Short-term side effects relate mainly to bowel bladder 
problems from the radiation. Longer-term side effects include impotence (inability to 
achieve an erection) and urinaiy problems. The percentage reported for impotence 
range from 25-60%, while for incontinence the range is up to 5%. Some 10% o f
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patients have diarrhoea/bowel problems and up to 30% have minor rectal bleeding 
problems. [5, 7]
Brachytherapy
Radioactive seed implants are used to deliver radiation to the targeted prostate tissue 
to provide therapy to localised prostatic tumours (early stages). The seeds are sealed 
radioactive isotope (i.e. iodine-125) encapsulated in a titanium shell. These are 
implanted permanently into the prostate using a manual needle loading system. This 
will be discussed in more detail in Section 2.7.
Side Effects
The adverse reaction associated with brachytherapy will vary depending on the nature 
and location o f the treatment area. Common side effects reported are: procedure- 
related bleeding, burning beneath scrotum, and passage o f blood in urine. Short-term 
urinary symptoms include: frequent, urgent or uncomfortable urination, dribbling, 
difficulties voiding may be experienced for several weeks after implantation. [5, 7]
2.5.4 Hormonal Treatment
There are in general two types o f hormonal treatment drugs. Drugs containing Alpha- 
blockers improves the relaxation o f urethra muscles. Testosterone is responsible for 
pro static cancer growth, Luteinizing Hormone Releasing Hormone (LHRH) or anti­
androgens are used to suppress growth o f the cancer by reducing circulating androgen 
levels and blocking the action o f testosterone. This can be used as adjuvant treatments 
to those outlined in this section.
Side Effects
In all standard hormonal therapy, side effects include impotence, loss o f libido (sex 
drive), breast swelling and hot flushes. If the treatment is given in the form of 
injections or tablets, sexual functions may return to normal after the end o f the 
treatment. [5, 7]
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2.6 Post Treatment
Verification
Ultrasonography images are used for 1-125 transperineal interstitial prostate 
brachytherapy treatment planning and a CT scan is later used for post treatment 
verification purposes. Radiographs are used to monitor the location o f the 
brachytherapy implanted seeds.
Follow-up
Post treatment services are available where patients are advised to attend all the 
check-up visits and report any bleeding conditions i.e. continuous bleeding to their 
doctors. The problem o f the prostate may re-occur.
2.7 Overview of Brachytherapy
2.7.1 Brachytherapy Implant
While the common method o f cancer treatment is by external beam treatment, 
brachytherapy is an alternative that is starting to see more widespread use. 
Brachytherapy is the use o f sealed radioactive sources in or in close proximity to the 
volume to be treated. For example, brachytherapy is used to treat localized human 
cancers including tongue, breast, cervical, prostatic, head and neck malignancies. [8]
The first published report on prostatic cancer treatment was in 1911 by Pasteau [9] 
concerning the insertion o f radium via a urethral catheter. By 1969, Flocks et al [10] 
had treated 1000 patients with the use o f interstitial colloidal gold to treat prostate 
tumours.
There are three major types o f brachytherapy treatment sources -  sources that are 
directly inserted to the tumour (interstitial), inserted into natural body cavity 
(intracavitary) or applied to the surface o f the body (surface applicator); these are 
listed in Table 2.2.
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Interstitial Surgically implanted to treat 
tongue, breast, vulva, prostate 
and anus.
Iodine-125 seeds 
Palladium-103 seeds 
Iridium-192 seeds 
Photon, Fluorescent X-rays, X- 
ray and Gamma-emitting 
radionuclides
Intracavitary Treatment of gynaecological 
malignancies for cervix and in the 
vagina.
Caesium 137 pellets 
Nucletron Selectron-LDR 
Gamma-emitting radionuclide
Surface applicator Treatment of ocular tumours. 
Superficial tumours lying above 
particular sensitive normal 
tissues.
Strontium-90
Yttrium-90
Beta-emitting radionuclides 
Photon emitters
Table 2.2: Types of brachytherapy, adapted from [11]
Low Dose Rate LDR 7-20 Gy per day (30-90 cGy IT’)
Medium Dose Rate MDR 30-40 Gy per day (1.2-1.8 Gy If’)
High Dose Rate HDR 1-5 Gy m in' (60-300 Gy IT’)
Table 2.3: Dose rate range in clinical brachytherapy [11]
2.7.2 LDR, MDR and HDR
Abbreviations are often used to specify the dose rate o f the treatment system. These 
can be divided into three ranges, as shown in Table 2.3.
LDR afterloading treatment began in the late 80’s. Over the years o f operation and 
research, systems o f source distribution and dosimetry have become well established, 
with extensive clinical data available to assess the outcome o f therapy.
HDR treatment became more common due to the availability o f high activity sources 
and the development o f remote afterloading system. The noticeable difference 
between HDR and LDR is the considerable decrease in treatment time. A standard 
HDR treatment can be conducted in fractions o f  minutes, while LDR can be up to 24 
hours. This is certainly good news for the patients, where their movement are possibly 
restricted for a long period o f time during LDR treatment.
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Afterloading systems
In the past, medical staff in theatre implanted all radioactive sources; exposing 
themselves to high radiation doses. Nowadays, the implementation o f remote after­
loading system significantly reduces the unnecessary doses.
An afterloading system is a method where an applicator, guide or catheter can be 
positioned into/onto a patient, through which the sources are later delivered directly to 
the target o f treatment. Theatre staff were previously under time pressure over implant 
and insertions in view o f avoiding radiation exposure. Now most o f the time is spent 
on treatment planning and optimising the prescribed dose to the treatment target area. 
The accuracy o f source position has been greatly improved by the use o f radiographic 
checks once the applicators are in place.
Manual Afterloading
Manual systems are the use o f pre-implanted catheters for iridium wire treatments and 
applicator systems for gynaecological insertions. Although the theatre staff and 
surgeons would receive no radiation in the manual afterloading treatment, the ward 
staff are exposed to radiation during nursing procedures.
Remote Afterloading system
Remote afterloading systems are the preferred choice in brachytherapy, where staff 
are exposed to virtually zero dose during treatment implementation or nursing o f the 
patient. All the radioactive sources are contained in a shielded lead safe, and delivered 
outside the treatment room by a remote control panel once all the staff have vacated. 
The treatment process can be paused at any time where all the sources will be 
retrieved back into the safe. After nursing, the treatment will continue precisely from 
the elapsed time.
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2.7.3 Radionuclides used in brachytherapy
Different types o f sealed radioactive sources are used in the construction o f 
brachytherapy seeds. Distribution o f the radionuclides within the internal core o f the 
source is either throughout the internal core or adsorbed across the surface o f the 
internal core o f the source [12]. The common sources and their physical 
characteristics are briefly described in this section. [8]
Iodine-125
Iodine-125 decays via electron capture to the first excited state o f tellurium-125, with 
a half-life o f 59.4 days. This undergoes 93% internal conversion and 7% gamma 
emission o f a 35.5 keV photon. The electron capture and internal conversion 
processes give rise to characteristic X-rays: 27.4 and 31.4 keV. The low-energy 
photons from 1-125 ensure that the surface dose rate from a patient in which sources 
have been implanted is insufficient to require any restriction on their movement. Thus, 
the seeds are safe for use as permanent implants
Palladium-103
Palladium decays via electron capture, to the first and second excited states o f 
rhodium-103, with a half-life o f 17.0 days. Rh-103 undergoes internal conversion 
leading to the production o f characteristic X-rays (20.1 and 23.0 keV) and gamma 
emission. The average photon energy is 21 keV. Palladium-103 sources are similar in 
active source size and encapsulation to 1-125 sources. The active material is coated 
onto two graphite pellets. These sources are used in permanent implants to treat faster 
growing tumours o f the prostate.
Gold-198
Compared to 1-125 and Pd-103, the Gold-198 has a much shorter half-life of 2.7 days 
and is used for permanent implants. It has a number o f gamma ray energies and the 
dominant energy is 412 keV. Gold-198 is normally supplied in the form o f cylindrical 
grains or seeds and used in sites such as the tongue and prostate.
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Caesium-137
The radionuclide caesium-137 is a commonly used source for brachytherapy. The 
half-life is 30.0 years and the isotope emits both beta particles and 662 keV gamma 
rays. Cs-I37 is supplied in the form o f tubes for use in gynaecological applicators, 
needles for implants, and cylindrical or spherical beads for afterloading systems. The 
long half-life is the main advantage and sources can be used in afterloading systems 
for many years.
Iridium-192
Iridium-192 undergoes beta decays with a half-life o f 74 days. The principal gamma 
ray has energy o f 370 keV. Ir-192 is supplied in the form o f wire and seeds. These 
sources are used for breast and tongue implants, and various HDR intracavitary and 
interstitial treatments.
2.7.4 The AAPM TG-43 Report
The Dosimetry o f  Interstitial Brachytherapy Sources Report [13] was written by the 
Radiation Therapy Committee in 1995. This committee o f the American Association 
o f Physicists in Medicine (AAPM) also known as Task Group 43 was founded in 
1988, primarily to review the publications on the dosimetry o f interstitial 
brachytherapy sources. The report includes recommendations for a dosimetry protocol 
together with a formalism for dose calculations and a data set for the values o f 
dosimetry parameters.
The report defines the necessary physical quantities for dosimetry o f brachytherapy 
sources, for example, air kerma strength, radial dose function, anisotropy function, 
and dose rate constant. The appendix o f the report includes a detailed review o f 
previous dosimetric studies o f 1-125, Ir-192 and Pd-103 sources.
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Towards the end o f 1990s, due to the increasing number o f interstitial brachytherapy 
sources, the American Association o f Physicists in Medicine (AAPM) radiation 
therapy committee issued a recommendation o f dosimetric prerequisites for routine 
clinical use o f these new sources [14]. The recommendation provided guidance to 
manufacturers and regulatory agencies involved in the development and approval of 
new sealed brachytherapy sources, these recommendations can be summarised as 
follow;
1. Dosimetric Characteristics -  each new product should be evaluated by at least 
one, and preferably two, independent investigators excluding the manufacturer. 
At least one and preferably two experimental studies o f the dose distribution 
should be made using a phantom. At least one o f these must include absolute 
dose-rate measurements. Finally, a Monte Carlo study should be made by an 
independent investigator, which includes calculation o f the absolute dose rate 
per unit air-kerma strength. The measurements and Monte Carlo calculations 
should cover a sufficient range o f distances and polar angles that dose-rate 
constant, radial dose functions, anisotropy functions, anisotropy factors and 
anisotropy constants can be estimated. Monte Carlo simulation will be 
discussed in detail in later sections.
2 . Calibration -  the seed’s calibration should be traceable to the National 
Institute o f Standards and Technology (NIST) primary air-kerma strength 
standard [15]. This primary standard (See Section 3.1) is based upon an 
absolute measurement o f air kerma rate free in air at a reference distance from 
the source along its transverse axis using a wide angle free air chamber 
(WAFAC) for brachytherapy sources with photon energies o f 50 keV or less. 
[1 6 ]
3. Good Manufacturing Practice -  a system o f verifying constancy and accuracy 
of the calibration procedure should be in place and verified at regular intervals 
(at least once every three months). The manufacture should collaborate with at 
least one independent laboratory, such as NIST or an AAPM approved 
laboratory. The different seed batches should be calibrated by vendor and sent 
to the network o f independent laboratories for constancy verification.
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2.7.5 The Updated TG-43 Report
Since the publication o f the TG-43 by the AAPM in 1995, the number o f 
commercially available brachytherapy sources has dramatically increased. Various 
advances in the dosimetry procedure itself have been made, including the introduction 
o f a new primary standard o f air-kerma strength by the National Institute o f Standards 
and Technology (NIST) and the increase o f brachytherapy dosimetry literature with 
improved dosimetry methodologies and dosimetric characterization o f difference 
source models. In response to the major advances, the AAPM published an update o f 
the TG-43 protocol in 2004 [17] for the calculations o f dose-rate distributions around 
photon-emitting brachytherapy sources. The updated TG-43 includes:
- a revised definition o f air-kerma strength;
- the elimination o f apparent activity for specification o f source strength;
- the elimination o f the anisotropy constant in favour o f the distance-dependent 
two-dimensional anisotropy function (See Section 2.7.8);
- guidance on extrapolating tabulated TG-43 parameters to longer and shorter 
distances;
- correction o f minor inconsistencies and omissions in the original protocol and its 
implementations.
Furthermore, the updated report proposes a unified approach to comparing reference 
dose distributions derived from different investigators to develop a single critically 
evaluated consensus dataset. In addition, the report provides the guidelines for 
performing and describing future theoretical and experimental single-source 
dosimetry studies.
The final part o f the report includes consensus datasets, where the dose-rate constant, 
radial dose functions, one-dimensional and two-dimensional anisotropy functions, for 
all lower energy brachytherapy sources that satisfy the AAPM dosimetric 
prerequisites are tabulated. [14]
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2.7,6 Types of 1-125 seeds
The 1-125 seed Model 6711, also known as OncoSeed™, is commonly used 
throughout oncology centres worldwide. The seeds are available singly or in strands 
o f ten and marketed as the RAPID Strand™ Iodine-125 seeds Model IMC 7000. The 
iodine 1-125 seeds Model 6733/6735 also known as Echo Seed™ with grooved 
surfaces allow enhanced visualization under ultrasound (See Chapter 7). Other 1-125 
seeds are commercially available from manufacturers in the United States, China, 
Germany, Belgium and Canada. Common brachytherapy seeds in use include: Syncor 
PharmaSeed BT-125-I, UroMed SymmetraI25.S06, SourceTech Medical '^^Implant 
STM 1251, Med-Tec I-PIant Model 3500, International Brachytherapy, Inc. Inter 
Source'^^ 125IL, Best Medical International Model 2301, Amersham Model 6702, 
UroCor ProstaSeed I125-SL, Imagyn IsoSTAR 12501, Mentor’s loGold MED3631- 
A/M and Draximage BrachySeed LS-1. Due to the large number o f brachytherapy 
seeds currently in use, each with different dosimetric characteristics and physical 
characteristics, Heintz et al [12] conducted a comparison o f eleven commercially 
available 1-125 sources with the Amersham 6711 OncoSeed™. The dosimetric 
characteristics o f each source were measured using TLDs, film, ion chambers, and 
diodes. The calculations were performed with Monte Carlo techniques. The physical 
characteristics were thoroughly compared including the cross-sectional drawings 
together with tables showing the details o f the internal design for each 1-125 source.
The physical characteristics can be divided into three categories:
1. The physical construction o f the source
2. The source imaging visualization properties
3. The distribution o f the radioactivity within the internal core o f the source 
There are two typical source design types: Rod/Wire/Cylinder and Sphere. The 
internal physical design has an effect on their visibility under x-ray fluoroscopy, 
conventional radiography and CT Imaging. The material used to construct the internal 
core can be divided into four main types: Resin, Ceramic, Glass and High atomic 
number material. The distribution o f 1-125 is either absorbed throughout the internal 
core or adsorbed across the surface o f the internal core. The radiographic markers 
used for constructing the internal core are silver, palladium, aluminium, gold, gold- 
copper, platinum, iridium, or tungsten wires.
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O n co S eed  6711 2001 Monte Carlo Solid/liquid water C apote R [18]
1998 Scintillator/ 
Monte Carlo
Liquid W ater W eaver KA [19]
1993 t l d Solid Water Nath R [20]
1991 Monte Carlo Solid/liquid water Williamson JF [21]
1983 TLD, D iodes Liquid water Ling CC [22, 23]
1989 TLD Solid water W eaver KA [24]
1988 Monte Carlo Liquid water Williamson JF [25]
A m ersham  6702 2001 Monte Carlo Solid/liquid water C apote R [18]
1998 Scintillator/ 
Monte Carlo
Liquid W ater W eaver KA [19]
1993 TLD Solid Water Nath R [20]
1991 Monte Carlo Solid/liquid water Williamson JF [21]
1989 TLD/
MonteCarlo
Solid water W eaver KA [24]
1987 D iode Liquid water Schell M [26]
E ch o S eed  6733 2002 TLD Solid/liquid water M eigooni AS [27]
2002 Monte Carlo Solid/liquid water Sow ards KT [28]
T h eraS eed  200 2001 M onte Carlo Solid/liquid water C apote R [18]
1998 Scintillator/ 
Monte Carlo
Liquid W ater W eaver KA [19]
1993 TLD Solid Water Nath R [20]
1990 M easurem ents Liquid water M eigooni AS [29]
1991 TLD Liquid water Chiu-Tsao ST [30]
2000 Scintillator Solid/liquid water Nath R [16]
2000 Monte Carlo Solid/liquid water Williamson JF [31]
2002 Monte Carlo Liquid water M onroe Jl [32]
B EST 2300 1993 TLD Solid water Nath R [33]
BEST 2301 2000 TLD Solid/liquid water M eigooni A S [34]
2002 Monte Carlo Solid/liquid water Sow ards KT [35]
MED 3631 2001 Monte Carlo Liquid water Rivard MJ [36]
MED 3 6 3 1 -A/S 1998 TLD Liquid water W allace RE [37]
loGold 1999 TLD Liquid water W allace RE [38]
M ED363 A/M
P harm aS eed  BT- 2000 Monte Carlo Liquid water P op escu  CC [39]
125-1
Sym m etral25 .S06 2001 TLD Solid water Patel NS [40]
l-Plant 35 00 2001 TLD Solid water D uggan DM [41]
2001 TLD Solid water W allace RE [42]
2002 Monte Carlo Liquid water Rivard MJ [43]
20 0 3 Monte Carlo Liquid water Medich DC [44]
Table 2.4: Measurements and calculations conducted on different brachytherapy seeds
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2.7.7 Dosimetry calculations for 1-125 seeds
The parameter studies have led to the derivation o f an equation, which converts the 
Model 6711 OncoSeed™ source strength to an equivalent strength o f the new source. 
In Heintz’s investigation, the one-dimensional TG-43 point dose calculation
formalism equation Equ. ( 1 ) was used to compare the D{r) dose rates for each 
source.
Ô (r )  =  5'. X j  X X 0 . , ,  C )
Sk is the Source Strength (see Section 2.7.8) measured in air kerma strength unit (U) 
which is a convenient combination o f units such that 1U= 1 p,Gyni^h’' = 1 cGy cm^h’’; 
A is the Dose Rate Constant (cGy/hrxU); Mr~ is the Inverse Square Law; g(r) is the
Radial Dose Function and is the Anisotropy Factor. The radial dose function 
(Equ. ( 2 ) )  accounts for the effects of absorption and scatter in the medium along the 
transverse axis. G {i\6 )  is the geometry factor accounts for the variation o f relative 
dose due the distribution o f activity within the source, r is the radial distance from 
source centre, where ro = 1 cm.
g ( r )  =  Ô o %Ûo) G O o , Û q)  ( 2  )
D(/'o,Ûo)G(r,ÛJ
As the energy o f 1-125 photons is relatively low, significant absorption will occur in 
the titanium shell. This absorption, together with the unavoidable position uncertainty 
associated with markers, has made difficult both calculations and measurements o f the 
dose distribution at distances closer than 1 cm to the seed. Following the 
recommendations o f the AAPM Radiation Therapy Committee TG-43 report [13], 
Heintz found that calculating the dose rate at 1 cm provided the best approximation to 
determine the source strength. The source strength calculation equation (Equ.( 3 )) 
was derived from Equ. ( 1 ) with respect to the dose rate at 1 cm of the 6711 source.
Though the report comprehensively compared the dosimetric and physical, 
characteristics o f a number o f 1-125 sources, it did not investigate the source visibility 
and signature in radiographs. The imaging properties o f each source should be 
investigated under fluoroscopy, on planar radiographs and on CT studies.
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To fulfil the first dosimetric prerequisites recommendation o f the AAPM, Monte 
Carlo studies have been carried out by researchers using various software modelling 
tools. MCNP was used to process the photon histories for each set o f in-water and in­
air calculations [44]. An in-house Fortran-77 program (Photon Transport Code) was 
used to track scattered photons through geometrically complex arrangements of 
absorbing media [21]. PTRAN code was used to simulate photoelectric absorption 
characteristic X-ray emission as well as coherent and incoherent scattering [35]. A 
newer simulation tool, GEANT has been created exploiting software engineering and 
object-oriented technology and implemented in the C++ programming language [45]. 
The relation between these codes will be further described in Section 3.10.
2.7.8 General 2D formalism
One o f the recommendations o f the updated AAPM TG-43 report [36] was the 
elimination o f the anisotropy constant in favour o f the distance-dependent two- 
dimensional anisotropy function
Anisotropy function
The 2D anisotropy function, F(r, 0), defined in Equ.( 4 ),describes the variation in dose 
as a function o f polar angle relative to the transverse plane, where 0^= tt 12 (or 90°)
D(r,^) (4 )
The F(r, 0) on the transverse plan is defined as unity, the value o f F(/^ 0) away from the 
transverse plane will decrease as r decreases, as 0  approaches 0° or 180°, as 
encapsulation thickness increases, and as photon energy decreases. Gi{r,0) is the 
geometry function for line source approximation,
P(r,0)
Figure 2.3: Coordinate system used for brachytherapy dosimetry calculations [171
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Geometry function
In brachytherapy dose calculations, the purpose o f the geometry function, Gl(j% 9), is 
to account for effects that are predictable directly from the inverse-square law and the 
gross shape o f the sample (i.e. its overall geometry). This leaves the anisotropy 
function to describe in more detail those features o f the dose distribution that depend 
on the exact construction details. The geometry function neglects scattering and 
attenuation, but provides an inverse square-1 aw correction based upon the spatial 
distribution o f radioactivity within the source. Thus for a point source, the geometry 
function would be simply
= -p-
Whilst for the line source illustrated in Figure 2.3, we have:
G A ’->0) = -{Lr sin 0  1
/4
if
, i f ^  = 0
( 5 )
(6)
Sin {L/2^sin6
■yjL /^4 + — LrcosO
\  r
+ Sin~^ {L/2)sind
L X rsinO
( 7 )
It has been noted [17] that the point source approximation is insufficient for prostate 
brachytherapy seeds. The corresponding formulae for calculating the geometry 
function Gi{r,6) for line source approximation, derived in Appendix D is shown in 
Equ.( 6 ). is the angle, in radians, subtended by the tips o f the hypothetical line 
source at the calculation point P(r, 6). In the case o f the 6711 seed, L, the source length, 
is 3 mm. r denotes the distance in centimetres from the centre o f the active source to 
the point o f interest, and 6  denotes the polar angle specifying the point-of interest. 
Equ. ( 7 ) shows the cosine formula used in the calculation o f Gi(r, 0) for 0 ^ 0 .
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Dose Rate
The dose rate equation from AAPM TG-43 is given in Equ. ( 8 ):
b(r,6)  =  S ,  ■ A . . F{r,6)  ■ g(r) ( 8 )
Where Sk is the Air-Kerma strength, the measured source strength o f the source at 1.0 
cm from the source in units o f U where 1 U= 1 jj,Gym^h’’= 1 cGycm^h"', A is the 
dose rate constant at reference point for the source and surrounding medium in units 
o f cGyh 'u  ', G(r, 6) is the geometi'y function in units o f cm'^, r denotes the distance 
in centimetres ftom the centre o f the source to the point o f interest, ro denotes the 
reference distance which is specified to be 1 cm in the protocol, g(r) as before is the 
radial dose function, account for dose fall-off on the transverse-plan due to photon 
scattering and attenuation and is defined later, in Equ ( 10 ) .
Air-Kerma Strength
The air-kerma strength, %, has units o f //Gym^lf* was introduced by the AAPM TG- 
32 report in 1987 [46].
Air-kerma strength, Sk, is the air-kerma rate, Kg (d ) , due to photons o f energy greater
than S, at distance d  fiom the source centre to the point o f Kg { d ) , multiplied by the 
square o f this distance cf as shown in Equ. ( 9 ) .
3*  (( f)6 f: ( 9 )
Note that K g(d)  is evaluated on the plane bisecting the source transversely 
= 0Q = 9 0 °). The energy cut-off, ô, is intended to exclude low-energy or 
contaminant photons (e.g. characteristic x-rays originating in the outer layers o f steel
or titanium source cladding) that would increase K g(d) without contributing to dose
at distances great than 0.1 mm in tissue, ^ is  typically 5 keV for low-energy photon- 
emitting brachytherapy sources.
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Dose rate constant
The dose-rate constant in water, A , is the ratio o f dose rate at the reference position, 
P{rQ,0Q) and Sk. A has units o f cG yh'‘U ''. A depends on both the radionuclide and
source model, and is influenced by both the source internal design and the
experimental methodology.
A  = ,10)
■s.
Radial dose function
The radial dose function, g(r% describes the dose fall-off on the transverse-plan due to 
photon scattering and attenuation, excluding fall-off induced by the geometry function. 
g(r) is defined by Equ.( 11 ). At ro (1 cm), g(r) is equal to unity.
= A f + f J & O k M  (11)
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Chapter 3 Theoretical & Experimental Methods of Dosimetry
3.1 Ion Chambers Dosimetry
3.1.1 The primary standards
In the United Kingdom, the national primary standards are set by the National Physics 
Laboratory (NPL). For photon radiation from Cobalt-60 to 19MV x-rays, the primary 
standard measures the absorbed dose to graphite using a graphite calorimeter [47]. For 
electron dosimetry o f initial energy from 4 to 19 MV, NPL uses a primary standard 
graphite calorimeter to provide a directly calibration o f an ionisation chamber in terms 
o f absorbed dose to water. For x-rays below 300 kV, the absorbed dose is determined 
using a free-air ionisation chamber. As recommended by the IPEM, secondary 
standard equipment should be calibrated by the NPL against the NPL primary 
standard, and as a result all calibrations are traceable to a national primary standard.
The UK Codes o f Practice for photons [48], electrons [49] and x-rays [50] are 
published by the Institute o f Physics and Engineering in Medicine (IPEM) which 
provide the methods for measuring the dose in a beam and methods for comparing 
field instruments to the secondary standard for megavoltage and medium/low energy 
x-rays respectively. The secondary standard is calibrated by NPL every three years 
and is used to calibrate the field chambers and electrometers combinations annually, 
these are used for daily routine measurements. The chambers (models and 
manufacturers) used must be approved by the NPL. The standard instrument sent to 
NPL will be given a calibration factor No, which is the NPL calibration factor for the 
radiation quality to convert the corrected instrument reading to absorbed dose to water.
D = R N , (
D  (Grays - J/kg) is the absorbed dose to water.
This calibration factor is obtained under controlled condition o f pressure and 
temperature (760mmHg and 20°C). The standard humidity index is 50%. The 
calibration result is expressed in terms o f the instrument reading R.
2 6
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The primary standard parallel plate free-air ionisation chamber is maintained by the 
NPL for the realisation o f air kerma (kinetic energy released per unit mass) in terms of 
the base units, i.e. 1 Gy = 1 Jkg’'. The air kerma K is defined as:
dE..K = dm ( 1 3 )
Where dE,r is the sum o f the initial kinetic energies o f all the charged particles 
liberated by uncharged particles in air o f mass dm.
Using the definition o f air kerma with respect to a free-air chamber yields Equ.( 14 );
K = m e (1 -  g) ( 1 4 )
Where Q is the measured charge, m is the mass o f air in the collecting volume, ——  ise
the energy required to produce an ion pair in dry air, F, total correction factor is the 
product o f various correction factors applied to the free-air chamber and g  is the 
fraction o f ionisation due to bremmsstrahlung.
Collecting electrode 
Guard of length L Guard
electrodeelectrode
Defining 
plane \
Aperture 
of area A
X-ray
beam
Collecting
volume Guard barsHT electrode
Figure 3.1: Schematic diagram of the NPL primary standard free-air ionisation chamber
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A schematic diagram o f the free-air chamber is shown in Figure 3.1, where a mono- 
directional beam o f  X-rays passes through an aperture o f area A. The beam enters a 
metal box and passes out through a hole on the other side interacting only with air. 
The separation o f the electrodes is such that electrons released in the collecting 
volume lose all the energy before reaching the electrodes or chamber walls. This 
ensures that the electrons are completely stopped by air. A high potential difference o f 
the order o f 100 V/cm is maintained between the high-voltage electrode and the 
collecting electrode o f length L, which sweeps the ions o f one sign produced between 
the dotted lines (See Figure 3.1) to the collecting electrode. The ions are collected 
from the collecting volume and the charge is measured, this volume is defined by the 
aperture area A and length L.
3.1.2 The Ion Chamber
The most common method of measuring ionising radiation is by the use o f ion 
chambers. Dosimetry o f ionising radiation with ion chambers has a long histoi-y and 
the general principle is well understood, such that measurements can be easily and 
reliably performed. The determination o f ionisation in air (or any other medium) due 
to ionising radiation remains the standards o f all dosimetric techniques.
Although other systems may be used for relative measurements, ionisation chambers 
are the only instruments employed in the hospital for absolute dosimetry 
measurements, where accuracy is important.
The details o f the ionometric determination o f x-ray, described in three main steps, are 
shown schematically in Figure 3.2.
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Incident Photons
Losses
Interaction with 
electrons in matter
Scattered
photons
Secondary electrons
Interaction: 
Ionisation, deposition 
of energy
Radiactive losses:
Characteristic x-rays, 
Bremsstrahlung, 
Positron annihilationIons
Collection of ions
RecombinationElectrometer signal 
= dose reading
Figure 3.2: Schematic diagram of the ionometric determination of X-rays [51]
The first step is related to the kinetic energy released per unit mass -  quantity kerma 
K. In homogenous material, the kerma is directly proportional to the photon energy 
and the number o f photons. [51]
The second step refers to the quantity collision kerma, which is the release o f kinetic 
energy and deposition in the material. Some o f the electrons from the first step lose 
energy due to radioactive losses such as bremsstrahlung.
2 9
C h a p t e r  3 T h e o r e t ic a l  &  E x p e r im e n t a l  m e t h o d s  o f  d o s im e t r y
The generated ions are collected using an electric field and the charge is measured in 
the third step typically by using an electrometer. The number o f ions produced in the 
chamber (the recorded charge) depends on the electric field and therefore, on the 
applied voltage.
Ion chambers can be applied to measure absorbed dose (the energy absorbed per unit 
mass). The technique is based on the Bragg-Gray principle, where the absorbed dose 
A jj (Grays - J/kg) in a given material can be deduced from the ionisation produced 
within the gas-filled cavity within that material:
D,„=WS,„P ( 1 5 )
W (J/ion pair) is the average energy loss per ion pair formed in the gas, S„, is the 
relative mass stopping power (energy loss per unit density) o f the material to that o f 
the gas and P  (ion pairs/kg) is the number o f ion pairs per unit mass formed in the gas. 
[52]
3.2 Diode Dosimetry
During the interaction o f radiation and semiconductors, electrons are raised from the 
valence layer (corresponding to those outer-shell electrons that are bound to specific 
lattice sites within the crystal) to the conducting layer (representing electrons that are 
free to migrate through the crystal). The energy required for this process is 
approximately 10% o f the energy required to create an ion pair in air. (= 1 eV for 
semiconductor)
Diodes are sensitive devices with linear response and are often used in arrays to 
measure real-time dose distribution. A disadvantage o f diodes is the susceptibility to 
radiation damage over time by prolonged exposure to heavy ions. When the source- 
surface distance (SSD) increases, the correction factor must increase accordingly, as 
diodes tend to underestimate the dose when the SSD increases [53]. Diodes are energy 
and temperature dependent devices, and must be calibrated at room temperature for 
the measurement o f specific energy range. The shape and geometiy o f the diode give 
rise to directional dependences, the incident beam should be measured at an angle 
perpendicular to the diode [52].
3 0
C h a p t e r  3 T h e o r e t i c a l  &  E x p e r i m e n t a l  m e t h o d s  o f  d o s i m e t r y
3.3 Thermoluminescence Dosimetry
3.3.1 Thermoluminescence dosimeters
Thermoluminescence dosimeters (TLD) are inorganic crystals widely used in medical 
physics especially in the area o f radiotherapy, nuclear medicine, diagnostic radiology 
and radiation protection. TLDs are used for monitoring staff and patient dose, and for 
dose verification purposes. TLDs are ideal for measuring superficial skin dose. The 
main advantage is the lightweight and small physical size, which allows the TLDs to 
be placed directly onto a patient without distorting diagnostic radiography images or 
causing unnecessary patient discomfort. This section investigates the sensitivity of 
Lithium Fluoride (LiF) Model TLD-7000 TLDs. One o f the major reasons for the 
popularity o f LiF-based materials is the close match between their mean atomic 
number and that o f soft tissue. In a later section, TLD dosimetry data will be 
compared with Monte Carlo calculated results.
TLDs are made o f inorganic crystals such as lithium fluoride, lithium borate, calcium 
sulphate and calcium fluoride; the crystals consist o f a valence band where bound 
electrons sit and a conduction band where electrons are free to migrate within the 
crystal. [52] The gap between the energy bands is known as the bandgap. In theory, an 
ideal insulator at room temperature, the electrons are bound in the valence band and 
would not cross the energy gap. In reality, crystal contain defects, which consist o f 
high concentration o f trapping centres for electrons, these are regions o f positive 
charge. The electrons are elevated from the valence to the conduction band by the 
incident radiation and captured at various trapping centres.
After irradiation, the TLD goes through a heating process, where thermoluminescence 
light emission are detected by the Photomultiplier Tube (PMT) and convert into an 
electrical signal linearly proportional to the detected photon fluence and an 
electrometer is used for recording the PMT signal as a charge or current. An 
electromechanical lift is used to raise the dosimeter up to the heating element. Each 
individual TLD chip is placed in a stream o f heated gas and its temperature 
progressively raised. The TLD chip will undergo various heating cycles: preheat, read, 
anneal and cool. The read cycle will last, typically for 16 seconds with temperature 
peak at 240°C followed by the anneal cycle for 16 seconds at 300 °C.
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See section 5.5 for a full analysis o f the usage o f LiF TLD chips.
3.3.2 Doped Radiosensitive Glass
Optical fibres have been proposed as low cost re-readable thermoluminescence 
material for radiation dosimetry [54]. A number o f commercial optical fibres have 
demonstrated high reproducibility, wide dose range (0.1 Gy to several kGy) and 
minimal fading effect [55]. Germanium-doped optical fibre used in this study is a type 
o f Doped Radiosensitive Glass (DRG). The commercially available Ge-doped optical 
fibres have a number o f desirable features including sensitivity, dose linearity and 
limited fading [56]. The investigation utilising doped radiosensitive glass can be 
found in Section 5.5.5.
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3.4 Film Dosimetry
Silver halide films are used for dosimetry purposes especially in quality assurance 
tests. Film dosimetry provides a visual record o f the radiation field in the plane in 
which the film lies. The darkening o f the film which is characterised by the optical 
density (OD) can be related to dose, by an appropriate calibration.
Optical density is defined as:
0 , ^OD = log] ( 1 6 )
where lo is the intensity o f light incident on a region o f film and h is the intensity of 
light transmitted through that region.
First, a calibration curve o f optical density against delivered dose must be drawn up, 
this can be done on the day o f use. For brachytherapy autoradiography, films are 
generally used for positional checks. For radiotherapy treatment, the prescribed dose 
must be delivered reproducibly for each patient. To achieve this, ionisation chambers 
are used to monitor dose output. The units o f dose recorded by these are referred to as 
monitor units (MU). As a typical standard setting, 1 MU is calibrated to equal 1 cGy 
at 100 cm SSD for a 10 x 10 cm^ field size at the point o f maximum dose (dmax) in 
water (water phantom). The film calibration curve is obtained by exposing the film at 
different MU settings then the optical density for each exposure can be measured 
directly from the developed film using an optical densitometer. An example o f an 
optical density vs. dose calibration curve is shown in Appendix B.
This report uses a type o f newly developed GAFCHROMIC® radiochromic film 
(RCF), which is a radiation-induced auto-developing x-ray analysis film used for 
diagnostic and therapeutic radiation dosimetry. Its dosimetric properties are especially 
suitable for low dose rate brachytherapy sources.
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3.4.1 Radiochromic Film
GAFCHROMIC® radiochromic film (RCF) is a radiation-induced auto-developing x- 
ray analysis film used for diagnostic and therapeutic radiation dosimetry. The films 
have been developed by International Specialty Products Corporation (Wayne, NJ, 
USA) for the measurement o f absorbed dose and the mapping o f radiation fields 
associated with external beam radiotherapy and brachytherapy. Different types 
currently available are: External Beam Therapy (EBT), Highly Sensitive (HS), 
Radiotherapy Quality Assurance (RTQA) and X-Ray (XR).
The newly developed HS films are suitable for the 0.5 to 40Gy range. The EBT [57] 
and RTQA [58] films are the most sensitive to date and for use in the measurements 
in the 0.1 to 8 Gy range. XR type is suitable for low energy range applications due to 
its relative energy independence and high sensitivity [59], it is developed specifically 
for the measurement o f absorbed dose o f low-energy photons with energies less than 
200 keV.
Radiochromic films have various advantages over previous silver halide films, 
properties such as flat energy response, are independent o f dose-rate, self-developing, 
and insensitive to visible light, and they have low atomic number elements [60], a 
long shelf life (greater than 1 year) and good post irradiation properties [61]. Stevens 
et al have demonstrated the films can be read out with conventional flatbed scanners 
in reflective mode as a mean o f high-resolution dosimetry [62].
Due to the increasing use o f computed and digital radiography in diagnostic imaging, 
the availability o f film processor for radiotherapy quality assurance is diminishing. 
One cannot expect general departmental film processors to be available for many 
more years; therefore a self-developing film is an ideal solution [58]. Self­
development eliminates the variation associated with the film developing processes, 
insensitivity to visible light allows ease o f handling and the film to be cut into 
desirable shapes. GAFCHROMIC® radiochromic EBT film has shown 6% to 9 % 
increase in post-irradiation optical density within the first 12 hours o f irradiation 
compared to 15% and 19% respectively for XR Type and HS radiochromic films. The 
recommended period for post irradiation analysis is at least 6 hours [61].
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The elemental composition o f GAFCHROMIC® films [63] is similar to that of 
PRESAGE™ described in the next section (see Table 3.1). The mass density for 
PRESAGE™ is 1.05 to 1.12 g cm’^  depending on the exact formulation and 
1.15 g cm'^ for GAFCHROMIC® film. PRESAGE™ has visible absorbance maximum 
at 633 nm and GAFCHROMIC® film at 617 nm and 675 nm.
Elem ent PRESAGE™ Radiochrom ic Film
0 61% 64%
0 20% 15%
N 10% 12%
H 9% 10%
Table 3.1: Chemical composition comparison [631
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3.5 Gel and Solid Polymer Dosimetry
Diodes and TLD will adequately provide effective point dose information within a 
phantom. For dose distribution information over a volume, an array o f diodes, TLDs 
or volume of films will be required, the practical problem in using such dosimeters is 
the setup time and cost. Secondly, the ionisation through different medium will be 
another issue o f  concern since there will be air gaps within the dosimeter array setup; 
the amount o f absorption would differ. Furthermore, the finite dimensions o f solid 
water phantoms do not provide full scatter build-up. [21]
Gel dosimetry has become an active area o f  research in recent years and the DOSGEL 
international conferences had been dedicated to this subject (DOSGEL 99 [64], 
DOSGEL 01 [65], and DOSGEL 04 [66]). Gel dosimetry may be the solution for 
recording three-dimensional dose distributions. Different types o f radiosensitive gel 
include: polyacrylamide gel PAG (BANG, MAGIC [67, 68]), ferrous sulphate-based 
(Fricke) [69], Ferrous Xylenol Gel (FXG) [70] and the newly developed polyurethane 
based solid dosimeter PRESAGE™ [71].
These dosimeters are effective due to their polymerization, oxidation-state change or 
colour changing properties during exposure to ionising radiation. The radiation- 
initiate polymerized gel can be feasibly probed with conventional imaging modalities, 
for instance Nuclear Magnetic Resonance (NMR) [72], Raman Spectroscopy [73], X- 
ray Computed Tomography (CT) [74], and Ultrasound [75, 76]. A number o f different 
Optical Computed Tomography (Optical-CT) tools are under innovative development. 
The advantages o f Optical-CT over MRI are its compact size, low overhead and 
maintenance cost and relatively low start-up cost. Light sources currently in use 
include lasers [77, 78], broad beam [79] and LEDs [80]. Incorporating the light 
sources with high-speed photodiode detectors or CCD-based camera, high-resolution 
3D digital images are obtainable via the technique o f filtered backprojection 
reconstruction (FBP).
Effort to optimize the use o f the gel dosimeters had been an active area o f research. 
For example, to accurately measure three-dimensional radiation dose distribution in 
radiotherapy, the attenuation o f diagnostic energy photons through the gel dosimeter 
must first be evaluated, work have been carried out in the past to examine the
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properties o f polymer gel dosimeters in order to enhance the dose information 
obtained by CT [81].
3.5.1 Previous Applications of Gel Dosimetry in Brachytherapy 
There are increasing numbers o f publications in the field o f gel dosimetry as applied 
in brachytherapy, particularly in high dose rate (HDR) Ir-192 sources [82-88] and low 
dose rate (LDR) Cs-137 sources used in afterloading systems [89, 90].
Practical experimental difficulties exist in interstitial brachytherapy 1-125 seeds with 
significantly lower Icerma strength than HDR sources. The prolonged irradiation time 
leading to the complication o f diffusion in polymer gels was encountered and 
presented by Heard and Ibbot [91]. Physicochemical mechanisms e.g. oxygen 
permeability and monomer-diffusion-related effects are the main factors during 
irradiation. The problem associated with Fricke gel dosimetry is the diffusion o f ferric 
and ferrous ions in the gel during and between irradiation and scanning. The diffusion 
o f the ions results in the blurring o f  the dose profile at close proximity o f the 
brachytherapy source. The main problem reported in monomer or polymer gel 
dosimetry is the oxygen permeability o f the catheter as oxygen inhibits the radiation 
induced polymerization reaction [92, 93].
For these reasons, other authors have investigated various polymer gels formulations 
to limit the diffusion problem [94, 95]. To date, all the acrylic polymer gel dosimeters 
must be manufactured, stored and irradiated under hypoxic conditions, which limits 
their use and stability. Fong et ai has developed a new type o f polymer gel named 
MAGIC (Methacrylic and Ascorbic cid in Gelatine Initiated by Copper) that can be 
prepared in normal atmosphere [67]. The MAGIC gel in contrast to the previous 
polymer gels require the presence o f oxygen to be effective and can be imaged by 
MRI.
Solid polyurethane-based dosimeter -  PRESAGE™ [96] is a new type o f solid 
polymer dosimeter currently applied to prostatic brachytherapy dosimetry in our 
centre. The radiochromic components in the polyurethane dosimeter are radiochromic 
leuco-dyes and free radical initiators. The polyurethane has elemental composition o f 
C at 61%, H at 9%, N at 10% and O at 20%. The dosimeter is transparent, rigid and
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easily machineable, is stable during a prolonged irradiation period, and has good post­
irradiation storage properties. It also displays a linear response at low energies [97] 
and is insensitive to oxygen, unlike many previous polymer gels systems. [98]
3.6 Introduction to Monte Carlo codes
In the 1940s, Monte Carlo (MC) particle transport techniques were originally 
developed for the design o f atomic weapons. Since then, MC simulations have been 
applied in different areas o f research, for example radiotherapy [99], radiation 
protection/dosimetry [100], and nuclear medicine [101]. A review covering the basics 
and applications o f Monte Carlo techniques in medical radiation physics was 
published by Andreo [102].
For external radiotherapy photon beams, a topical review on Monte Carlo modelling 
has been published by Verhaegen et al [103] with functional details o f the commonly 
used MC codes. Most o f these codes are written in FORTRAN programming 
language with the exception o f GEANT, which is written in C++. The codes that are 
frequently used for radiotherapy beams modelling are ETRAN/ITS [104], EGS4 [105], 
EGSnrc [106], MCNP4 [107], PENELOPE [108], GEANT3 [109], and GEANT4 
[45] A newer version o f MCNP, MCNP5 has recently been made available [110].
The choice o f MC code is determined by the specific requirements o f the application 
proposed. In the case o f low dose brachytherapy dosimetry, the features o f particle 
transport that are o f particular interest are the energy loss o f the incident particles and 
secondary electrons in tissues as well as Bremsstrahlung process and the emission o f 
fluorescence X-rays.
The ability to specify small step lengths [111] is clearly relevant for highly localised 
dose distributions, whilst there is a need for a low cut-off energy threshold to examine 
the disti'ibution o f local dose deposition.
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3.7 Requirements for Monte Carlo Calculations
The AAPM TG-43 would like to promote a universal approach for Monte Carlo 
calculations, thus the updated protocol [17] included for the first time a set o f 
requirements for calculating brachytherapy dosimetry parameters. The main points o f 
the recommendations are summarised as follow:
1. Dosimetry calculations should be performed in a 30cm diameter liquid water 
phantom.
2. Enough histories to accommodate for statistical errors i.e. <2% at <5cm.
3. Modern, post-1980 cross section libraries should be used, preferably those 
equivalent to the current NIST XCOM database such as DEC-146 or EPDL97.
4. Manufacturer published source dimensions and compositions o f encapsulation 
and internal components should be verified.
5. Point source modelling is unacceptable.
Since the last publication o f the TG-43 protocol, the half lives, abundance and 
energies o f photons emitted by unfiltered 1-125 sources have been re-evaluated by 
NIST. The current recommended nuclear data are listed in Table 3.2. These values 
were implanted as source spectra in Monte Carlo calculations. In the updated TG-43 
protocol, the 1-125 spectrum is described in terms o f five different photon energies 
compared to only three in the previous report.
1-125 (half-life=59.50 ±0.01 days)
Photon energy (keV) P hotons per disintegration
27 .2 0 2 0 .406
27 .4 7 2 0 .757
30 .98 0 .202
31.71 0 .0 4 3 9
35 .4 9 2 0 .0 6 6 8
Table 3.2: Recommended nuclear data for 1-125 for brachytherapy dosimetry [17]
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Water is used as the recommended medium for reference dosimetry o f interstitial seed. 
The composition o f pure, degassed water is two parts o f hydrogen atoms and one part 
oxygen atoms, with a mass density o f 0.998 g cm"  ^ at 22°C. Air gap exist in the iodine 
seed core, the reference conditions for dry air are 22°C and 101.325 kPa (760mm Hg) 
with mass density o f 0.001196 g cm'^. The composition o f air may vary according to 
the relative humidity, this effect is presented in Table 3.3. The proportional weight o f 
water in air o f 100% relative humidity varies from 1% to 2%, for temperature between 
16°C and 26°C and pressure between 735 mm Hg and 780 mm Hg. For this 
arrangement o f temperature and pressure, the change in mass density o f saturated air 
is no more than 1%. Taking into account o f both moist and dry air, the mass density 
will be set at 0.00120 g cm’^ . The updated TG-43 recommended relative humidity to 
be 40%, this corresponds to the relative humidity in an air-conditioned environment 
where measurements are carried out.
R elative  
humidity (%)
Hydrogen Carbon Nitrogen Oxygen Argon
0 0 0 .0 1 2 4 7 5 .5 2 6 8 23 .1781 1 .2827
10 0.0181 0 .0 1 2 4 7 5 .4 0 4 8 23.2841 1 .2806
40 0 .0 7 3 2 0 .0 1 2 3 7 5 .0 3 2 5 2 3 .6 0 7 7 1 .2743
60 0 .1101 0 .0 1 2 3 7 4 .7 8 3 7 2 3 .8 2 3 8 1.2701
100 0 .1842 0 .0 1 2 2 7 4 .2 8 3 5 2 4 .2 5 8 5 1 .2616
Table 3.3: Composition (percent mass) of air as a function of relative humidity at a pressure of
101.325 IcPa.
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3.8 GEANT4 Monte Carlo Simulation
GEANT4 [45] is a free Monte Carlo simulation toolkit. The software was developed 
by the GEANT4 Collaboration, consisting o f 100 scientists from Europe, Japan, and 
North America. The first version was released in 1998 [112]. GEANT4 is widely used 
in the field o f high-energy physics, medical physics, and space sciences.
In brachytherapy calculation, the accuracy o f the Monte Carlo simulation relies on the 
capability o f low energy dosimetry as well as the precision o f the dimension and 
composition o f the brachytherapy seed. Although initially developed in the high- 
energy particle physics domain, GEANT4 is suitable for low energy dosimetry 
calculations, with capability o f tracking low energies, down to 250 eV [111]. The 
wide range o f geometry implementation and physical processes available are the 
Rayleigh effect, the photoelectric effect, the Compton effect, pair production, the 
Auger effect, ionization, bremsstrahlung, positron annihilation, atomic relaxation and 
multiple scattering. However, it would probably be fair to say that less exhaustive 
testing o f the low-energy range has occurred than with other codes.
Validation o f GEANT4 simulation for point source simulation has been recently 
published [113]. The radial dose from a Strontium-90/Yttrium-90 (Sr-90/Y-90) 
encapsulated sources were calculated. The encapsulated Sr-90/Y-90 source has a 
similar structure to the 1-125 Model 6711 seed. For a simulation o f 20 000 000 
primary particles with production threshold set to 40 keV for electrons and 10 keV for 
gammas, the statistical relative uncertainty was less than 1.5% for radim<^mm. The 
relative difference o f the radial depth-dose between EGSnrc and GEANT4 is less than 
7.5% for r  < 8 mm. The validation demonstrated that GEANT4 produced comparable 
results to other major Monte Carlo code such as MCNP, EGSnrc and EGS4.
Low energy processes are valid for energies ranging from 250 eV to 100 GeV, where 
elements with atomic number 1 to 100 are covered. All the processes involve two 
phases: 1) the calculation o f total cross section, 2) the generation o f the final state. 
These phases adopt the cross section data libraries: EPDL97 (Evaluated Photons Data 
Library) [114, 115], EADL (Evaluated Atomic Data Library) [116] and EEDL 
(Evaluated Electron Data Library) [117, 118].
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The data libraries cover the energy range from 100 GeV to 1 eV for the Rayleigh and 
Compton effects, down to the lowest binding energy for each element for the 
photoelectric effect, down to 10 eV for Bremsstrahlung and to the lowest subshell 
binding energy for each element for ionization [111]. The accuracy o f the simulation 
is also dependent on one other important factor -  the photon cross-section data, where 
the measured absolute photon interaction cross-sections and attenuation coefficients 
are defined. For low-energy brachytherapy seeds measurement, the different versions 
o f cross-section data can result in intra-variation as high as 10% for 20 keV and 30 
keV photons in the photoelectric data [119].
Materials in the GEANT4 simulations are specified as G4Element with details o f the 
material, atomic weight, atomic symbol, atomic number, density and molecular 
structure. (Programming Syntax 1)
//Water 
density = 1.0*g/cni3;
G4M ateriaP Water = new G4Material(name="Water", density, ncomponents=2); 
Water->AddElement(elH, natoms=2);
Water->AddElement(elO, natoms==l);
//I-125 Source Material 
a = 125*g/mole;
G4Element* ell = new G4Element(name="Iodine", symbol="I", z=53., a); 
density = 4.94*g/cni3;
G4Material* Iodine = new G4Material(name="iodine", density, ncomponents=l); 
Iodine->AddElement(elI, natoms= 1 );
Programming Syntax 1: GEANT4 Material Specification
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Dimensions {G4LogicalVolume) are pre-deflned as standard volumes such as 
G4Sphere, G4Box, G4Tiibs. The location o f the logical volume are detailed in the 
G4VphysicalVolume in the form o f G^7777^eeTec/o7'(0.*cm,0.*mm,0,*micrometer) 
detailing the three dimension x, y, z co-ordinates.
Variations o f dimension and composition has a significant effect on the localized dose 
distribution. Taschereau et ah [120] demonstrates an example o f the use o f GEANT4, 
in which the relative biological effectiveness (RBE) o f 1-125 brachytherapy has been 
calculated for seeds designs where shell and core dimensions and composition were 
varied independently. Results have shown that by increasing the shell thiclcness the 
RBE would enhance and optimum results were obtained by using lower atomic 
number elements. Material such as molybdenum, yttrium and zirconium were also 
simulated in which the RBE enhancement was at least 5-7% (closer to the source).
3.8.1 Previous Applications of GEANT4
Monte Carlo calculations using the code GEANT4 have been performed on 
brachytherapy sources such as the Phosphorus-32 beta source wire [121]. The 
calculations were used to characterize the dosimetric parameters o f the catheter-based 
P-32 source. The anisotropy function results obtained with code GEANT4 showed 
non-negligible differences to PENELOPE. The origin o f these differences has not yet 
been clarified and may be due to the physics included in the simulations or to the 
tracking procedure.
Recent adaptation o f GEANT4 to Monte Carlo dose calculations based on CT data 
has showed good agreement with commercial treatment planning systems [122]. 
However, the feasibility o f using GEANT4 for routine treatment planning is still 
impractical with the current computational efficiency but it is sufficient for re­
calculation o f plans for research purposes. For example, a Linux cluster system with 
30 CPUs with 2.2 GHz Athlon processors with 2 Gbyte RAM would take up to 30 
hours to simulate a 6-field paranasal sinus (PNS) treatment plan.
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3.8.2 GEANT4 in action
In GEANT4, particle transport is controlled over different levels:
Run Initialization, 
termination, and 
overall control of 
running a pre­
defied number of 
histories
G4Run G4RiinManager G4 UserRunAction
Event Simulation of one 
History
G4Event G4EveiitManager G4UserEvent Action
Track An intermdediate 
level between 
event and step
G4Track G4 TrackingManager G4UserTrackingAction
Step Advancing one 
step
G4Step G4SteppingManager G4UserSteppingAction
Table 3.4: GEANT4 Particle Transport Levels Structure
Each interaction is implemented with a process class, where the propagation of 
particles is handled as a process (G4Transportatio7'i).
4 4
C h a p t e r  3 T h e o r e t ic a l  &  E x p e r im e n t a l  m e t h o d s  o f  d o s im e t r y
3.9 MCNP Monte Carlo Simulation
The MCNP (Monte Carlo Neutral Particle) -  MCNP and MCNPX are two similar 
Monte Carlo transport code systems developed and maintained by Los Alamos 
National Laboratory [107]. Both codes are available through the Radiation Safety 
Information Computational Centre (RSICC) at Oak Ridge National Laboratory. The 
radiation transport code deals with transport o f neutrons, gamma rays and coupled 
transport (transport o f secondary gamma rays resulting from neutron interactions), and 
also with the transport o f electrons, both primary source electrons and secondary 
electrons created in gamma-ray interactions [123]. MCNP and MCNPX have a wide 
variety o f source terms and tallies features available to users.
3.9.1 Previous Applications of MCNP in Brachytherapy
Monte Carlo dosimetric studies with MCNP were used to characterise the 
InterSource-125 iodine seed [124] in 2001. This resulted in the successful 
determination o f dosimetric functions enabling comparison with other seed model 
such as the well-known model 6711 and 6702.
By implementing an updated cross section library for low energy (20-40 keV) photon 
emitting radioactive seeds, Bohni et al suggested MCNP to be an effective tool for 
brachytherapy dosimetry o f 1-125 and Pd-103 sources [125]. The study shows that 
MCNP calculations o f the radial dose function and dose rate constant agreed well with 
other published results [21, 23, 31], where the air kerma and depth dose in water can 
be verified.
Dose calculations by MCNP o f beta-emitting sources for intravascular brachytherapy 
were conducted by Wang et al [126]. The code was used in the study o f depth dose 
curve for broad parallel beam o f electron, radial dose distribution o f an isotropic point 
electron source and radial dose distribution o f a Sr-90/Y-90 source.
4 5
C h a p t e r  3 T h e o r e t ic a l  &  E x p e r im e n t a l  m e t h o d s  o f  d o s im e t r y
3.9.2 Structure of MCNP input file
The MCNP input file includes details o f source dimension, materials, source 
specifications, number o f particle histories and the types o f tally calculations to be 
carried out. The structure o f the MCNP input file follows the format outlined in Table 
3.5. Comments can be added throughout the input file to describe the function o f any 
given section. The command lines begin with C or c followed by a space, these lines 
are ignored by MCNP. Anything following a $ sign on a line are also ignored. The 
specification o f geometry is described in detail in the MCNP manual [127]. The 
geometry specifications in MCNP are defined in terms o f regions bounded by surfaces. 
The cell card is the first set o f entries that defines the areas o f interest. Cells are 
defined by intersections, unions complements o f the regions and contain materials 
information. The cells are areas within which the user may specify the calculation of 
energy deposition and other quantities o f interest.
Programming Syntax 2 shows an example o f a line o f code from the cell card section. 
The first number is the unique identifier o f the cell, followed by the material number, 
density (g/cm^), surface boundaries (-Irinside surface 1, 6:outside surface 6, -5:inside 
surface 5) and importance o f the cell. The importance card (im p:p=l) specifies the 
photon importance o f the cell (l=inside world volume, O=outside).
1 1 - 10.50  -1 6  -5 imp: p=l $ Silver Ro^
Programming Syntax 2: Cell card example
Message Block Optional
Blank line delimiter Optional
One Line Problem Title Card Essential
Cell Cards Essential
Blank line delimiter Essential
Surface Cards Essential
Blank line delimiter Essential
Data Cards Essential
Blank line terminator Optional
Table 3.5: MCNP input file structure
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MCNP adopts a 3-dimension (x,y,z) Cartesian coordinate system. All dimensions are 
defined in centimetres. Each cell is specified by a surface or multiple surfaces 
boundaries. For example, a cube would have six surface planes that set the boundary 
for the cube cell. Eveiy (x,y,z) point must be part o f the surface or the cell. There can 
be no points that belong to no cell or surface. Each cell and surface are defined by the 
user using a unique numerical identifier.
The surface card is the next essential set o f entries. It defines the surfaces that 
envelope the cells o f interest. Common surfaces used in MCNP are two- dimensional 
planes and three-dimensional shapes such as spheres, cylinder and cones.
Programming Syntax 3 shows an example o f a line a code from the surface card 
section. The first number is the unique identifier o f the surface, followed by the type 
o f surface (px: plane normal to x-axis) and the axis location (plane at x=0.15cm).
The data card provides the problem specifications other than the geometry. It is used 
to define the elemental composition o f the cells, the radiation source, the scoring o f 
results (tallies), number o f particles histories and the type o f radiation transport 
calculations to be performed (n=neutron, p=photons, e=electrons). The number o f 
particle histories is set to provide the statistical error o f less than 2% as recommended 
by the AAPM. The execution o f the MCNP input file is completed when the set 
number o f particle histories has been reached.
Programming Syntax 3: Surface card example
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Simulation for Photons
+++++++++++++++++++++++
C + + + + + + + - H - + + + + + + + + + + + +
c 
c
mode p
c +++++++++++++++++++++++
c Material Card
c +++++++++++++++++++++++
ml 47000 1 $ Silver
c ++++++++++++++++++++++++++++++++
c Source Specification
c ++++++++++++++++++++++++++++++++
sdef erg=d3 par=2 pos=0 0 0 axs=l 0 0 ext=dl rad=d2
sil -0.15 0.15
spl 0 1
si2 0.0249 0.025
sp2 -21 1
si3L  0.027202 0.027472 0.03098 0.03171 0.035492 $ Nuclear Data for 1-125 
sp3 0.406 0.757 0.202 0.0439 0.0668
f + - + + + + + + -C + 4  
C
C + 4
f6:p 
C + 4
c No of Particles Events 
c
nps 10000000
F+++++++++++ 
Energy Deposition
F + + + + + + + + 4 - + + + + + + + + + + + 4 - + + + + + + +
111 211
- + + + + + + + + + + + + + + + + + + + + 4 - + + +
Programming Syntax 4: Data card example
Programming Syntax 4 shows the main elements o f the data card. The simulations of 
photon was selected. For the material card, the first part is unique material number 
(m l: material 1) followed by the elemental composition, and the cross section 
compilations to be used. In this example, material I designates 47000 identify 
elemental silver, atomic number Z=47. The three zeros in each designation are place 
holders for the atomic mass number. For gamma ray and electron transport, one need 
only specify the atomic number. The density is not specified here, but rather in the 
cell section.
In the source specification section, the SDEF command defines the source and type of 
radiation particles for an MCNP problem, it defines all the characteristics o f all 
sources in the problem. The first part specifies the energy (MeV), erg=d3 specify that 
the energy follows a distribution d3. PAR is the type o f particle source emits 
(l=neutron, 2=photon, 3=electron), POS is the reference point for positioning
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sampling, AXS is the reference vector for EXT and RAD. EXT specifies the distance 
from POS along AXS, and RAD provide the radial distance o f the position from POS 
or AXS. SI is the source information card and SP is the source probabilities card.
In the tally specification section, f6:p is selected for energy deposition tally for 
photons only.
An MCNP run is terminated when a set number o f particle histories have been 
reached or when a desired computing time has been exceeded. These cut-offs are 
specified by NPS. In this example, the MCNP calculation will stop after 10 million 
source particles have been run.
3.9.3 Statistical Analysis
3.9.3.1 Statistical Tests
The MCNP output results represent the average o f all the histories sampled in the 
simulation. An important factor relating to the results is the statistical error or the 
uncertainty associated with the results. MCNP provides a tool for assessing the 
reliability o f results in terms o f tally mean, relative error, figure o f merit, variance o f 
the variance, and probability density function. A total o f ten statistical tests are 
performed on the tally. Using the test result table, the user can assess the quality o f the 
confidence interval and the seriousness o f any failed test. The different statistical tools 
and the ten statistical tests are described in this section.
3.9.3.2 Means, Variances and Standard Deviations
Ify(x) is the probability density function for selected random event that scores x to the 
tally being estimated, the true mean is the expected value ofx, E(x), where:
E(x) = Jxf(x)dx  ^ ^
The true mean is estimated by the sample mean x  where:
(18)
Xi is the value o f x selected from f(x)  for history and N is the number o f histories 
calculated. The sample mean x is the average value o f the score x, for all the histories 
calculated in the problem. The variance o f the population o f x values is the measure o f 
spread o f these values given by:
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-  E(x)Y f i x )  dx = Eix^)~  i E ( x ) f
The square root o f the variance is a, which is the standard deviation o f the population, 
also known as S, given by:
( r  —tFŸ —  —  1 A'
( 2 0 )N - \
The quantity S  is the estimated standard deviation o f the population o f x based on the 
values ofx, sampled. The estimated variance o f x is given by:
S ^ = —  ( 2 1 )N
Note that S-  is proportional to . Therefore, to obtain results with halve S - , the■yj N
original number o f histories must increase by four times.
3.9.3.3 Estimated Relative Error
The MCNP tallies are normalised to be per starting particle history and are printed in
the output with a second number (See Table 3.7), which is the estimated relative error,
R  defined as:
6"-R =  ^  (22)
X
The relative error represents the statistical precision as a fractional result with 
respect to the estimated mean; this is an indication o f the precision o f the tally 
mean. The general guideline for interpreting the relative error is show in Table 3.6.
R ange o f R Quality of the tally
0 .5  to 1 G arbage
0 .2  to 0 .5 Factor of a few
0.1 to 0 .2 Q uestionable
< 0 .1 0 G enerally reliable ex cep t for point detector
< 0 .0 5 G enerally reliable for point detector
Table 3.6: Guidelines for interpreting the relative error R [128]
cell 111 5.50048E-05 0.0073
Table 3.7: MCNP results
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3.9.3.4 Figure of Merit
The Figure o f Merit {FOM) is an important statistic generated by MCNP and is a tally 
reliability indicator. The FO M  o f a tally should be approximately a constant and is 
defined as:
FO M  = - 4 — ( 23 )R^T
The estimated relative error square R^ is proportional to — as derived from
Equ.( 22 ), and the computation time T  should be directly proportional to N. T  is 
subjected to the specifications o f the computer, hence the same simulation on a 
different computer will produce different FOMs. R^T should be approximately a 
constant within a Monte Carlo simulation.
3.9.3.5 Variance of the Variance
The relative variance o f variance VOV is an indicator o f the accuracy o f R.
The estimated relative VOV is defined as:
Where is the estimated variance o f x  and is the estimated variance iiiiS i.
The VOV involves the estimated third and fourth moments o f the tally distribution ,/(x) 
and is sensitive to fluctuations in large history scores than is R, which is based on the 
first and second moments o f J{x). The VOV is a measure o f the relative statistical 
uncertainty in R, where S  must be a good approximation o f  cr in order to use the 
Central Limit Theorem to form confidence intervals.
The VOV should decrease as —  as shown in Equ.( 24 ), this behaviour is tested in oneN
o f the ten statistical tests under VOV. The VOV should be less than 0.1 for all types of 
tallies.
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3.9.3.6 Probability Density Function
The Probability Density Function PDF j{x) is plotted by MCNP to assess the quality 
o f the confidence interval estimated for the tally mean. There are three kinds o f 
possible outcomes in simulating a problem with large history scores:
1. Correctly converged result with statistically correct confidence interval.
2. The sampling o f an infrequent event with a large score that causes the mean 
and R to increase and the FO M  to depress significantly. This scenario can be 
detected by observing the behaviour o f R and FOM,
3. The results appear to have converged based on the behaviour o f R, FO M  and 
VOV, but in fact may be substantially underestimated because large scoring 
histories were not well sampled. MCNP performs analysis o f the high tally tail 
o f  the PDF.
The main difficulty is to determine the number o f histories required to make a valid 
estimate o f the confidence interval. The central limit theorem (CLT) states that the 
mean will appear to be sampled from a normal distribution if  N  is sufficiently large; 
the confidence intervals calculated by MCNP is based on this normality assumption. 
MCNP uses the highest 201 histories to estimate the slope o f the PDF’s high tally tail. 
This is done by fitting a Pareto function.
The slope is estimated by:
SLOPE  = 1H—  { 26 )k
In the MCNP output file, the output plot o f the PDF  shows the Pareto fit in strings of 
s’s, and the tally mean by m ’s. For the high end tail to be acceptable, a sufficient 
number o f histories must have been calculated in order to justify the CLT and the 
SLOPE  must be above 3.
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3.9.3.7 Confidence Intervals
MCNP estimates the confidence intervals for the tally from the relative error R. As the 
estimated mean and uncertainty in the mean are correlated, the mid-point o f the 
confidence interval may shift slightly from the mean. The amount o f the midpoint 
shift SHIFT  for the confidence interval is calculated by MCNP. This should decrease 
1as — .N
3.9.3.8 MCNP Ten Statistical Tests
1. The tally sample mean x  must exhibit, for the last half o f the simulation, only 
random fluctuations as N  increases. No up or down trend must be exhibited.
2. The relative error R  must be less than 0.1 (or 0.05 for point/ring detectors).
3. R must decrease monotonically with N  for the last half o f the calculation.
4. R  must decrease as —^  for the last half o f the calculation.
5. The variance o f variance VOV  must be less than 0.1 for all types o f tallies.
6. VOV must decrease monotonically with N  for the last half o f  the calculation.
7. VOV must decrease as — for the last half o f the calculation.N
8. Figure o f merit FO M  must remain statistically constant for the last half o f the 
calculation.
9. FO M  must exhibit no monotonically up or down trends in the last half o f the 
calculation.
10. The probability density function slope determined from the 201 highest 
scoring histories must be great than 3.
At the end o f the simulation, upon the failure o f any statistical test, a warning is 
printed out together with a plot o f/(x ). I f  all tests are passed, the asymmetric and 
symmetric confidence intervals for the mean at different sigma levels are calculated.
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3.10 Comparison of codes
This section cross-compares the results o f MCNP and GEANT4 with other common 
Monte Carlo codes.
The use o f MCNP for low-energy photon transport calculations is common in 
dosimetry characterisation o f brachytherapy sources. A dosimetric study o f the 
InterSource 1-125 seed was performed by Renier et al [124], where measurements 
were made with LiF thermoluminescent dosimeters and calculations were obtained by 
MCNP. The MCNP calculation and the TED measured TG43 functions are in 
excellent agreement with the anisotropy function mean difference o f less than 3%.
Dose comparisons o f PENELOPE, MCNP and EGS4 were conducted by Ye et al 
[128], where the dose rate constant o f the three code agreed within approximately 
±2% in the range of 20-150 keV. Some published results suggested that the choice 
cross-section libraries has a significant effect in low-energy photon transport, and the 
dose rate constant calculation by MCNP has been reported to show differences o f up 
to 9% when compared with other codes (PENELOPE & EGS4) [128]. Reniers et al 
[119], also reported the radial dose flinction calculated with MCNP is up to 17% 
higher than other code (EGSnrc). MCNP users must be aware o f this effect.
A Monte Carlo codes comparison study between EGS4, EGSnrc and MCNP codes by 
Wang et al [126] have shown radial dose differences o f within 5% for r < 3mm and 
between 5% to 20% deviation for distant radial position o f 3mm < r < 10mm due to 
different models o f electron transport and multiple scattering theories used in these 
codes.
The photon and electron physics o f GEANT4 has been validated by Carrier et al [113] 
and compared well with other major Monte Carlo code such as MCNP, EGSnrc and 
EGS4. The radial dose from a Strontium-90/Yttriuni-90 (Sr-90/Y-90) encapsulated 
sources showed that for a simulation o f 20 million primary particles the statistical 
relative uncertainty was less than 1.5% for r < 8mm. The relative difference o f the 
radial depth-dose between EGSnrc and GEANT4 is less than 7.5% for r < 8mm.
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Dosimetry characterisation o f a P-32 intravascular brachytherapy source wires was 
conducted by Torres et al [121] using GEANT4 and PENELOPE. As GEANT4 is a 
relatively new Monte Carlo toolkit, the result shown by GEANT4 results shows 
disagreement when compared with PENELOPE and previous MCNP results. The 
appreciable discrepancies as suggested by the author may be due to the physics 
included in the simulations or the tracking procedures.
In conclusions, the commercially available MCNP Monte Carlo code has been used 
extensively in different areas o f photon transport calculations. GEANT4 Monte Carlo 
toolkit is fteely available and is a relatively new code. GEANT4 is still in the early 
stage o f development and had already produced broadly comparable results to other 
common Monte Carlo codes.
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Chapter 4 Introduction to the 1-125 Model 6711 OncoSeed™
4.1 Introduction
To investigate the feasibility o f gel dosimetry as an accurate three-dimensional dose 
verification applied to prostatic brachytherapy, the model 6711 OncoSeed™ was 
selected for a pilot study using experimental methods and Monte Carlo simulations. 
The dosimetric characteristics o f the OncoSeed^"^ have been well documented by 
previous authors. This enables the verification and cross comparison with the pilot 
study.
This chapter includes a detailed study o f the 6711 OncoSeed™, a comparison o f the 
anisotropy with the previously published consensus results, Monte Carlo and 
experimental results. The factors affecting the anisotropy are also examined.
4.2 Physical description of the seed
Attention in the following sections will be focused particularly on the radioactive 
seeds used to treat early stage prostate cancer at our collaborating hospital, the Royal 
Surrey County Hospital (RSCH). The brachytherapy permanent implant o f iodine I- 
125 seeds utilises a manual needle loading system. The advantage o f using this type 
o f seed is the low energy o f the emitted photons, typically between 20 to 35 keV with 
average energy o f 28 keV and half-life o f 59.4 days. This is particularly important for 
radiation protection purposes where the operator may be in regular contact with the 
radioactive source for an extended period o f time. The half-value thickness o f lead for
1-125 is 0.025 mm. Therefore, a 0.25 mm lead sheet will provide > 99% reduction in 
exposure.
The 1-125 seed Model 6711, also known as OncoSeed™, is currently used at the 
RSCH. The physical characteristics o f the 4.5 mm x 0.8 mm seed consist o f a silver 
rod carrier; with 1-125 adsorbed on a silver-halide rod (i.e. surface distributed) and 
contained in a 0.05 mm thick titanium shell, with minimum and maximum source 
strength o f 7.07 MBq (0.19 mCi) and 37.37MBq (1.01 mCi), and a laser welded semi-, 
circled end design. Figure 4.1 shows the OncoSeed™ designed and manufactured by 
Amersham Pic., which merged with the urology business (cryotherapy) o f Galil 
Medical Ltd. Therapy units, and in 2004 acquired by GE Healthcare to create leaders
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in prostate cancer disease management. Other brachytherapy seeds produced by GE 
Healthcare include: TheraSeed™ Palladium-103 Implants and the new EchoSeed™ 
Iodine-125 seeds.
0.5 mm 1-125 coated orto 0.06 mm ttnckt z Titanium CeqsuleI .1 15 0.8 mm
3.0 mm
4.5 mm
Figure 4.1: Model 6711 OncoSeed™
4.3 Previous experimental measurements
Since the 1980s, the 1-125 seed Model 6711 has been well-investigated using various 
theoretical, calculated and measured methods. For example, for the Model 6711 seed, 
Williamson [25] conducted theoretical evaluation o f dose distribution in water with 
success in estimating dose rate at distance as small as 1mm from the seed centre. The 
software modelling also simulated the dose anisotropy arising from the titanium 
encapsulation and internal components o f the seed. The angular normalized dose and 
exposure for degrees o f 0° to 90° was also compared with measured data. Furthermore, 
a comparison o f measured and calculated dose rates in water [21] includes 
experimental dose measurements in liquid and solid water. The Monte Carlo 
calculations demonstrate that use o f a solid-water measurements medium 
progressively underestimate the specific dose rate constant by 4.1%, dose to water by 
4% at 1 cm and 16% at 5 cm for the model 6711 when compared with liquid water 
medium. This was corrected with relative correction factors. The transverse axis dose 
distribution data was displayed graphically between the distances o f 1 to 20 cm, 
where the results for range 0 to 1 cm were indistinguishable from the graphs (See 
Figure 4.2). This is particularly important in low-dose dosimetry measurements.
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I
i t
Dialane* (cm)
Figure 4.2: Model 6711 1-125 Seed Transverse Axis Dose Distribution Monte Carlo Data 1201
stiffened abtorbeble braided carrier Cutting groove Model 6711 seed
Spacing Jig
Figure 4.3: Model 7000 RAPID Strand™
To further improve the efficiency o f the brachytherapy implant operation, Amersham 
produced the RAPID Strand™ Iodine-125 seeds Model 7000. The RAPID Strand™ is 
made o f 11 violet coloured biologically absorbable suture seeding spacers and 10 
Model 6711 seeds spaced at a fixed distance within an absorbable braided carrier, 
stiffened and then sterilised by ethylene oxide. (See Figure 4,3). The stiffened 
absorbable braided carrier holds seeds in place in the tissue being treated to enable 
proper placement and to minimise seed movement. Absorption o f the carrier material 
is essentially complete between the 60*'^  and 90^ '^  days after implantation. [129].
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4.4 Current consensus values
The anisotropy function will be examined in the study o f the 6711 OncoSeed™. The
2-D anisotropy function as defined in Equ.( 4 ), describes the variation in dose as a 
function o f polar angle relative to the transverse plane. Table 4.1 shows the 
anisotropy function measured by Nath et al. in 1993 in a solid water phantom using 
TLD dosimeters [20]. Table 4.3 shows the ¥{r,0) o f a EGS4 Monte Carlo study by 
Capote et al. 2001 [18]. At angles over 40°, both Nath and Capote’s ¥(r,0) results 
show anisotropy values over unity close to the source.
To date, the EGS4 Monte Carlo dataset shown in Table 4.2 by Weaver 1998 [19] 
are the most uniform and complete as compared to the anisotropy functions by Nath et 
al. and Capote et oL, it has been recommended by the updated AAPM TG-43 as the 
consensus conF(7^^ values for seed model 6711.
R adius
(cm)
Polar angle  0 (d egrees)
0 10 20 30 40 50 60 70 80 90
1 0 .35 0 .4 2 3 0 .6 2 8 0 .826 0 .9 5 3 1 1.03 1.04 1.02 1
2 0 .439 0 .5 4 9 0 .6 9 0 .8 1 6 0 .9 0 3 0 .9 5 4 1 1.06 1.04 1
3 0 .452 0 .529 0 .6 1 2 0 .7 5 4 0 .8 8 8 0 .7 9 5 0 .877 1.07 1.07 1
4 0.521 0 .582 0 .6 8 8 0 .7 9 8 0 .842 0 .8 6 6 0 .935 0 .9 6 9 0 .998 1
5 0 .573 0 .6 0.681 0 .7 9 3 0 .8 8 8 0 .9 0 3 0 .922 0 .9 1 5 0 .9 8 5 1
Table 4.1: F(r, $) of Seed Model 6711 by Nath 1993 [20]
R adius
(cm )
Polar an g le  0 (d egrees)
0 10 20 30 40 50 60 70 80 • 90
1 0 .370 0 .5 3 7 0 .7 0 5 0 .8 3 4 0 .9 2 5 0 .972 0.991 0 .9 9 6 1 1
2 0 .442 0 .580 0 .7 2 7 0 .8 4 2 0 .9 2 6 0 .970 0 .987 0 .9 9 6 1 1
3 0 .488 0 .609 0 .7 4 3 0 .8 4 6 0 .9 2 6 0 .969 0 .987 0 .9 9 5 0 .999 1
4 0 .520 0 .630 0 .7 5 2 0 .8 4 8 0 .9 2 8 0 .969 0 .987 0 .9 9 5 0 .999 1
5 0 .550 0 .645 0 .7 6 0 .8 5 2 0 .9 2 8 0 .969 0 .987 0 .9 9 5 0 .999 1
Table 4.2: Consensus AAPM F(r, 0) of Seed Model 6711 by Weaver 1998 [19]
R adius
(cm )
Polar angle  0 (d egrees)
0 10 20 30 40 50 60 70 80 90
1 0 .3 1 3 0 .482 0.701 0 .8 4 0 0 .9 2 8 0 .989 1 .025 1 .039 1.042 1
2 0 .423 0 .574 0 .7 5 3 0 .8 5 7 0 .9 2 9 0.981 1 .014 1.031 1.036 1
3 0 .4 7 5 0 .620 0 .7 7 4 0.861 0 .9 1 7 0 .965 1.000 1 .017 1.028 1
4 0 .5 1 4 0 .6 5 3 0.791 0 .8 6 9 0 .9 2 5 0 .968 0 .9 9 9 1 .017 1.024 1
5 0 .565 0 .6 7 5 0 .802 0 .8 7 4 0 .9 2 9 0 .969 0 .9 9 8 1 .014 1.023 1
Table 4.3: F(r, 0) of Seed Model 6711 by Capote 2001 [18]
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4.5 Percentage difference of anisotropy functions
Radius
(cm )
Polar angle  0 (d egrees)
0 10 20 30 40 50 60 70 80 90
1 -5 .4 -21 .2 -10 .9 -1 .0 3 .0 2 .9 3 .9 4 .4 2.0 0 .0
2 -0 .7 -5 .3 -5.1 -3.1 -2 .5 -1 .7 1.3 6 .4 4.0 0 .0
3 -7 .4 -13.1 -17 .6 -10 .9 -4.1 -18 .0 -11.1 7 .5 7.1 0 .0
4 0.2 -7 .6 -8 .5 -5 .9 -9 .3 -10 .6 -5 .3 -2 .6 -0.1 0 .0
5 4.2 -7.0 -1 0 .4 -6 .9 -4 .3 -6 .8 -6 .6 -8 .0 -1 .4 0 .0
Table 4.4: F(r,0) of Seed Model 6711 Percentage difference Nath vs. Weaver
Radius
(cm )
Polar angle  0 (d egrees)
0 10 20 30 40 50 60 70 80 90
1 -15 .4 -10 .2 -0 .6 0.7 0.3 1.8 3 .4 4 .4 4.2 0 .0
2 -4 .3 -1 .0 3.6 1.8 0 .3 1.1 2 .8 3 .5 3 .6 0 .0
3 -2 .6 1.9 4.2 1.8 -1 .0 -0 .4 1.3 2.2 2 .9 0 .0
4 -1 .2 3 .7 5.1 2 .5 -0 .4 -0.1 1.3 2 .2 2 .5 0 .0
5 2 .8 4 .7 5.5 2.6 0.1 0.0 1.1 1.9 2 .4 0 .0
Table 4.5: F (r,^  of Seed Model 6711 Percentage difference Capote vs. Weaver
Table 4.4 shows the difference o f up to 21% difference during the comparison o f 
¥(r,0) o f seed Model 6711 between Nath and Weaver’s published values. The 
differences are found to be higher at distances close to the seed (1 cm to 3 cm). 
Limited number o f experimental data were available due to the practical difficulties in 
measuring dose at close distance from the source.
Table 4.5 shows the percentage difference o f between Capote’s and Weaver’s 
published values. For values above polar angle o f 30° the difference is found to be 
less than 5%. The maximum difference o f 15% was found at distance o f 1 cm and 0°. 
Again, the largest differences are found at distances below 2 cm. According to the 
author, the insufficient knowledge o f  the source structure is accountable for the 
discrepancies observed [18].
The large difference in F(r, 0) will have a severe effect on the dose rate according to 
the dose rate equation (Equ. ( 8 )).
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In the case o f a typical treatment, where Sk=0.578 cGy cm^h'*, A =0.98 cGy cm^ / U
h, g(r) and is unity. By adopting the ¥(ro,6Q) result o f Weaver (0.37) and
Capote (0.313) yields the dose rate D{i%6) o f 0.209 cGy h '' and 0.177 cGy h"' 
respectively. To achieve a dose o f 2 Gy would require the treatment time of 954 hours 
according to Weaver and 1128 hours according to Capote. When the same treatment 
time (954 hours) is adopted, this is equivalent to 2 Gy (Weaver) and 1.63 Gy (Capote), 
which result in 15.40% under-dose. This is a severe error where the prescribed dose 
can be 15% lower than expected. According to Capote’s calculation, in the case where 
the treatment time is 1128 hours W eaver’s dose rate would yield 2.7 Gy, equivalent to 
15% over-dose. Notice that all o f  these values are very significant in excess o f what 
would be tolerated in external beam therapy. The main reason that they may be 
accepted in brachytherapy is probably that the short range o f radiation means that 
organs at risk outside the PTV are unlikely to be adversely affected.
Previous experimental measurements are in error by up to 21% and Monte Carlo 
calculations are up to 15%. The large differences in anisotropy functions found in 
both Nath and Capote’s results suggest that further investigation in distances close to 
the seed is required. With the predicted precision in relative measurements o f «3%, 
the use o f our gel dosimetry measurement may be the solution to the dosimetric data 
required at close proximity to the seed and provides the rationale for this study.
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Chapter 5 Simulation and Experimental Measurements of the 
1-125 Model 6711 OncoSeed™
5.1 MCNP Monte Carlo Simulation
5.1.1 MCNP Model of 6711 Seed
All MCNP simulations discussed in the thesis aimed to fulfil the recommendations o f 
the updated AAPM TG-43 recommendations for Monte Carlo studies. The degree of 
fulfilment o f the recommendations are summarised in Table 5.1.
Figure 5.1 shows the cross-section view of the MCNP model o f 6711 seed. The 
numbers denote the unique identifier for different surfaces. The blue region represents 
the silver rod, green is the air gap and orange is the titanium capsule.
The MCNP input syntax file o f the 6711 seed model can be found in Appendix D.
Dosim etry calculations should be performed in a 
30cm^ liquid water phantom.
The M CNP simulation consist o f  a 30cm^ liquid 
water phantom
Enough histories to accom m odate for statistical 
errors i.e. less than 2% at r<5cm.
For 100 m illion histories, the statistical error o f  
3.32%  was found at 0°, 5cm. This can be 
improved further with more particle histories, (see  
Section 5.1.3.4)
Modern, post-1980 cross section libraries should 
be used, preferably those equivalent to the current 
NIST XCOM  database such as D LC -146 or 
EPDL97.
Photon library version m cplib02 and electron 
library version el03 were used. This is the default 
libraries used across the department and cannot be 
altered individually (see Section 5.1.2 and 5 .1.3.7)
Manufacturer published source dim ensions and 
com positions o f  encapsulation and internal 
com ponents should be verified.
External dim ensions can be measured by calliper, 
but internal structure cannot be verified
Point source m odelling is unacceptable. Line source approximation were adopted in the 
simulation
Table 5.1: Fulfilment of the APEM TG-43 Recommendations
Figure 5.1: Cross-section view of MCNP model of 6711 seed
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The F(;', ^  values o f the MCNP TG-43 based simulation are shown in Table 5.2, 
MCNP calculations were made o f the fluence in water, with the assumption that dose 
is proportional to fluence. Notice the anisotropy function shown in the consensus data 
(Table 4.2) and simulation (Table 5.2) follows a similar trend. The V{r,6) is defined as 
unity at the transverse plan (90°), where the value o f F(r, 0) decreases as r decreases or 
as 6^ approaches 0° or 180°.
Table 5.3 shows the difference in V{r,9) between the published and simulated data. 
The anisotropy flmctions are in good agreement (less than 5% difference) with the 
consensus results for polar angle above 40°. The difference is significant at polar 
angle o f 0° to 20°.
R adius
(cm )
Polar angle 0 (d eg rees)
0 10 20 30 40 50 60 70 80 90
1 0 .445 0 .5 7 4 0 .7 1 4 0 .8 0 9 0 .8 8 5 0 .9 4 5 0 .9 6 7 0 .9 7 5 0 .969 1
2 0 .579 0 .6 9 3 0 .7 8 8 0 .858 0 .9 0 4 0 .9 4 9 0 .9 8 0 0 .9 8 7 0 .990 1
3 0 .663 0 .7 5 6 0 .823 0 .870 0 .926 0 .963 0 .9 8 0 0 .9 9 5 0 .989 1
4 0 .660 0 .772 0 .8 4 6 0 .903 0 .938 0 .968 0 .9 7 9 0 .992 0 .997 1
5 0 .706 0 .802 0 .866 0 .8 9 7 0 .938 0 .9 6 5 0 .972 0 .9 9 8 0 .988 1
Table 5.2: 10 Million Particles MCNP Simulation F (r,^  of Seed Model 6711
R adius
(cm )
Polar angle  0 (d eg rees)
0 10 20 30 40 50 60 70 80 90
1 20 .3 6 .8 1.2 -3 .0 -4 .4 -2 .8 -2 .4 -2.1 -3.1 0 .0
2 31 .0 19 .4 8.3 1.9 -2 .4 -2.1 -0 .7 -0 .9 -1.0 0 .0
3 35 .9 24.1 10.8 2 .8 0 .0 -0 .6 -0 .7 0 .0 -1.0 0 .0
4 26 .9 22 .6 12 .5 6 .5 1.0 -0.1 -0 .8 -0 .3 -0.2 0 .0
5 2 8 .4 24 .4 13.9 5 .3 1.1 -0 .4 -1 .5 0 .3 -1.1 0 .0
Table 5.3: Percentage difference ofF(r,0) of seed model 6711 between published and MCNP
simulation
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Figure 5.2 shows the MCNP anisotropy results at 1 cm together with the results of 
other authors. Notice the Y{r,9) result by MCNP at polar angle 0° was significantly 
greater than other authors’ results. At polar angles above 30°, the results by MCNP 
matched closely with the AAPM consensus results by Weaver. Table 5.5 illustrates 
the percentage differences at I cm for different polar angles, at some polar angles the 
^{r,9) results by MCNP are in closer agreement with the consensus values than the 
results published by Nath and Capote. The average percentage differences over the 
polar angles from 0° to 80° for Nath, Capote and MCNP are: 6.1%, 4.6% and 5.1%.
« 0.8 
I
I  0,6
I " ‘ 5
0.2 4
a i
■  MCNP
■  Weaver (Consensus) 
ONath
X Capote
10 20 30 40 50
Polar Angle (°)
60 70 80 90
Figure 5.2: MCNP F (r,^  vs. other authors at 1 cm
Authors Polar angle 0 (d egrees)0 10 20 30 40 50 60 70 80 90
Nath 0 .350 0 .4 2 3 0 .62 8 0 .8 2 6 0 .953 1.000 1.030 1.040 1.020 1
C apote 0 .313 0 .482 0.701 0 .8 4 0 .928 0 .989 1.025 1.039 1.042 1
W eaver (C o n sen su s) 0 .370 0 .537 0 .7 0 5 0 .8 3 4 0 .9 2 5 0 .972 0.991 0 .996 1.000 1
MCNP 0 .4 4 5 0 .5 7 4 0 .7 1 4 0 .8 0 9 0 .8 8 5 0 .945 0 .967 0 .9 7 5 0 .969 1
Table 5.4: MCNP F(r,0) at 1 cm vs. other authors
Authors Polar angle 0 (d egrees)0 10 20 30 40 50 60 70 80 90
Nath -5 .4 -21 .2 -10 .9 -1 .0 3 .0 2 .9 3 .9 4 .4 2.0 0 .0
C apote -15 .4 -10 .2 -0 .6 0 .7 0 .3 1.8 3 .4 4 .3 4.2 0 .0
MCNP 20 .3 6 .9 1.3 -3 .0 -4 .3 -2 .8 -2 .4 -2.1 -3.1 0 .0
Table 5.5: Percentage difference comparison of F (r,^  with the consensus values at 1 cm
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Authors Polar angle 0 (d eg rees)0 10 20 30 40 50 60 70 80 90
MCNP 0 .579 0 .693 0 .7 8 8 0 .8 5 8 0 .9 0 4 0 .949 0 .9 8 0 .9 8 7 0 .99 1
W eaver (C o n sen su s) 0 .442 0 .5 8 0 0 .7 2 7 0 .8 4 2 0 .926 0 .970 0 .9 8 7 0 .9 9 6 1.000 1
Nath 0 .439 0 .549 0 .6 9 0 0 .8 1 6 0 .903 0 .9 5 4 1.000 1.060 1 .04 1
C apote 0 .423 0 .5 7 4 0 .7 5 3 0 .8 5 7 0 .929 0.981 1 .014 1.031 1.036 1
Table 5.6; MCNP F(r,^ vs. other authors at 2 cm
Authors Polar angle 0 (d egrees)0 10 20 30 40 50 60 70 80 90
MCNP 31 .0 19 .5 8 .4 1.9 -2 .4 -2 .2 -0 .7 -0 .9 -1 .0 0 .0
Nath -0 .7 -5 .3 -5.1 -3.1 -2 .5 -1 .7 1.3 6 .4 4 .0 0 .0
C apote -4 .3 -1 .0 3.6 1.8 0.3 1.1 2 .7 3 .5 3.6 0 .0
Table 5.7: Percentage difference comparison of F(r,0 with the consensus values at 2 cm
Table 5.7 shows the percentage differences at 2 cm of different authors against the 
consensus results. The results by MCNP diverged significantly from the consensus for 
polar angles 0° to 20°, whereas for angles 30° and above, the MCNP results presented 
here are in much better agreement. Between angles 60° to 80°, the results are closer to 
the consensus than those o f either Nath or Capote.
5.1.2 Source of discrepancies
Weaver et al found the seed model 6711 anisotropy data by Nath [20] published in the 
AAPM TG43 report [13] in 1995 exhibit large nonmonotonic variations that are 
unrealistic; particularly at 3 cm distance. Weaver suggests the experimental and/or 
interpolation uncertainly may be the source o f discrepancies in the data [19]. The 
author further summarises the uncertainties in the anisotropy function data as three 
main sources: uncertainty in the in-air measurements (dead time and room-scatter 
corrections), inaccuracy in the empirical angular-distribution equation, and 
uncertainty in the Monte Carlo calculations.
The differences between authors in anisotropy functions may also be due to the lack 
o f detailed source design information, other authors [130] have reported the 
importance o f detailed knowledge o f seed structure and had used different models to 
model the seed, one where photons are emitted only from the cylindrical core surface 
(partial emission), and another emitting photon from the whole surface (total 
emission).
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Investigations by Meigooni et al [131] shows that the anisotropy functions and 
anisotropy factors were considerably affected by the thiclmess o f the capsule wall 
thickness and end caps. In contrast, the radial dose function and the dose rate constant 
were not significantly affected by these parameters. The number o f histories used in 
the simulation is essential to obtain acceptable statistical dosimetric characteristics at 
larger distances.
The Monte Carlo cross-section libraries used in the department are potentially another 
factor accounting for the discrepancies between this work and previous authors. The 
default libraries for photon and electron transport are mcplib02 and el03. For low- 
energy photon transport with different cross-section libraries, the dose rate constant 
calculation by MCNP has been reported to show differences o f up to 9% lower in the 
range o f 20-100 keV when compared with other Monte Carlo codes [128]. Rentiers et 
al [119] also reported the radial dose function calculated with MCNP is up to 9% 
higher than other codes at 7cm from 1-125 seed and 17% at 5cm from a Pd-103 seed. 
All MCNP versions would require modification or replacement o f the default 
photoionization cross section [132] to meet the AAPM requirement. As the MCNP 
software is installed on the departmental network, it cannot be customized 
individually without compromising the requirement o f other MCNP users.
5.1.3 The factors affecting the anisotropy function
The dosimetric characteristics o f the source are largely dependent on the source 
geometry and internal construction. These factors include weld thickness, 
radioactivity carrier construction, the presence o f silver, source material and capsule 
wall thickness etc. This section investigates the different factors affecting the 
anisotropy function.
5.1.3.1 The effect of the capsule end caps
The MCNP simulation is aimed at testing the significance o f the titanium capsule end 
caps on the anisotropy function. Two simulations were conducted with and without 
the end caps. The simulations were based on photon interaction where a total o f 10 
million particles were simulated. Other conditions such as composition, dimensions o f 
the seed, water phantom and world volume remained the same.
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The anisotropy functions ¥{r,0) for seed model 6711 was calculated from the MCNP 
simulation results. The percentage differences between the anisotropy functions are 
shown in Table 5.8 and are presented graphically in Figure 5.3.
The percentage difference was most significant for F (r ,^  below polar angles o f 30°, 
with the highest difference o f 30.70% at radius o f I cm and polar angle o f 0°. The 
absence o f end caps and thus the lack o f photon scattering may be accountable for this 
difference, the effect is apparent at lower polar angle o f 0° to 30°. The result o f this 
simulation is in agreement with Reniers et al study [119] where the presence o f end 
caps has a negligible effect on the dose on the transverse axis. This is expected, as the 
low polar angles take in regions that are closer to the end caps.
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Figure 5.3: Graph of percentage difference of F(r, 9) in the presence and absence of 5 mm end
caps
R adius
(cm )
Polar angle 0 (d egrees)
0 10 20 30 40 50 60 70 80 90
1 30 .7 18.1 5 .0 1.8 0.8 0 .4 0.1 0.0 0.0 0 .0
2 14.7 10.9 3 .8 1.5 0.8 0.4 0.1 0.1 0.0 0 .0
3 9 .9 7.6 2 .6 1.5 0 .7 0.4 0.2 -0.1 0.0 . 0 0
4 6 .2 8.0 2 .8 1.4 0 .6 0 .5 0.2 0.1 0.0 0 .0
5 10.8 6 .3 2 .5 1.6 0 .6 0.4 0.2 -0.1 0.0 0 .0
Table 5.8: Percentage difference of F(r,0) in the presence and absence of 5 mm end caps
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5.1.3.2 The effect of end caps thickness
The effect o f end caps thiclmess on F(r, ^  was studied in this simulation by 
comparing the anisotropy functions o f 3.5 mm with 5.0 mm end caps. The simulation 
adopted the same parameters as Section 5.1.1 but with 3.5 mm instead o f 5mm oval 
shaped end caps. The percentage differences o f F(r, 6) at each distance and polar angle 
are presented in Table 5.9.
The percentage difference o f V{r,9) is noticeable at polar angle 0° to 20°, the 
percentage difference above 30° is negligible (< 0.2%). The percentage differences o f 
F(r,0) at each distance and polar angle are presented graphically in Figure 5.4. The 
average percentage difference peaks at polar angle 0° at 2.2% and gradually decreases 
to 0.45% at 20°, percentage difference beyond 30° is negligible.
R adius
(cm )
Polar angle 0 (d egrees)
0 10 20 30 40 50 60 70 80 90
1 -5 .6 -3 .0 -0 .7 -0 .2 -0.1 0 .0 0.0 0 .0 0 .0 0 .0
2 -2 .6 -1 .8 -0 .5 -0.1 -0.1 0 .0 0 .0 0 .0 0.0 0.0
3 -1 .4 -1 .3 -0 .5 -0 .2 -0.1 -0.1 -0.1 0 .0 0.0 0 .0
4 -0 .7 -0 .8 -0 .4 -0 .3 -0.1 -0.1 0 .0 -0.1 0.0 0 .0
5 -0 .7 -0 .8 -0 .3 -0.1 -0.1 0.0 0 .0 0 .0 0.1 0 .0
Avg.%
DIff
2 .2 1.5 0 .5 0 .2 0.1 0.0 0.0 0 .0 0.0 0.0
Table 5.9: Percentage difference of F(r,^ for 3.5 mm and 5 mm end cap thickness
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Figure 5.4: Graph of percentage difference of F(r,0 for 3.5mm and 5mm end cap thickness
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5.1.3.3 The effect of 1-125 source end coating
The 6 7 1 1  source consists o f a titanium capsule, which contains a 3.0mm long silver 
rod onto which 1-125  is adsorbed. The manufacturing process would include dipping a 
long silver rod into 1 -125  solutions before being machined into 3.0mm sources. For 
this reason, the ends o f the silver rod do not have 1-125  coating. This simulation 
assesses the degree o f difference in anisotropy with and without the 1-125  coating at 
both ends o f the silver rod.
The simulation is based on the same parameters as Section 5.1.1 without the 1-125 
coating at both capsule ends. A total o f 10 million particles were tracked.
The percentage differences o f F(r, ^  at each distance and polar angle are presented in 
Table 5.10. Notice the largest differences were recorded at 1 cm from the source 
centre. The absence o f the 1-125 1pm end coating has a significant effect on the 
anisotropy function. The percentage difference on comparing the anisotropy functions 
o f simulation with and without 1-125 coated ends was up to 8% with maximum 
differences saturated at polar angle o f 0°. A difference o f less than 3% was observed 
beyond 2 cm for polar angle 10° to 90°.
Radius Polar angle 0 (d eg rees)
(cm ) 0 10 20 30 40 50 60 70 80 90
1 7 .8 5.1 4 .2 3 .8 4 .9 4 .4 4 .6 3.0 2 .0 0 .0
2 4 .0 2 .4 1.8 1.1 2 .3 2 .0 1.9 2 .4 2 .7 0.0
3 1.4 0 .4 0 .9 2 .4 0 .9 0.9 2.0 1.2 1.9 0 .0
Table 5.10: Percentage difference of F(r,^ in absence of 1-125 coated ends
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5.1.3.4 Comparison of relative errors
The comparison o f the estimated relative errors (Equ.( 22) for each polar angle and 
distance from source centre involves simulating a 100 k, 10 million, 100 million 
particles under the same simulation specification as recommended by the AAPM TG- 
43 report. The percentage o f relative error (= i? x 100) o f 100 k, 10 million and 100 
million particles are shown in this section.
R adius
(cm )
Polar an gle 8 (d egrees)
0 10 20 30 40 50 60 70 80 90
1 23.1 6 .4 4 .0 3.0 2 .6 2 .3 2.1 2.1 2 .0 2 .0
2 43 .4 8.1 5 .4 4 .3 3 .6 3 .4 3.2 3 .0 2 .8 2 .8
3 100 .0 10.9 6.7 5 .4 4 .6 4 .7 4.0 4 .0 3 .7 3 .7
4 100 .0 14.1 8 .8 6 .3 5 .5 5.2 4.7 4 .7 4 .9 4 .3
5 74 .8 14.8 9.7 8.1 6 .8 6.1 5.7 5 .4 5 .7 5.6
Avg.% 68.3 10.9 6.9 5 .4 4 .6 4 .3 4 .0 3 .8 3 .8 3 .7
Table 5.11: Percentage relative error for 100 k particles
Radius
(cm )
Polar an gle 9 (d eg rees)
0 10 20 30 40 50 60 70 80 90
1 2.3 0 .6 0 .4 0 .3 0 .3 0.2 0.2 0 .2 0.2 0.2
2 4.0 0 .9 0 .6 0 .4 0 .4 0 .3 0 .3 0 .3 0 .3 0 .3
3 5 .9 1.0 0 .7 0 .6 0 .5 0 .4 0 .4 0 .4 0 .4 0 .4
4 8.1 1.3 0 .9 0 .7 0 .6 0 .5 0 .5 0 .5 0 .5 0 .5
5 10.6 1.5 1.0 0 .8 0 .7 0 .6 0.6 0 .6 0 .6 0 .5
Avg.% 6.2 1.1 0 .7 0 .6 0 .5 0 .4 0 .4 0 .4 0 .4 0 .4
Table 5.12: Percentage relative error for 10 million particles
R adius
(cm )
Polar angle  6 (d eg rees)
0 10 20 30 40 50 60 70 80 90
1 0.7 0 .2 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1
2 1.3 0 .3 0 .2 0.1 0.1 0.1 0.1 0.1 0.1 0.1
3 1.9 0 .3 0.2 0 .2 0.2 0.1 0.1 0.1 0.1 0.1
4 2 .5 0 .4 0.3 0 .2 0 .2 0 .2 0 .2 0.2 0.1 0.1
5 3.3 0 .5 0 .3 0 .3 0.2 0 .2 0.2 0.2 0.2 0 .2
Avg.% 2.0 0 .3 0 .2 0 .2 0.2 0.1 0.1 0.1 0.1 0.1
Table 5.13: Percentage relative error for 100 million particles
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The guideline for interpreting the percentage relative error i? is shown in Table 5.14, 
this is the percentage equivalent o f the interpretation given in Table 3.6. For the 100k 
particles simulation, the percentage error indicated that the quality o f the tally results 
at polar angle o f 0° is between the range o f 20% to 100% which signifies the results 
as “Factor o f a few” or “Garbage” . The percentage relative errors are generally 
“Questionable” under low polar angles and gradually become more reliable as polar 
angle increases. The results showed that the photon energy deposition at higher polar 
angles (i.e. at 90° to the seed) occur more frequently than at lower polar angles (i.e. at 
0° near the end caps). This trend is apparent, as the percentage results shown at 90° 
has the least percentage relative error at all distances from the source centre.
For the 10 million particles simulation, the same trend was observed (See Table 5.12) 
where the percentage relative error decreases as the polar angle increases. Reliable 
results at polar angle o f 0° (under 10%) were observed. Tally results for polar angle o f 
10° to 90° has percentage relative error below 2%. This indicates that the number of 
particles simulated has produced sufficiently reliable tally for polar angles o f 10° to 
90°, The overall number o f particles simulated must be increased in order for tally 
results at polar angle o f 0° to achieve the percentage relative error o f less than 2%.
The percentage relative error for the 100 million particles simulation showed a clear 
increase in reliability, with less than 0.5% percentage relative error for polar angle 
above 0° at all distances from source centre. With the exception o f tally results at (0°, 
4cm) and (0°, 5cm), all other tally results at other polar angles and distances have 
shown percentage relative error o f less than 2%. Since the dosimeter used in the gel 
dosimetry practical experiment (Section 5.6) is a cylinder o f diameter 6cm and height 
6.5cm, the MCNP results with 100 million histories will provide sufficient reliability 
and comparable to the practical experimental results.
R an ge of R (%) Quality of the tally
50% to 100% G arbage
20%  to 50% Factor o f a few
10% to 20% Q uestionable
<10% Generally reliable ex cep t for point detector
< 5% G enerally reliable for point detector
Table 5.14: Guidelines for interpreting the percentage relative error R [107]
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5.1.3.5 Comparison of 10 & 100 million particles histories simulation
The comparison o f statistical errors involves the simulation o f 10 million, 100 million 
particles. The ratio differences between the anisotropy functions are shown in Table 
5.15.
Increasing the number o f particles histories by a factor o f ten from 10 million to 100 
million resulted in an average decrease o f estimated relative error by a factor of
VÏÏÏ = 3.2 as described in Equ.( 21 ). The total simulation time for 100 million 
particles was 2725.24 minutes, equivalent to 45 hours 25 minutes or 1.89 days, while 
the simulation for 10 million particles was 273.67 minutes, equivalent to 4 hours 37 
minutes. In conclusion, with a small ratio difference o f 3.2, 10 million particles will 
produce generally reliable tally results, where the 100 million particle histories 
simulation will decrease the estimated relative error by three times at all polar angles 
and distance from source centre. The user must decide the trade off between accuracy 
and simulation time.
R adius
(cm )
Poiar an g le  0 (d egrees)
0 10 20 30 40 50 60 70 80 90
1 3.2 3.2 3.1 3 .0 3 .3 3.3 3.0 3 .3 3.3 3 .3
2 3.2 3.2 3.1 3.1 3.1 3.0 3.1 3.2 3.2 3.2
3 3.2 3.2 3.1 3.1 3.1 3.1 3.1 3 .2 3.1- 3.1
4 3.2 3.1 3 .2 3 .2 3 .2 3.1 3.1 3.1 3 .3 3.2
5 3.2 3.1 3 .2 3.1 3 .2 3 .2 3.1 3.1 3 .2 3.2
A verage 3 .2 3 .2 3.1 3.1 3 .2 3.1 3.1 3 .2 3 .2 3.2
Table 5.15: Ratio of percentage relative error for 10 million and 100 million particles
Radius
(cm )
Polar angle  0 (d egrees)
0 10 20 30 40 50 60 70 80 90
1 0.0 0 .2 0 .3 0.0 -0.1 0 .4 -0.2 0 .6 0.2 0.0
2 0 .4 1.4 0 .0 -0.1 -0 .7 -0.2 0 .6 0.1 -0.1 0.0
3 0 .8 2 .0 0 .3 -0 .9 0 .4 1.0 0 .5 1.1 -0 .6 0.0
4 -5 .0 0 .3 0 .3 1.1 0.8 0 .9 0.2 0 .2 0.2 0.0
5 -3 .0 1.1 0 .9 -0 .3 0 .6 0.1 -0 .4 0 .8 -0 .7 0.0
A verage -1 .4 1.0 0 .4 -0.1 0.2 0 .4 0 .2 0 .6 -0 .2 0 .0
Table 5.16: F(r,û) Percentage difference 10 million vs. 100 million particles
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5.1.3.6 The ten statistical tests results
The ten statistical tests for 10 million particles histories were conducted at different 
distances from source centre at 1 to 5cm in 1 cm intervals. The results showed that 3 
out o f the 5 tally bins have not passed all ten statistical checks, the failure occurred at 
3 cm, 4 cm and 5 cm. 1 out o f 5 tally bins had relative errors greater than 
recommended, the failure occurred at 5cm from source centre. The detail results are 
shown in Figure 5.5.
r e s u l t s  o f  10 s t a t i a c i c a l  c h e c k s  f o r  t h e  e s t lw a te c i  e u so e c  f o r  th e  C ttiiy  f l u c t u a t i o n  c h a r t  ( t f c )  b l n  o f  t a l l y  3c»
—m ean— la n c e  o f t h e  v a r ia n c e ------- — i l o u r e o f m e r i t —
b e h a v io r b e h a v io r d e c r e a s e d e c r e a s e  r a t e d e c re a s e d e c r e a s e  r a t e v a lu e b e h a v io r
d e s i r e d random < 0 .10 y e s l / s q r t ( n p s ) l / n p s c o n s ta n t random
o b s e rv e d random 0 .0 6 yes c o n s ta n t random
p a s s e d ? yes
r e s u l t s  o f  10 s t a t i s t i c a l  c h e c k s  f o r  t h e  e s t im a te d  a n su e r  f o r  th e  t a l l y  f l u c t u a t i o n  c h a r t  ( t f c )  b i n  o f  t e l l y  4c»
—m ean— ------ v a r ia n c e  o f  th e  v a r ia n c e ------- — f i g u r e
b e h a v io r b e h a v io r v a lu e d e c re a s e d e c r e a s e  r a t e v a lu e d e c c e a a e d e c r e a s e  r a t e v a lu e b e h a v io r s lo p e
d e s i r e d random < 0 .1 0 y e s 1 /s c r r t  (nps) y es l / n p s c o n s ta n t random >3 ,00
o b s e rv e d random O.DS yea c o n s ta n t random
p a s s e d ? y es y e s y e s yea y es yes
r e s u l t s  o f  10 s t a t i s t i c a l  c h e c k s  l o t  t h e  e s t im a te d a n s o e r  f o r th e  t a l l y  f l u c t u a t i o n  c h a r t ( t f c )  b i n  o f  t a l l y  5cm
—mean— e r r o r _________ ------ v a r ia n c e  o f  t h e  v a r ia n c e ------ — f i g u r e o f  m e r i t —
b e h a v io r b e h a v io r v a lu e d e c r e a s e d e c r e a s e  r a t e v a lu e d e c re a s e d e c r e a s e  r a t e v a lu e b e h a v io r
d e s i r e d random < 0 .1 0 y e s 1 /s c r r t  (nps) c o n s t a n t random
o b s e rv e d random 0 .1 1 y e s c o n s t a n t random
p a s s e d ? y e s yea y es y es y es y es y es
Figure 5.5: The ten statistical checks at 3 cm (from top), 4cm and 5cm -  10 million histories
r e s u l t s  o f  10 s t a t i s t i c a l  c h e c k s  f o r  t h e  e s t im a te d  a n s v e r  f o r  t h e  t a l l y  f l u c t u a t i o n  c h a r t  ( t f c )  b l n  o f  t a l l y  3c»
------ v a r i a n c e  o f th e  v a r ia n c e ------- o f  m e ric  —
b e h a v io r b e h a v io r v a lu e d e c r e a s e d e c r e a s e  r a t e v a lu e d e c re a s e d e c r e a s e  r a t e v a lu e b e h a v io r s lo p e
d e s i r e d random < 0 .1 0 y e s l /3 C ir t(a p 3 ) l / n p s c o n s t a n t random > 3 .00
o b s e r v e d random 0 .0 2 c o n s ta n t random
p a s s e d ? y e s
r e s u l t s  o f  10 s t a t i s t i c a l  c h e c k s  f o r  t h e  e s t im a te d  a n s v e r  f o r  t h e  t a l l y  f l u c t u a t i o n  c h a r t  ( t f c )  b l n  o f  t a l l y  ■Sera
--m e a n -- — r e l a t i v e ------ v a r ia n c e  o f th e  v a r ia n c e — -— o f m e r i t - -
b e h a v io r b e h a v io r d e c r e a s e d e c r e a s e  r a t e v a lu e d e c re a s e d e c r e a s e  r a t e v a lu e to eh a v io r S lo p e
d e s i r e d random y ea l / s q r t t n p s ) y es l / n p s c o n s t a n t random
o b s e rv e d random 0 .0 3 c o n s t a n t random
p a s s e d ? y e s
r e s u l t s  o f  10 s t a t i s t i c a l  c h e c k s  f o r  t h e  e s t im a te d  an sw er f o r  t h e  t a l l y  f l u c t u a t i o n  c h a r t  ( t f c )  b i n  o f  t a l l y  Sc»
—mean— — r e l a t i v e ------ v a r ia n c e  o f t h e  v a r ia n c e ------ — f i g u r e  o f  m e r i t —
b e h a v io r b e h a v io r vH lue d e c r e a s e d e c r e a s e  r a t e v a lu e d e c re a s e d e c re a s e  r a t e v a lu e  b e h a v io r s lo p e
d e s i r e d random < 0 .1 0 i / s c i r t ( n p 3 ) yea l /n p s c o n s t a n t  random > 3 .0 0
o b s e r v e d random 0 .0 3 c o n s t a n t  random
p a sse d ? y e s y ea y e s yea y es y e s  yes yes
======-—===:
Figure 5.6: The ten statistical checks at 3 cm (from top), 4cm and 5cm -  100 million histories
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The test for probability density function slope failed at 3 cm, 4 cm and 5 cm from 
source centre. The desired value was >3.00 and the observed value was 0.00, hence 
the test failed. The failure indicates that insufficient number o f histories have been 
calculated in order to justify the CLT, where the SLOPE must be above 3. The relative 
error value test failed at 5cm where the desired value was <0.10 (10%) and the 
observed value was 0.11 (11%). Ail o f these failures were resolved by increasing the 
number o f particle histories simulated to 100 million (See Figure 5.6). The probability 
density function slope value observed was greater than 3.00 at 10.00 for 3 cm, 4 cm 
and 5 cm. The relative error at 5cm decreased to 0.03 (3%).
5.1.3.7 Cross-Sections Library
The default MCNP photon cross-section library used in the department is version 
mcplib02, which is not confirmed to meet the requirement o f the AAPM TG-43 report. 
For this reason, mcplib03 was installed on a local computer to match the current NIST 
XCOM database. The photon cross-section library version mcplib03 is equivalent to 
EPDL97 as recommended by the AAPM.
A comparison has been conducted for anisotropy functions obtained using the 
mcplib02 and mcplibOS. The results showed no difference and had produced identical 
results for energy deposition and relative errors. This eliminates one possible 
explanation o f the outstanding differences between this simulation and the consensus 
values.
7 4
C h a p t e r  5 S im u l a t io n  a n d  E x p e r im e n t a l  M e a s u r e m e n t s
5.2 GEANT4 Monte Carlo Simulation
5.2.1 GEANT4 Model of the 6711 Seed
GEANT4 Monte Carlo code is used in the simulation o f a three-dimensional dose 
mapping o f the 6711 seed. The simulation consists o f a lOcm^ cube water phantom 
where the 6711 seed is embedded at the centre (See Figure 5.8). A total o f 10 million 
particles were tracked and the dose data is recorded with millimetre precision (1 pixel 
== 1 mm). The three-dimension dose map enables the calculation o f the anisotropy 
functions at different distances and polar angles from the source centre. The results 
are presented in Table 5.17.
R adius
(cm )
Polar angle 0 (d eg rees)
0 10 20 30 40 50 60 70 80 90
1 0 .79 0 .7 9 0 .78 0 .9 8 1.05 1.09 1.15 1.08 1.09 0 .79
2 0 .72 0 .7 2 0 .88 0.91 0 .96 1.09 1.12 1.05 1.03 0 .72
3 0 .7 4 0 .6 9 0 .8 4 0 .9 9 1.02 0 .98 1.04 1.02 1.01 0 .7 4
4 0 .5 4 0 .7 5 0 .80 0 .82 0 .86 0 .99 0 .9 7 0 .97 0 .95 0 .5 4
5 1.34 1.54 0 .92 1 .04 1.10 1.15 0 .9 7 1.10 0 .97 1.34
Table 5.17: Anisotropy function of 6711 seed 10 million particles
Authors Polar an gle 0 (d eg rees)0 10 20 30 40 50 60 70 80 90
GEANT4 0 .8 0 .8 0 .8 1.0 1.0 1.1 1.2 1.1 1.1 1.0
W eaver 0 .3 0 .5 0 .7 0 .8 0.9 1.0 1.0 1.0 1.0 1.0
% Difference -1 37 .7 -51 .3 -8 .7 -15 .4 -12 .9 -12 .6 -16 .3 -8 .6 -9 .4 0 .0
Table 5.18: Percentage difference comparison of F/r, B) with the consensus values at 1 cm
Authors Polar an gle 0 (d eg rees)0 10 20 30 40 50 60 70 80 90
GEANT4 0 .7 0 .7 0 .9 0 .9 1.0 1.1 1.1 1.1 1.0 1.0
W eaver 0 .4 0 .6 0 .7 0 .8 0.9 1.0 1.0 1.0 1.0 1.0
% Difference -62 .7 -23 .9 -2 1 .4 -8.1 -3 .7 -12 .3 -13 .2 -5 .8 -3 .5 0 .0
Table 5.19: Percentage difference comparison of F(r, 0) with the consensus values at 2 cm
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5.2.2 GEANT4 Results Analysis
In the pilot study o f the Model 6711 OncoSeed^'’^ , the anisotropy functions showed 
considerable variation from the consensus data. The differences at lower polar angles 
at all distances from source were apparent. The anisotropy functions were consistently 
higher than the consensus values at most polar angles and distances. Despite the 
results showing much fluctuation with respect to polar angles, a general trend can be 
observed.
The sources o f discrepancies are principally due to the factors such as the 6711 
geometric specification, elemental composition, program structure and particles 
tracking at low energies. The use o f GEANT4 in this study is relatively new; there are 
no published data with GEANT4 applications on the Model 6711 OncoSeed^^i. In 
addition there is less departmental experience in the use o f GEANT4 and the results 
may reflect an incomplete understanding o f this large and complex code base. Since 
GEANT4 is an open source Monte Carlo code, further use o f this Monte Carlo code 
and participation in the user group forum may improve the accuracy o f this simulation.
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Figure 5.7: GEANT4 F(r, ff) vs. consensus values at 1 cm (left) and 2 cm (right)
Figure 5.8: GEANT4 3-D view of 1-125 seed simulation
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5.2.3 Global Comparison
Figure 5.9 shows the MCNP, GEANT4 and consensus anisotropy functions 
comparison at I cm and 2 cm respectively. At 1 cm, the MCNP values matched well 
with the consensus values and the GEANT4 values are consistently higher than both 
the MCNP and consensus values. At 2 cm, both the GEANT4 and MCNP values are 
significantly higher than consensus values at lower polar angles. The MCNP values 
are in excellent agreement at higher polar angles while the GEANT4 values showed 
some fluctuation.
5.2.4 Conclusions
In this section, the I-I25 Model 6711 OncoSeed™ brachytherapy seed has been 
studied in detail through MCNP and GEANT4 Monte Carlo calculations.
At present, there are insufficient data in the literature to provide an extensive 
uncertainty analysis for Monte Carlo-derived anisotropy functions. Further 
investigation is required, particularly in the area o f identifying the physical parameters 
to which Y{r,6) is sensitive. In this study, the effect o f capsule end-cap thickness, 
source specification and statistical errors were explored.
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Figure 5.9: F(r, 0) of MCNP, GEANT4 and consensus values at 1 cm (left) and 2 cm (right)
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5.3 Optical-CT System Scanning Preparation
The Optical-CT system is based in the optical lab at the department o f physics, 
University o f Surrey. This section briefly describes our in-house Optical-CT system 
and the process o f pre-scan preparation, acquiring projection images and final image 
reconstruction. The Optical-CT system consists o f an ultra bright LED light source, a 
scanning tank with motorised platform and a low-noise air-cooled charge-coupled 
device CCD camera (Orca 1024 BTII, Hamamatsu Photonics, Japan, part C4742-98- 
26KAG). The characteristics o f this in-house Optical-CT system have recently been 
published [80, 133]. All the components are bolted onto the workbench to avoid any 
accidental movement to the system. The system setup is shown in Figure 5.10.
Scanning Procedures
Since this is a cold CCD camera, before the image scanning takes place, the camera 
controller must be switched on 30 minutes in advance to enable the camera to reach 
the operating temperature o f -50°C. See Figure 5.11.
Once the CCD camera has reached the operating temperature, connect all the serial 
cables from the motor controllers to the scanning tank motor. Switch on the LED 
controller. Clean the scanning tank windows from any dust particles with the 
dedicated lens wipes.
Figure 5.10: Optical-CT system setup
Keys:
1) CCD Cam era, 2) Scanning tank, 3) LED light source, 
4) LED controller.
Figure 5.11: CCD camera 
controller
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Figure 5.12: PRESAGE™ dosimeter top view (left), PRESAGE™ dosimeter side view inside
scanning tank (right)
C.i*l O f  7; lo in o g f a p h y  c o n t io l  w iiu k iv
Current status: jbiadive
Frame Projection
No. pioieetionj: j
N o » ¥ « 09«  p «  pioiecliort p  
Wobble arrpttudefrm l [ 5
Wobble tuncbon engaged? r
Image baeeNeneme
Tomvartviog
Figure 5.13: Optical-CT scanning software (top). Tomography control window (bottom)
Centre the PRESAGE™ sample onto the scanning plate and secure it with three bolts 
(See Figure 5.12 left). With the drainage tap at the closed position, fill the scanning 
tank with the high reflective index match liquid. Lower the scanning platform into the 
scanning tank allowing it to sit securely on the motorised turntable platform (See 
Figure 5.12 right). Remove any visible bubbles and dust particle that would cause 
image distortions.
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Switch on the Optical-CT computer system and start-up the in-house IDL-based 
scanning software program. (See Figure 5 , 1 3  left)
Press the “Acquire single image" button to acquire an image and use the square region 
selection mask to select the region o f interest for scanning. On the Window menu 
select tomography control, the tomography control window will appear, (See Figure 
5,13 right)
The number o f projections and the directory to store the tomography images can be 
specified here. The current status shows the status “ inactive" which signifies the 
tomographic scans has not commenced. Press the “OK" button to save the settings 
and exit the control window. On the Acquire menu select tomography. The 
tomographic scan will commence automatically. The images will be stored at the 
predefined directory. During the scan, the Optical-CT computer system will 
synchronise the rotation o f the turntable platform in the scanning tank with the CCD 
camera shutter.
0  015
2 0,010
« 0 .005
0  000
-2 0 - 1 0 0 10 20
Transverse Distonce From Seed Centre (mni)
Figure 5,14: Optical-CT single projection, total of 1000 projections over 180° (top left), Optical- 
CT single slice reconstruction, pixel size: 0,36 m m \ slice thickness: 0,18 mm (top right) and line 
profile across reconstruction image (bottom)
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A total o f 1000 projections are stored, where each projection image is equivalent to a 
rotation o f 180 4- 1000 = 0.18°. The duration for a complete tomographic scan would 
be around one hour, some scans were also conducted with 400 projections to shorten 
overall scanning time. Single projection images (Figure 5.14) are stored automatically 
in numerical order. After tomographic scanning has ended, the 1000 projections 
would be compiled and ready for 3-D reconstructions using the in-house IDE 
reconstruction program and adopting the filtered backprojection method. An example 
o f a single slice reconstruction image is shown together with a line profile across the 
reconstruction image (See Figure 5.14). Note that for the Optical-CT images o f 
PRESAGE™ dosimeters used in this report assumed a linear relationship between 
optical density and dose, hence no calibration was conducted for different batch of 
PRESAGE™ dosimeters. This assumption was based on our preliminary studies of 
PRESAGETM using spectrophotometry [97].
81
C h a p t e r  5 S i m u l a t i o n  a n d  e x p e r i m e n t a l  m e a s u r e m e n t s
5.4 Radiochromic Film Preparation
The GAFCHROMIC® EBT film sized 25 x 20 cm was cut into 2.5 x iQ cm rectangles. 
Each sheet formed twenty 2.5 x 10 cm rectangles and the rectangles were labelled. 
The label allowed the film to be scanned in the same orientation in order to minimise 
the polarisation effects, which previous authors had reported with variations o f up to 
8% [134]. Gloves were worn during the handling o f films to reduce fingerprints and 
dusts that may affect the film optical clarity.
As recommended by the AAPM TG-55 [135], radiochromic films should be 
calibrated using a well-characterised uniform field. The GAFCHROMIC® EBT films 
were inserted into a PRESAGE™ dosimeter to provide a full scatter condition during 
all exposures. The absolute dose and dose rate were noted for each radiation exposure, 
and this allowed direct film calibration within the dose range o f interest.
The GAFCHROMIC® EBT films were exposed with photons at 6 MV at 200 MU/min 
(1 MU = 1 cGy), with a 10 x 10 cm field at 100 FSD, to the surface o f 1.5cm of solid 
water on top o f the films and 5 cm below the film. Following a 12 hours stabilising 
period, the exposed films were scanned by a flatbed scanner (Model: Epson 
Expression 1680 Pro, Seiko Epson Corporation) to produce the 42-bits RGB TIFF 
raw images. Figure 5.15 shows the raw images against dose; notice the darkening of 
colour as the dose increases. The results o f optical density against absorbed dose for 
RGB red colour channel are shown in Table 5.20.
O.OGy 0.1 Gy 0.2Gy 0.3Gy 0.5Gy 0.7Gy I.OGy
1.5Gy 2.0Gy 2.5Gy 3.0Gy 3.5Gy 4.0Gy 4.5Gy
Figure 5.15: Raw images of exposed GAFCHROMIC® EBT films at 0.0 to 4.5 Gray
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Monitor
Units
D o se
(Gy)
Optical D ensity  
(R ed C hannel)
Optical D ensity  
(G reen C hannel)
0 0.0 0 .00 0.01
10 0.1 0 .02 0 .00
30 0 .3 0 .07 0 .02
50 0 .5 0 .12 0 .0 4
70 0.7 0 .17 0 .0 5
100 1.0 0 .22 0 .08
150 1.5 0.31 0.11
200 2.0 0 .3 8 0 .1 4
250 2 .5 0 .4 4 0 .17
300 3.0 0 .50 0 .20
Table 5.20: Raw scanner output from the red channel as a function of dose
55 1 
50 
45 4 
40 
35 
30 
25 - 
20  -  
15
0 0.5 1.5 Dose (Gy) 2.5
Figure 5.16: Raw scanner output from the red channel as a function of dose delivered to EBT
films using 6MV x-rays.
QO
0
0
0
♦  red cal 
■ green  cal0
0
0 .
O P #
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Figure 5.17: Calibration curve of GAFCHROMIC® EBT films
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The raw red channel signals were translated into the net optical density (OD) by 
deriving from the OD o f an exposed film from that o f an unexposed film using an in- 
house program developed by Thomas et al [58], According to the recommendations of 
the AAPM TG-55 [135], the sensitive emulsion layers o f radiochromic films absorbs 
most strongly in the red wavelength at 660 nm; as a result there is a great variation o f 
net optical density as a function o f dose in the red channel (see Figure 5.17). For all 
GAFCHROMIC® EBT films experiments used in this section, the RGB red channel 
will be extracted from the raw TIFF images in order to calibrate the irradiated 
GAFCHROMIC® EBT films as a function o f dose.
5.5 Thermoluminescence Dosimetry Preparation
The TED reader (TOLEDO, Surrey, UK) used was developed by Pitman Instrument 
Ltd and designed by M. Robertson [136] at the University o f Surrey. Throughout all 
experimental procedures, tweezers were used to handle the TLDs, the reason is to 
prevent any dirt or grease that would be burn into the TLD materials during readout. 
This would reduce light output and in result give incorrect readings. The TLDs are 
stored in a numbered plastic tray therefore each TLD is used according to its number. 
The numbering is important since the TLDs have slightly different sensitivity and the 
relative sensitivity (calibration factor) for each TLD chip must be obtained in order to 
calculate the absorbed dose.
Before the initial TLD readout, the TLD reader was connected to a nitrogen supply. 
The nitrogen flow was set at 400ml/min using the flow meter on the front panel o f the 
reader. While the TLD drawer was opened, calibration mode was selected and the 
internal light source check was conducted. The mean o f ten readings should give 
10396 ±0.5%. The drawer is then closed and checked that the dark reading is around 2. 
The heat mode is selected and sensitivity set at the default setting o f 12200 with 
decimal 3. This settings is designed to give a reading that approximates to cGy and 
ranges from 1 cGy to 10 Gy. The TLD reader is now setup ready for readout.
8 4
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5.5.1 TLD Experimental Procedures
Each individual TLD has different sensitivity to radiation; this section describes the 
process o f TLD calibration and how to relate the TLD readings to dose. A total of 
twelve TLDs were irradiated during this experiment. The TLD chips are first given a 
reference number and annealed ready for irradiation. The twelve TLDs were loaded 
onto the rotating carousel to allow uniform irradiation by a U-shaped Sr-90 p-particle 
source. The radioactivity record shows that in May 1982, the LiF TLD chips received 
a dose o f 8.44 x 10’^  Gy in 25 minutes. After irradiation has finished, the irradiated 
chips are readout and the relative sensitivity (calibration factor) is calculated. Given 
that the half-life o f the Sr-90 source is 28.78 years, use Equ. ( 27) to calculate the 
current dose rate from the source.
Old dose rateDose Rate = 1 number o f half lives (27)
The current dose rate together with irradiation time will yield the actual dose 
delivered to the whole batch o f TLD chip. Table 5.21 shows the calculated calibration 
factor, which is the ratio o f the actual dose delivered and the measured dose. This 
factor is later used to multiply the individual TLD readings to compensate for the 
differences in sensitivity.
Chip No M easure D o se  (cG y) Actual D o se  (cGy) Calibration Factor
1 0 .4 2 5 0 .3 8 2 1.11
2 0 .440 0 .3 8 2 1.15
3 0 .459 0 .3 8 2 1.20
4 0 .440 0 .3 8 2 1.15
5 0.491 0 .3 8 2 1.29
6 0 .4 4 4 0 .3 8 2 1.16
7 0 .4 5 5 0 .3 8 2 1.19
8 0 .4 5 4 0 .3 8 2 1.19
9 0 .5 2 8 0 .3 8 2 1.38
10 0 .4 4 3 0 .3 8 2 1.16
11 0 .4 1 7 0 .3 8 2 1.09
12 0.431 0 .382 1.13
Table 5.21: Calculation of calibration factor
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A total o f 12 LiF TLD chips (Dimension: 1 mm x l mm x 6 mm) were irradiated at 
intervals o f 5 minutes. The measured dose results obtained from the TLD reader are 
compared with the theoretical calculated dose as shown in Table 5.22. The calculated 
dose and measured dose matched closely, with average percentage difference o f 2.4%. 
Chip number 9 seems to have a large percentage difference when compared to the 
calculated dose. The sensitivity o f each chip may vary and respond differently due to 
the impurity in the crystal during the manufacturing process.
1.400 1
1.200 -
><
? 1.000 -
m
o 0.800 -Q
% 0.600 -n
0.400 -
<
0.200 -
0.000 -
♦  Calculated Dose 
■  Measured Dose
10 20 30 40 50 60
Exposure Time (Mins)
70
Figure 5.18: Graph of Absorbed Dose Vs Measured Dose
Chip
Number
Exposure Time 
(Mins)
Calculated D o se  
(cG y)
M easured D ose  
(cGy)
P ercen tage Difference 
(%)
1 5 0 .0 9 5 0 .100 -4 .5
2 10 0.191 0 .189 0 .9
3 15 0 .286 0 .287 -0.2
4 20 0 .382 0 .392 -2 .5
5 25 0 .477 0 .453 5.2
6 30 0 .573 0 .559 2 .4
7 35 0 .668 0 .647 3.2
8 40 0 .7 6 4 0 .727 4.8
9 45 0 .859 0 .693 19.3
10 50 0 .9 5 5 0 .944 1.1
11 55 1.050 1.045 0.5
12 60 1.146 1.163 -1 .5
A verage 2 .4
Table 5.22: Comparison of Measured and Calculated Dose
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5.5.2 Presage™ TLD Experiment
A cylindrical shaped PRESAGE™ sample was prepared at the workshop for a 
dosimetry experiment involving TLDs. The dimension o f the PRESAGE™ dosimeter 
is 3 cm in diameter and 6.5 cm in height. A centre hole with diameter 1.3 mm was 
drilled to the depth o f 1.5 cm where the brachytherapy seed would sit. Six addition 
holes were drilled to the same depth at 1 cm from the source centre and a further six 
holes were drilled at 2 cm. The 6711 seed was implanted into the PRESAGE™ 
dosimeter and left in the lead safe to irradiate for a total o f 20 days, 23 hours and 37 
minutes (503.62 hours). Using the AAPM TG-43 recommended 2D formalism for 
dose rate calculation (Equ. ( 8 )).
b(r,0)  = \  ■ F(r,6) ■ g(r)
(2D Formalism)
1 cm 2 cm
s , 0.571 0.571 cG y h’^
A 0 .98 0 .98 cG y cm^ / U h
gr (C on sen su s) 1 0 .814
F ( r ,^ ) 1 1
G(/",^)
G(To,6>o) 0 .9 7 6 0 .244
0 .5 4 6 0 .115 cG y h'^
In 11 /11 /2005 16:55
Out 0 2 /1 2 /2 0 0 5 16:32
Duration
D ays Hours Minutes
20 23 37 Total Hours
= 480  Hours 23 0.62 5 03 .62
Radius D o se  R ate Duration (Hrs) C alculated D o se  (cG y)
1 cm 0 .5 46 503 .62 2 4 3 .9 0
2 cm 0 .1 1 5 503 .62 4 9 .5 8
1.5cm
Centre
Position
6 5cm
' 1cm
2cm
Keys
•  Central Hole
•  Holes at 1cm
•  Holes at 2cm
Figure 5.19: PRESAGE™ dosimeter side view (left), PRESAGE™ dosimeter the top view (right)
87
C h a p t e r  5 S i m u l a t i o n  a n d  e x p e r i m e n t a l  m e a s u r e m e n t s
5.5.3 Results and discussions
The dose at 1 cm and 2 cm were obtained through the average reading o f the TLDs. 
The results are shown in Table 5.23.
It was found that the difference between the TLD results and the theoretical calculated 
results at I cm differ by = 9% and at 2 cm by ~ 44%. The differences are significant 
and may due to various experimental errors as described in the next section. Previous 
studies by different investigators have shown disagreement o f 35% suggests that the 
signal-to-noise ratio o f the TLD dosimeters makes precise measurements very 
difficult at large distances [21].
Theoretical R esults  
(cGy)
P ercen tage  
Difference (%
D istance from source TLD Experimental 
R esults (cG y)
222.32 243.90
27.27 49.10
Table 5.23: TLD dose results vs. theoretical results
5.5.4 Conclusions and Experimental Errors
The anisotropy function is a ratio o f two dose rates, and as a result some o f the 
systematic errors may cancel out, and uncertainty in determination o f anisotropy 
function can be estimated to be ±5% (standard error o f mean) from random errors in 
dose measurements as reported by Nath [20].
TLDs are sensitive to light, and therefore the seed implantation process and TLD 
readouts were carried out in dimmed lighting. The brachytherapy seed is implanted 
into the centre o f the PRESAGE'^^ dosimeter where the drilled hole (1.3 mm diameter) 
is slightly larger than the seed (0.8 mm diameter). Hence, the dwelling position o f the 
seed may not be exactly vertical throughout the time of irradiation.
The TLD chips dose calibration procedures may not be the ideal setup. Firstly, the 
calibration was conducted in-air while the final experiment was conducted in- 
PRESAGE^'^; hence the amount attenuation and scatter by the different surrounding 
material may give rise to differences in the final absorbed dose. Since the chips are 
loaded onto the rotating carousel for uniform irradiation by a U-shaped Sr-90 source.
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there is a delay in reaching the set rotation speed, namely the spin up time. It would 
be ideal to have a system similar to a record player where the source would move in 
place once the preset rotational has been reach. This is impractical as the source is 
heavily shield by lead blocks for radiation protection purposes.
For practical reasons, it is difficult to accurately measure dose for distances below 
0.5cm using the TLD experimental method. Further theoretical and Monte Carlo 
simulations are warranted to fill this important gap.
The initial results from the TLD experiment showed some discrepancies when 
compared with calculated dose. Further investigation is required to clarify the origin 
o f these differences, this include the characteristics o f the LiF TLD, the individual 
TLD calibration process and other possible errors in the theoretical dose calculations. 
It was concluded that time was not warranted for these investigations and that the use 
of TLD as a dosimeter for our studies was not feasible at present.
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5.5.5 Doped Radiosensitive Glass Experimental Procedures
The Ge-doped fibre optics used here had diameter o f 0.22 mm. The outer polymer
layer was stripped using a fibre optic stripper (Miller, USA). Removal o f the outer
layer leaves a 0.13 mm Ge-doped core with density o f 2.51 g cm'^. The core was then
cleaned using methyl alcohol and wiped with cotton cloth. The fibre was cut into 7
mm pieces with a professional fiber cutter (Part no: IF-FCI, Industrial Fiber Optics,
USA)
Factors affecting the utility o f TLD materials includes TL sensitivity, stability, 
precision and minimum detectable absorbed dose. Other major effects are classified as 
environmental factors (e.g. temperature, humidity and ultraviolet irradiation) and 
physical handling factors (e.g. cleaning and storage). Prior to use, the fibres were 
annealed in a high temperature furnace (Model: Eurothermal) at 500°C for I hour to 
standardise their sensitivities and background, then cooled at a controlled manner for 
18 hours to avoid thermal stress. When not in use, the fibres were kept in lightproof 
containers.
Figure 5.20: Ge-doped fibre optics (top left), fibre optic stripper (top right) and Solaro TL reader
(bottom)
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5.5.6 Calibration Procedures
The fibre optics were exposed with photons at 6 MV at 200 MU/niin (1 MU = 1 cGy), 
with a 10 X 10cm field at 100 FSD, to the surface o f 1.5 cm o f solid water on top of 
the fibres and 5cm below the fibres. Following a 12 hours stabilising period, the 
exposed fibre optics were read out using a Solaro TL reader (Vinten TLD, Reading, 
UK) under a nitrogen flow of 450 ±50 ml/min. The readout parameters used in this 
work were: preheat temperature 160°C for 10 s; readout temperature 300°C for 25 s, 
and; a stepped heating regime at a rate o f 25”C/s.
5.5.7 Results
During the readout analysis, many of the fibre optics broke in half due to their brittle 
nature. The TL response was dependent on the mass o f optical fibre; another difficulty 
encountered was how to accurately determine the mass o f the fibre optics. In the 
situation when weighing a single or a few strands, there was no apparent difference 
from the readings o f a 4-decimals (5 Significant figures) scale. The TL readout has 
revealed that higher dosed fibre optics resulted in higher TL response; however, 
without the accurate mass, a calibration curve o f mass versus TL response could not 
be obtained. It is recommended to weigh at least ten or more strands o f fibre optics in 
order to obtain a reliable reading. Due to the foreseeable prolonged time in preparing 
and reading out the fibre optics, the application o f optical fibres as a 
thermoluminescence material for radiation dosimetry was also not investigated further.
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5.6 Brachytherapy Seed Implant Experiment (Methods)
5.6.1 Experiment 1 - Vertical Seed Implant
The purpose o f the experiment is to examine the feasibility o f the solid polyurethane 
based dosimeter -  PRESAGE™ [96] as an accurate three-dimension dose verification 
method applied to pro static brachytherapy.
The 1-125 seed Model 6711, also Icnown as OncoSeed™, is currently used at the 
Royal Surrey County Hospital (RSCH). The aim is to implant the seed directly into 
the dosimeter through a prepared channel, where the seed resides for a length o f time, 
and is then removed for diagnostic imaging using the Optical-CT system.
5.6.1.1 Experimental Procedures
The brachytherapy experiment was conducted through a time period o f 20 days. A 
hole was drilled in the solid dosimeter providing a passage for the seed implant. The 
size o f the hole was 1.3 mm in diameter and 3 cm deep; the hole was designed to be 
slightly larger than the actual seed for easy implantation as well as extraction. Care 
must be taken, as the drilling will produce heat and rough edges resulting from 
friction. The dosimeter was securely clamped with its base flat on the bench and 
drilled vertically under a bench drill press. The 1-125 seed used in this experiment had 
an activity o f 17.4 MBq (0.47 mCi) with dose rate o f 0.57 cGyh"\ The total absorbed 
dose at 1 cm from source centre was approximately 2.4Gy and 0.48Gy at 2 cm (See 
Table 5.24). The density o f PRESAGE™ (1.05 g/cm^) is similar to that o f water 
(0.998g/cm^), hence the dosimetric calculation based on water will provide a close 
estimate for the absorbed dose in PRESAGE™; this will be discussed in Section 6.2.2.
Top View Side View
2.7 cm 6.5 cm
2.7 cm
DOSMETER
6.2 cm Diameter 6.2 cm Diameter
Figure 5.21: Schematic diagram of the PRESAGE™ dosimeter implant experiment
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According to Equ. ( 8 ), the average dose at 1 cm after 1 week o f irradiation is around 
0.8 Gy. Other experimental precautions are summarised in the next section.
b ( r , e )  = S , A -  . g (r )
(2D  Formalism)
1 cm 2 cm
0.571 0.571 cG y h'^
A  (in water) 0 .98 0 .98 cG y cm^ / U h
gr (C o n sen su s) 1 0 .814
F ( r ,^ ) 1 1
G ( r ,^ )
G{ro,0o) 0 .9 7 6 0 .244
0 .5 2 8 0 .107
In 11 /11 /2005 16:55
Out 0 2 /1 2 /2 0 0 5 16:32
1 Duration
D ays Hours Minutes
20 23 37 Total Hours
= 480  Hours 23 0 .6 1 6 6 6 7 50 3 .6 1 6 7
1 cm 0 .528 503 .6 235 .8
2 cm 0 .1 0 7 503 .6 4 7 .8
Table 5.24: Calculation of absorbed dose at 1 cm and 2 cm for 1-125 Model 6711 source
g
Figure 5.22: Lead shielded storage and protective barrier (top left), 1-125 seed storage (top right), 
PRESAGE^’'* implant equipment (bottom left), PRESAGE^^ with forceps (bottom right)
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5.6.1.2 Radiation Protection Issues, Health and safety 
Protective Barrier
All the seed handling and preparation procedures were conducted behind the 1 cm 
lead screen fixed on the preparation laboratory bench. (See Figure 5.22)
Source Handling
In line with the added protection offered by the inverse square law, forceps were used 
for all handling o f the seeds to increase their distance from the operator. (See Figure 
5.22)
Personal Dosimetry
A TLD fitted on a plastic ring can be provided during the seed loading preparation. A 
single treatment would consist o f around 80-90 seeds. Past TLD results have shown 
that after five treatments, the finger dosimeter showed no detectable dose. The dose is 
only detectable from background radiation after ten treatments. Due to the low 
activity involve, the finger dosimeter is not necessary in this case.
Protective Clothing
Based on results from the previously conducted finger TLD dosimetry, it was not 
necessary to wear protective clothing such as a lead apron.
Spillage/Splash Risks
The experiment involved only sealed radioactive sources, the seeds dimension are 
4 mm X 0.8 mm, there was no risk o f spillage or radiation contamination. For 
radiation protection purposes, a G-M Tube was used to survey the workbenches after 
implantation.
Shielded Storage
Once the seed had been implanted into the dosimeter, it was stored in a secure lead 
safe with warning labels detailing the seed activity, date o f implant and contact 
information. All unused seeds were stored in the 1-125 seeds safe. (See Figure 5.22)
9 4
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5.6.1.3 Optical-CT Analysis
The PRESAGE™ dosimeter was scanned with 1000 projections over 180°. The 3D 
distribution o f the dosimeter’s attenuation coefficient is then reconstructed from the 
projection data to form a 3D dataset with total o f 186 slices o f matrix size 256 by 256 
pixels. The pixel size is 0.25 mm^ and slice thickness is 0.25 mm.
5.6.2 Experiment 2 - Horizontal Seed Implant
Our in house Optical-CT scanner works well with the transparent PRESAGE™ 
dosimeter [96]. A problem arises when there are variations o f material density through 
the light path. A previous experiment in Section 5.6.1 showed that where a hole was 
drilled in the PRESAGE™ dosimeter, the refractive index differences between the 
PRESAGE™ lead to edge artifacts reducing the useful region of the dosimeter. The 
useful region is thus the reconstruction slices below the drilled hole. The horizontal 
seed implant technique describe in this section aims to overcome the above limitations 
by restricting the region with artifact to only those slices containing the hole and to 
increase the volume o f useful region o f the dosimeter.
5.6.2.1 Experimental Procedures
A PRESAGE™ dosimeter (batch #90) with diameter o f 6.2 cm and 6.4 cm height was 
machined and prepared at the RSCH workshop. A 1.3 mm diameter hole was drilled 
horizontally to the depth o f 3.3 cm at 3.2 cm from the base o f the dosimeter. The hole 
was drilled slowly to avoid overheating and resulted in a smooth channel for the seed 
implant. The top and bottom of the dosimeter were machined to provide a flat base in 
preparation for the post irradiation Optical-CT scanning. The PRESAGE™ dosimeter 
was prepared as shown in Figure 5.23, the horizontal hole is highlighted in green.
Top View Side View
-►
6.2 cm Diameter
6.4 cm
3.3 cm
PRESAGE"'DOSIMETER
3.2 cm
6.2 cm Diameter
Figure 5.23: Schematic diagram of the PRESAGE^’'* dosimeter implant experiment
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5.6.2.2 Dosimetric Calculations
The 6711 seed was implanted into the PRESAGE™ dosimeter and the sample was left 
in the lead safe to irradiate for a total o f 14 days, 23 hours and 0 minutes (359 hours). 
Adopting the 2D dose-rate formalism as recommended by the AAPM TG-43, the 
estimated dose at 1 cm from source centre at 90° was 1.65 Gy and at 2 cm was 0.34 
Gy (See Table 5.25).
D {r , e )  =  S, ■ ■ F ( r , e )  - g (r )
(2D Formalism)
1 cm 2 cm
0 .5 2 5 0 .5 2 5 cG y h'^
A  (in water) 0 .98 0 .98 cG y cm^ / U h
gr (C on sen su s) 1 0 .814
F ( G ^ ) 1 1
G ( r ,^ )
G{ro,0^) 0 .9 7 6 0 .244
D (A -,m 0 .502 0 .102 cG y h'^
In 2 3 /1 1 /2 0 0 6 12:00
Out 0 8 /1 2 /2 0 0 6 11:00
1 Duration
D ays Hours Minutes
14 23 00 Total Hours
= 336  Hours 23 00 3 5 9 .0 0
1 cm 0 .50 359 165
2 cm 0.11 359 34
Table 5.25: Calculation of absorbed dose at 1 cm and 2 cm for 1-125 Model 6711 source
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5.6.2.3 Optical-CT Analysis
The same Optical-CT acquisition method was used as in Section 5.6.1.3.
It was noted from viewing the reconstruction slices (Z-axis) that the orientation o f the 
drilled channel was not on the same plane for each slice image. For this reason, the 
reconstruction slices were rotated slice by slice at a clockwise angle o f 23° to align all 
slice images with the drilled channel at 90° (see Figure 5.24B). Figure 5.24 shows the 
reconstruction image before and after the rotation. The effect o f the rotation is clearly 
shown in Figure 5.25, where the top three images shows slice view from the X-axis. 
The location o f the drilled hole (highlighted in green) for slice 135, 145 and 155 were 
located at (x,y) = (79,127), (79,131) and (79,135) respectively, the difference in y 
values indicated a systematic shift due to the drilled hole not being aligned to the 
same axis. The bottom three images show the slice view for slices 135,145 and 155 
after the 23° clockwise rotations where the drilled hole was located at x,y(79,125) for 
all slices. The image slices were successfully aligned ready for analysis.
Figure 5.24: Reconstruction slice view from Z-axis: (A) Original reconstruction image, (B) 
Reconstruction image rotated clockwise by 23“
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Slice No 135 
x.y( 79.127)
Slice No 145 
x,y(79,131)
Slice No 155 
x,y(79,135)
Slice No 135 
x.y(79.125)
Slice No 145 
x,y(79 125)
Slice No 155 
x.y(79,125)
Figure 5.25: Slice view from X-axis before and after 23“ rotations
5.6.3 Experiment 3 - Radiochromic Film
The experiment was performed in collaboration with the Royal Marsden Hospital 
(Sutton, UK) and conducted at the Royal Surrey County Hospital (Guildford, UK). 
The aim of the first experiment is to measure the dose distribution o f the 1-125 Model 
6711 brachytherapy seed with GAFCHROMIC® films and PRESAGE™ dosimeter. 
GAFCHROMIC® EBT radiochromic films investigated in this section were taken 
from Lot no 35146-003AI (ISP Technologies, USA) and PRESAGE™ dosimeters 
from Batch #156. The first experiment, where a PRESAGE™ dosimeter is first 
machined and cut horizontally at 2.2 cm from the top o f which 2 mm of PRESAGE™ 
was spared to ensure the 1-125 seed would not fall out during irradiation. Further 
cuttings were made at 0.5, 1.0 and 2.0 cm where GAFCHROMIC® EBT films were 
sandwiched and securely clamped in place (see Figure 5.26).
In the second experiment, a PRESAGE™ dosimeter was sliced in half and a hole was 
machined for the 1-125 seed to reside. Three GAFCHROMIC® films were stacked and 
sandwiched between the two halves o f the PRESAGE™ dosimeter to measure the 2D 
radial dose o f the 1-125 seed (see Figure 5.27).
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The dose distribution was recorded in 3D by the PRESAGE^^ dosimeter (Section 
5 .6 .1 )  and 2D by the GAFCHROMIC® films. After irradiation, the PRESAGE^" 
dosimeter was scanned with the Optical-CT scanner, and the film by a flatbed scanner. 
The results were cross-compared for dose distribution verification and anisotropy 
functions.
Side View
GAFCHROMIC» , Films2.2 cm 2cm
1.0 cm SSce3 8 cm
PRESAGE™
DOSIMETER
6 cm Diameter
Figure 5.26: GAFCHROMIC® sandwich films array
Top View Side View
Array of 
GAFCHROMIC^  Films
6 cm Diameter
21 cm
3.9 cm
DOSIMETER
6 cm Diameter
GAFCHROMIC* 
Films 
Array
Figure 5.27: Schematic diagram of GAFCHROMIC® films in PRESAGE^w phantom for 
anisotropy functions analysis (top), photo of PRESAGE^^ phantom (bottom)
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The 2D anisotropy analysis follows a similar method adopted for the Optical-CT 
images in Section 5.6. An in-house IDL program was used to extract the average dose 
values at various distances and polar angles from the centre o f the 1-125 source. 
Figure 5.28 shows the location o f the pixel regions taking the average o f 10 x 10 
pixels (surrounding 0.8 mm); used to calculate the anisotropy functions. The 
symmetric dose pattern o f the 1-125 allows two points to be extracted to provide an 
averaged absorbed dose value at each distance and polar angle. For example, the 
pixels highlighted in green colour are both at a distance o f 2 cm and polar angle of 
20° to the 1-125 source centre.
Figure 5.28: Anisotropy analysis using average pixel values
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5.7 Brachytherapy Seed Implant Experiment (Results)
5.7.1 Experiment 1 - Vertical Seed Implant
The optical density information was extracted using an in-house IDL program. 
Projection images o f size 256 x 256 pixels were reconstructed using standard filter 
back projection to form a 3-D dataset with slice thickness 0.19 mm and image slice 
reconstruction at 0.38 mm^ per pixel. The optical density at different distances and 
polar angles was obtained in order to calculate the anisotropy functions as presented 
in Table 5.26. This was done by placing various tally rings within the Optical-CT 3-D 
dataset at the particular distances and polar angles of interest, and from which the 
mean optical density was calculated (see Appendix F). The percentage difference 
between Optical-CT and the consensus results at 1 cm are shown in Table 5.27 
together with relative error (bottom row). At polar angle 0° and 10° large 
discrepancies o f -24% and -11% were observed; the results above polar angle o f 20° 
showed close agreement with both Monte Carlo and consensus results.
Radius
(cm )
Polar an gle 9 (d eg rees)
0 10 20 30 40 50 60 70 80 90
0 .5 0 .6 9 4 0 .7 1 7 0.891 0 .9 4 4 0 .958 0 .975 0 .9 7 5 0 .980 1.001 1
1.0 0 .4 1 5 0 .5 7 8 0.731 0 .852 0 .957 0 .967 1 .043 1 .055 0 .989 1
1.5 0 .332 0 .5 0 7 0 .6 3 9 0.811 0 .896 1.006 1.020 1.006 1.006 1
2.0 0.001 0 .1 5 6 0 .360 0 .4 7 5 0 .500 0 .843 0 .9 4 3 0.951 1.038 1
Table 5.26: Optical-CT Anisotropy functions
Authors Polar angle  0 (d egrees)0 10 20 30 40 50 60 70 80 90
OCT 0 .4 1 5 0 .5 7 8 0.731 0 .852 0 .957 0 .9 6 7 1 .043 1 .055 0 .989 1
MCNP 0 .4 4 5 0 .5 7 4 0 .7 1 4 0 .8 0 9 0 .8 8 5 0 .945 0 .9 6 7 0 .9 7 5 0 .969 1
C o n sen su s 0 .3 7 0 0 .5 3 7 0 .7 0 5 0 .8 3 4 0 .9 2 5 0 .972 0.991 0 .9 9 6 1 1
OCT vs. 
C o n sen su s -24.5% -11.3% -2.1% -0.7% -3.4% 0.5% -5.2% -6.0% 1.1% 0.0%
OCT
Relative
Error
7.3% 7.4% 7.6% 8.0% 9.4% 9.7% 12.2% 9.5% 10.1% 10.8%
Table 5.27; Comparison of Ffr, between consensus and Optical-CT results at 1 cm
Authors Polar angle  0 (d egrees)
0 10 20 30 40 50 60 70 80 90
OCT -24 .5 -11 .3 -2.1 -0 .7 -3 .4 0 .5 -5 .2 -6 .0 1.1 0.0
Nath (TLD) -5 .4 -21 .2 -10 .9 -1 .0 3 .0 2 .9 3 .9 4 .4 2 .0 0.0
C apote
(E G S4) -24 .5 -11 .3 -2.1 -0 .7 -3 .4 0 .5 -5 .2 -6 .0 1.1 0 .0
Table 5.28: Ffr, 0  of Seed Model 6711 Percentage difference Optical-CT, Nath and Capote vs.
Weaver at 1 cm
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Figure 5.29 shows the graph o f current consensus, Monte Carlo and Optical-CT 
anisotropy functions at 1 cm, Optical-CT are shown with error bars representing the 
relative error at each polar angle. The relative (or fractional) error was calculated as 
follow: For each polar angle, the standard deviation of the sample mean is calculated 
for the relevant region o f interest, this was divided by the square root o f the number o f 
points in that region; this is the standard error o f the sample mean. The relative error 
in dose is the ratio between the standard error and the sample mean. From Equ. ( 4 ),
we see that F{r,0)cc D{r ,0 ) l  D{r^ô^^), standard error propagation theory gives the 
relative error o f a quotient as the sum o f the relative errors o f the numerator and 
denominator. Hence, the relative error in dose was calculated for regions at 0and 9n. 
These two values were added and this value, expressed as a percentage is what 
appears in Table 5.27. The absolute error in V{r,6 ) plotted in Figure 5.29 is the 
product o f rows 2 and 6 in Table 5.27.
Table 5.28 presents the comparison o f percentage difference at I cm; Optical-CT 
produced comparable results to Nath and Capote at polar angle 20° to 90°. At low 
polar angles, Optical-CT shows good consistent agreement with Capote (EGS4) over 
Nath (TLD) results. The results indicate that the quantitative performance o f Optical- 
CT is at least as good as TLD and comparable to Monte Carlo results. Figure 5.29 
shows the graphical representation o f the comparison at 2 cm consensus anisotropy 
functions, the results show great discrepancies at lower polar angles and better 
agreement at higher polar angles. The error bars represents the large relative error 
associated with the low signal to noise at 2 cm.
ëoZc3U .
o A Optical-CT 
MCNP 
 Weaver
o
E 0.2 <
0 +
20 40 60
Polar Angle (°)
80
1
0.8
0.6
a 0.4
A Optical-CT 
MCNP 
 Weaver
0.2
0
0 20 8040 60Polar Angle (°)
Figure 5.29: Graph of F('r, 9) between consensus and Optical-CT results at 1 cm (left) and 2 cm
(right)
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5.7.1.1 Conclusions
In summary, at 1 cm from the source centre the anisotropy functions obtained through 
the Optical-CT images show some discrepancies from the consensus results at lower 
polar angles; results at higher polar angles compared well with consensus results and 
are generally in good agreement.
At 2 cm, Optical-CT results were disappointing. However, this was due almost 
entirely to an under-exposure o f the PRESAGE™ sample, leading to very poor image 
contrast. The discrepancies may be due to possible experimental errors, the 
PRESAGE™ dosimeter does not naturally have a flat base due to the method of 
manufacture; therefore it has to be machined to provide a flat base. An irregular base 
would lead to the dosimeter leaning in one direction; this would complicate the final 
backprojection reconstruction algorithm. In addition, a Monte Carlo simulation o f the 
PRESAGE™ seed implant experiment would provide results for cross-comparison 
with the experimental results.
5.7.2 Experiment 2 - Horizontal Seed Implant
The anisotropy functions for distance 0.5 to 2 cm over polar angles o f 0° to 90° were 
calculated from the optical density information extracted from the Optical-CT data 
using an in-house IDE program. The results are presented in Table 5.29.
Radius
(cm )
Polar angle  0 (d egrees)
0 10 20 30 40 50 60 70 80 90
0 .5 0 .653 0 .666 0 .818 0.851 0 .8 8 6 0.921 0 .942 0 .9 7 8 0 .9 7 5 1
1.0 0 .6 0 4 0 .8 1 0 0 .8 0 9 0 .8 3 8 0.861 0 .9 1 4 0 .9 4 3 0 .9 8 6 0 .9 7 3 1
1.5 0 .477 0 .8 7 9 0 .8 8 7 0.941 0 .9 5 4 0 .972 0 .990 1.068 1.007 1
2 .0 0 .409 0 .890 0 .9 4 4 0 .9 5 8 1.023 0 .985 1.022 1.047 1.006 1
Table 5.29: Anisotropy functions of 6711 seed calculated by Optical-CT
▲ Optical-CT
 MCNP
 Weaver
0
20 40 60Polar Angle (°) 80
1
0.8
u- 0.6
2 0.4 ▲ Optical-CT MCNP
 Weaver0.2
0 4.
20 40 60 80
Polar Angle (°)
Figure 5.30: Graph ofF(r,û) between Optical-CT and consensus at 1 cm and 2 cm
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Figure 5.30 shows the graph o f Optical-CT, Monte Carlo and current consensus and 
anisotropy functions at 1 cm and 2 cm. The percentage difference between Optical-CT 
and consensus at polar angle 0° showed large discrepancies o f 63%. Results above 
polar angle o f 30° showed good agreement with consensus and Monte Carlo results. 
The discrepancies may be related to a combination o f factors; the low aborbed dose at 
1 cm (1.6 Gy) and the location o f the drilled channel. The anisotropy function at 0° 
was within those slices containing the hole and thus was affected by the slice images 
with artifacts. At 2 cm, Optical-CT results were consitently higher than the Monte 
Carlo and consensus values, this was mainly due to the under-exposure (0.3 Gy at 2 
cm), resulting in poor image contrast.
5.7.2.1 Conclusions
The anisotropy functions obtained through the Optical-CT images o f a PRESAGE™ 
dosimeter with a horizontal seed implant showed large differences from the consensus 
results at lower polar angles; results at higher angles averaged at 10%. In general, the 
results seemed to be noisy when compared with results in Section 5.7.1. This may be 
due to the use o f a lower activity seed and the short irradiation time for this 
experiment. The rotation o f the reconstruction images (Section 5.6.2.3) may also have 
an effect on the overall anisotropy functions. The results o f this study have shown the 
importance o f calculating the total time o f irradiation in relation to the source activity. 
The time o f irradiation can result in optimum image contrast o f PRESAGE™ samples.
R adius (cm ) Polar angle  0 (d egrees)
0 10 20 30 40 50 60 70 80 90
Optical-CT 0 .6 0 4 0 .810 0 .8 0 9 0 .8 3 8 0.861 0 .9 1 4 0 .943 0 .986 0 .973 1
W eaver 0 .333 0 .519 0 .7 1 6 0 .8 4 6 0 .9 2 6 0 .972 0.991 0 .996 1 1
% D ifference 63.3% 50.8% 14.8% 0.5% -6.9% -6.0% -4.8% -1.0% -2.7% 0.0%
Radius (cm ) Polar an g le  0 (d egrees)
0 10 20 30 40 50 60 70 80 90
Optical-CT 0 .409 0 .890 0 .9 4 4 0 .9 5 8 1 .023 0 .9 8 5 1.022 1.047 1.006 1
W eaver 0 .370 0 .5 3 7 0 .7 0 5 0 .8 3 4 0 .9 2 5 0 .972 0.991 0 .9 9 6 1 1
% D ifference -7.5% 53.5% 29.8% 13.8% 10.5% 1.5% 3.5% 5.1% 0.6% 0.0%
Table 5.30: F(r,0) of Optical-CT and consensus at 0.5 (top) cm and 1 cm (bottom)
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5.7.3 Experiment 3 - Radiochromic Films
The 1-125 seed used in the first experiment had activities o f 16.65 MBq (0.45 mCi) 
with dose rate o f 0.54 cGyh’’. After two weeks o f irradiation, the equivalent dose at 1 
cm from source centre was approximately 1.7 Gy and 0.35 Gy at 2 cm (See Table 
5.31). The films were scanned with a flatbed scanner and the raw TIFF images were 
read into IDE and calibrated to dose by a lookup table based on the red channel o f the 
mean calibration data. The other colour channels were ignored.
Figure 5.32 shows the calibrated reconstruction image and line profile o f dose at 
0.425 and 0.925 cm from the centre o f the 1-125 seed. The white line indicates the 
dose profile across the reconstruction image. The dose profiles are smooth and less 
noisy than Optical-CT reconstruction images. The dip in the middle o f the two 
profiles specifies the location o f the drilled channel where the 1-125 seed resided.
D i r , 6)  = S. ■ A ■ ■ F i r . 9 )  ■ g i r )
(2D  Formalism)
1 cm 2 cm Units
s , 0 .5 4 0.54 cG y h-'
A 0 .98 0.98 cG y cm® / U h
gr (C on sen su s) 1 0 .814
F ( r ,^ ) 1 1
G (r,m
G{rQ,9^) 0 .9 7 6 0 .244
D ( r ,^ ) 0 .5 1 6 0 .105
In 0 8 /1 2 /2 0 0 6 13:33
Out 2 2 /1 2 /2 0 0 6 09:00
1 Duration
D ays Hours Minutes
13 19 27 Total Hours
= 312 Hours 19 0 .45 3 3 1 .4 5
1 cm 0 .516 3 31 .45 171 .47
2 cm 0 .1 0 5 3 3 1 .4 5 3 4 .99
Table 5.31: Calculation of absorbed dose at 1 cm and 2 cm for 1-125 Model 6711 source
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5.7.3.1 Anisotropy Analysis
The relative error o f the anisotropy functions obtained with GAFCHROMIC® EBT 
films at 1 cm ranged from 0.2% to 0.4% at polar angles 0° to 90°. Error bars to 
represent the standard error, would be o f the order o f (or smaller than) the size o f the 
plots symbols and so are omitted. At 1 cm from the source centre, the EBT film 
results agreed well with MCNP Monte Carlo results with average difference o f 3.3% 
over 10° to 80° (See Figure 5.31). Figure 5.32 shows the line profile at 0.425 cm and 
0.925 cm below the source centre, the dip observed at polar angle 0° may be due to 
the absorption by the end caps o f the seed.
1
0.8
0.6
GafChromic EBT Film 
MCNP Monte Carlo 
Weaver (Consensus)
Q . 0.4
0.2
0 4
20 40 60
Polar Angle (°)
80
Figure 5.31: Comparison of anisotropy functions at 1 cm
I g
Diatanca (mm)
Figure 5.32: EBT Film Slice at 0.425 cm with corresponding line profile (left), EBT Film Slice at
0.925 cm with line profile (right)
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5.8 Global Comparison
The Gafchromic EBT Films line profile was taken from a high-resolution image 
scaled at 300 pixels/inch ( I I 8.11 pixels/cm) with pixel size o f 0.085mm, the smooth 
line profile indicating high signal-to-noise ratio. Although, the results obtained from 
PRESAGE™ dosimeter were not calibrated to dose, the line profiles o f Optical-CT 
matched well with EBT Films and MCNP simulation. The difference associated with 
batch-to-batch sensitivity can be resolved by exposing the dosimeter at various dose 
and deriving a calibration curve.
Figure 5.33 shows the global comparison o f normalised dose profile o f MCNP (250 
million histories) Gafchromic EBT Film and Optical-CT at 0.425cm slice below the 
source centre. The profiles are in good agreement particularly at distance beyond ±0.3 
cm in the lateral position from the centre o f the source. The line profile o f Optical-CT 
matched the MCNP results particularly well within ±0.3 cm with normalised value 
down to 0.6, while the EBT film recorded a normalised value o f 0.8; a large 
difference o f 20%. The difference between the profiles within ±0.3 cm may be due to 
the source specification used for the Monte Carlo simulation. For experimental results, 
the variation o f source diameter during the manufacture process and the exact 
orientation o f the seed during irradiation may contribute to the differences. For 
anisotropy functions, except for small angles (<20°), the Optical-CT results are in 
good agreement with EBT films at angles above 20°, with average difference o f 3.2%.
 MCNP
EBT Films 
 Optical-CT
•3 ■2 ■1 0 2 31
D istance from  so u c e  cen tre  (cm)
MCNP 
* — EBT Film 
A Optical-CT 
— Weaver
u .
Q. 0.6 -
0.2
0 20 40 60 80
Polar Angle (“)
Figure 5.33: Global comparison of line profile at 0.425cm (left), global comparison of anisotropy
functions at 1 cm (right)
107
C h a p t e r  5 S im u l a t io n  a n d  e x p e r im e n t a l  m e a s u r e m e n t s
5.9 Multi-Seed Dosimetry -  Parallel Implant
The complete dosimetric study o f the single 1-125 seed model 6711 was covered in 
Section 5.1 to 5.7. This section extends the dosimetric investigation to a multi-seed 
implant scenario, where more than one 1-125 seed was implanted into a single 
PRESAGE™ dosimeter. The dose information obtained by Optical-CT (CCD) was 
compared with GAFCHROMIC® EBT films and MCNP Monte Carlo simulation. A 
fast laser scanning Optical-CT scanner [78] is currently under development at our 
centre; this has been used to provide some preliminary results. The potential outcome 
o f this work would be useful for validating dose distribution o f a real treatment 
scenario involving number o f seeds; which at present would be impracticable to verify 
in 3-D by other experiment means.
5.9.1 Experimental Procedures
Two channels were drilled at the top o f a PRESAGE™ dosimeter 1.5 mm diameter to 
a depth o f 2.5 cm with 1 cm separation in parallel between the source centres as 
shown in Figure 5.34. An 1-125 seed with activity o f 13.19 MBq (0.36 mCi) was 
implanted into each channel and allow to reside for a period o f 24 days equivalent to 
2 Gy at 1 cm and 0.4Gy at 2 cm from source centre. The combined dose information 
was recorded by the PRESAGE™ dosimeter (Batch #168). The PRESAGE™ 
dosimeters were scanned one day after irradiation using Optical-CT and laser-CT.
The equivalent experiment was conducted with GAFCHROMIC® EBT films. Where 
a PRESAGE™ dosimeter was sliced in half, with two grooves machined on one half 
to secure the 1-125 seed during irradiation. An array o f three GAFCHROMIC® EBT 
film were sandwiched between the two halves o f PRESAGE™ dosimeter to record the 
dose distribution.
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A MCNP Monte Carlo simulation was conducted to simulate the equivalent setup o f 
the multi-seed parallel implant experiment. Tally cells were placed at 4.25 mm and 
9.25 mm from the centre o f the 1-125 seeds. A total o f 250 million histories were 
calculated in fulfilment to the requirement o f the ten statistical tests.
Top View Side View
2 5 cm 2 3cm 2.8cmPRESSAGE’"
DOSIMETER
1cm
1cm 3 6 cm
PRESAGE' 
DOSIMETER
6 cm Diameter 6 cm Diameter
Drilled Hole for 1-125 Source Implant *  1-125 Source
Side View
1cm
2.2 cm ;
i;
3 8 cm I
2cm
PRESAGE"
DOSIMETER
GAFCHROMIC*
Films
Array
6 cm Diameter
Central Drilled Hole for 1-125 Source Implant "  1-125 Source
Top View Side View
6 cm Diameter 6 cm Diameter 6 cm Diameter
Figure 5.34: Experimental setup of parallel multi-seed dosimetry using PRESAGE™ (top), 
GAFCHROMIC® EBT films (middle) and MCNP Monte Carlo simulation (bottom)
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5.9.2 Results and Discussion
This section includes the comparison o f line profiles o f Optical-CT, GAFCHROMIC® 
EBT films and Monte Carlo slice images taken at the same slice distance from the 
source centre. Figure 5.35 shows the schematic diagram of the location o f the image 
slices o f which the line profile was taken across the drilled channel.
Side View
1cm
2.5 cm
3.6 cm
2.3cm 2.8cm
PRESAGE"'
DOSIMETER
-4---------- ------------ ►
6 cm Diameter 
•  Drilled Hole for 1-125 Source Implant
4.25mm
9.25mm
1-125 Source
0.039
0 007
0.00 375Distance (cm)
Ust I Save... I x -3 .6 7 , T -o .o i
0.007
0.00 3.90Distance (cm)
Ust I Save.. | Copy...
Figure 5.35: Location of line profile from 1-125 source centre (top), Line profile of Optical-CT at 4.25
(middle) and 9.25mm (bottom)
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Figure 5.36 shows the line profile comparison o f GAFCHROMIC® EBT films, Monte 
Carlo and Optical-CT (CCD) (Batch #168) at 4.25 mm from the centre o f source. The 
two drilled-channels can be clearly observed from all three modalities. While the 
shape o f GAFCHROMIC® BBT films and Monte Carlo showed some smooth profile, 
the Optical-CT (Laser) results appeared to be noisy. Figure 5.36 shows the line profile 
comparison at 9.25 mm from the source centre, the Optical-CT (CCD) line profile 
could not be obtained from the image slice (see Figure 5.35). The Optical-CT (Laser) 
was used instead to extract the dose distribution at 9.25mm; the line profiles were in 
good agreement at ±2 cm from source lateral axis with under-dose recorded at ±0.5cni.
Figure 5.36 (middle left) shows the comparison between Monte Carlo simulation and 
GAFCHROMIC® EBT film at 4.25mm slice below source centre. For the range o f ±2 
cm o f the lateral axis from centre o f source, the RMS mean difference is 2% with 
difference o f up to 13%; the standard deviation is 2.6%. The biggest difference 
occurred at the region near the drilled channels. Figure 5.36 (middle right) shows the 
comparison between Monte Carlo simulation and Optical-CT (CCD) at 4.25 mm. For 
the range o f ±2 cm from source centre, the RMS mean difference is 6% with 
difference o f up to 20%. The conclusion is that this was an unsuccessful Optical-CT 
experiment due to under-exposure o f the sample, and other technical problems rather 
than an inherent limitation o f the technique.
Comparison at 9.25 mm slice below the source centres showed minimal difference 
between Monte Carlo simulations and GAFCHROMIC® EBT film (see Figure 5.36 , 
bottom left) For the range o f ±2 cm lateral axis from centre o f source, the RMS mean 
difference is 2.5% with difference o f up to 6%. The RMS difference increased slightly 
as the distance away from the source centre increased. The comparison between 
Monte Carlo simulation and Optical-CT (Laser) had RMS difference o f up to 19.8% 
at the central axis o f the source centre lateral plane.
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Figure 5.36: Line profile comparison of multi-seed experiment at 4.25mm (top left) and 9.25mm 
(top right), RMS difference comparison of MCNP and EBT film at 4.25mm (middle left) and 
MCNP and Optical-CT (CCD) at 4.25mm (middle right), RMS difference comparison of MCNP 
and EBT films at 9.25mm (bottom left) and MCNP and Optical-CT Laser at 9.25mm (bottom
right)
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5.10 Multi-Seed Dosimetry -  Series Implant
5.10.1 Introduction
The dosimetry study o f the multi-seed parallel implant was covered in Section 5.8. 
This section focus on the dosimetric investigation o f a multi-seed series implant 
scenario, where tw^ o 1-125 seeds were implanted in series into one single PRESAGE™ 
dosimeter. The dose information obtained by Optical-CT (CCD) will be compared 
with GAFCHROMIC® EBT films and Optical-CT (Laser) results.
5.10.2 Experimental procedures
The side implant technique was adopted to investigate the dose distribution at 90® to 
the seed centre. One channel was drilled at the side o f a PRESAGE™ dosimeter at 1.5 
mm diameter to a depth o f 2 cm as shown in Figure 5.37. Two 1-125 seeds with 
activity o f 13.19 MBq (0.36 mCi) were implanted into each channel with I cm 
separation in series between the source centres. The total irradiation time was 24 days. 
The combined dose information was recorded by the PRESAGE™ dosimeter (Batch 
#168). The PRESAGE™ dosimeters were scanned 1 day after irradiation using 
Optical-CT and laser-CT.
The equivalent experiment was conducted with GAFCHROMIC® EBT films. Where 
a PRESAGE^"^ dosimeter was cut in half, with two grooves in series with 1 cm 
separation between source centres were machined on one half o f the PRESAGE™ 
dosimeter (see Figure 5.37 bottom). An array o f three GAFCHROMIC® EBT film 
were sandwiched between the two halves o f PRESAGE™ dosimeter to record the 
dose distribution. The films were irradiated for approximately 6 days.
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Figure 5,37: Experimental setup of series multi-seed dosimetry using PRESAGE™ for Optical- 
CT (top), projection Optical-CT image of PRESAGE™ (middle left), photo of film experiment 
(middle right), equivalent experimental set up of GAFCHROMIC® EBT films (bottom)
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5.10.3 Results and Discussions
The location of line profiles across reconstruction image slices for Optical-CT (CCD 
and Laser setup) together with GAFCHROMIC® EBT film at 3 mm, 5 mm and 1 cm 
are presented in Figure 5.38. The slice thickness for Optical-CT (CCD) was 0.20 mm, 
Optical-CT (Laser) was 0.55 mm and EBT film was 0.25 mm. According to the 
AAPM 2D formalism for calculation o f absorbed dose, the absorbed dose o f the 
PRESAGE™ dosimeter at 1 cm and 2 cm after 24 days o f irradiation was 
approximately 2Gy and 0.4Gy respectively. For the EBT film, the estimated absorbed 
dose after 6 days was 0.76 Gy at 1 cm and 0.15 Gy at 2 cm. The difference in 
irradiation time was selected according to the sensitivity o f the dosimeter.
Figure 5.39 shows the normalised line profile across Optical-CT (CCD and Laser 
setup) together with EBT film at 5mm and 1 cm from centre o f source. Figure 5.38 
shows the location at which the line profiles were taken ftom; for the image slice o f 
Optical-CT and EBT Film. The difference observed between Optical-CT (CCD) and 
EBT film at 5 mm below the source was <10% (±5 mm from the source centre central 
axis). The Optical-CT (Laser) had difference o f up to 2% when compared with EBT 
film results.
At 1 cm below the source centre, the normalised line profile across Optical-CT (CCD 
and Laser) showed a more noisy profile due to the effect o f low signal to noise at 
distances away from the source centre. However, EBT film exhibited a smoother line 
profile across the whole PRESAGE^^"^ dosimeter demonstrating its high sensitive and 
suitability for low dose dosimetry. A quantitative analysis was not carried out due to 
the low signal to noise o f the Optical-CT data.
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b(r,e) =  S, ■ A - ■ F(r,e) ■ g(r) (2D Formalism) Optical-CT
1 cm 2 cm
0.4291 0.4291 cG y h'^
A 0 .9 8 0 .98 cG y cm^ / U h
gr (C o n sen su s) 1 0 .814
1 1
G{ro,0o) 0 .9 7 6 0 .2 4 4
0 .4 1 0 4 0 .0 8 3 5 cG y
In 3 0 /0 1 /2 0 0 7 16:00
Out 2 3 /0 2 /2 0 0 7 14:25
Duration
D ays Hours Minutes
23 22 25 Total Hours
= 552 Hours 22 0.42 5 74 .42
1 cm 0 .4 1 0 4 574 .42 2 0 5 .6 9
2 cm 0 .0 8 3 5 574 .42 41 .8 5
b(r,0) =  S . . A  ■ ■ F(r,d) ■ g ( r ) (2D Formalism) EBT Film
1 cm 2 cm
0 .4 9 6 8 0 .4968 cG y h'^
A 0 .9 8 0 .98 cG y cm* / U h
gr (C o n sen su s) 1 0 .814
F ( r ,^ ) 1 1
0 .9 7 6 0 .244
0 .4 7 5 2 0 .0967 cG y h'^
In 2 3 /0 2 /2 0 0 7 14:40
Out 0 2 /0 3 /2 0 0 7 14:35
Duration
D ays Hours Minutes
6 23 55 Total Hours
= 144 Hours 23 0.92 167 .92
1 cm 0 .4 7 5 2 167.92 76 .63
2 cm 0 .0 9 6 7 167.92 15.59
Table 5.32: Calculation of absorbed dose at 1 cm and 2 cm for 1-125 Model 6711 source, parallel
setup (top), series setup (bottom)
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Optical-CT (CCD) Optical-CT (Laser) GAFCHROMIC® EBT film
8
Figure 5.38: Line profile of slice images for Optical-CT (CCD), Optical-CT (Laser) and 
GAFCHROMIC® EBT film at 5 mm (top row), 1 cm (bottom row)
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Figure 5.39: Line profile comparison at 5 mm (left) and 1 cm (right)
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5.11 Conclusions
In this chapter, different novel techniques o f dosimetry were investigated; including 
Monte Carlo simulations, Optical-CT, a horizontal seed implant technique, two 
innovative methods o f dosimetry (radiochromic films and doped radiosensitive glass) 
and multi-seed dosimetry. Results o f anisotropy functions obtained from the 
horizontal seed implant technique seemed to exhibit more noise over the previous 
vertical implant technique. The difference may be associated with the short irradiation 
time and the artifacts in the PRESAGE’"'^  dosimeter during the manufacturing process 
or the method o f analysis (rotation o f reconstruction images). To isolate this source o f 
error, the vertical implant technique has been selected for all future experiments.
Radiochromic films were first used in this chapter in the determination o f 2-D 
anisotropy functions and dose profiles at various depths from source centre. Results 
from GAFCHROMIC® EBT films were in excellent agreement with both Monte 
Carlo and Optical-CT results. The films were digitised at high resolution of 118 pixels 
per cm with pixels size o f 0.085 mm. The smooth anisotropy functions and line 
profile indicated a high signal-to-noise ratio. Except for small angles, the anisotropy 
functions showed average difference o f 3.3% when compared with Monte Carlo and 
3.2% with Optical-CT. With the successful applicaton o f EBT films in the dosimetry 
o f Model 6711 OncoSeed™, similar technique will be used for the dosimetry of 
alternative sources described in Chapter 6 and Chapter 7.
The potential o f doped radiosensitive glass fibre as a thermoluminescence material for 
radiation dosimetry was also investigated. Before the glass fibres can be used as a TL 
dosimeter, it had to be cut, striped and cleaned with professional tools and afterwards 
an annealing process o f 19 hours in a high temperature furnace; followed by a time- 
consuming calibration process (iiradiation, readout and weighing). Due to the 
foreseeable prolonged time in preparing and reading out the fragile glass fibres, this 
method o f dosimetry was deemed not feasible for this study.
The anisotropy function is a dosimetric parameter for measuring the dose distribution 
around a single source. For the multi-seed dosimetry scenario, the line profiles at 
various depths from source centre were studied instead. The EBT films compared well
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with Monte Carlo results with average RMS difference o f 2%, and Optical-CT 
showed 6% average RMS difference with Monte Carlo results. The multi-seed 
vertical implant method is recommended as it provides a secure dwell position for the 
OncoSeed™ during irradiation.
It is clear that the radiochromic film measurements had a much higher signal-to-noise 
ratio than the CCD-based Optical-CT measurements for the single 6711 seed. One 
might justifiably ask why there is any need for Optical-CT and PRESAGE™. The 
answer lies in the side-by-side seed experiment o f Section 5.9. It is clear that the dose 
distribution produced is not axially symmetric. This means that a single 
GAFCHROMIC® EBT film cannot capture all the required information.
11 9
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Chapter 6 Study of the Ir-192 High Dose Rate Source
6.1 Introduction
The microSeiectron-HDR Ir-192 source manufactured by Nucletron has a half-life of 
73.83 days and emits high-energy photons typically between 201-884 keV with 
average energy o f 370 keV. The source is commonly used in oncology centres 
worldwide in conjunction with remote afterloaders for gynaecological treatments o f 
the cervix and vagina as well as for boost treatments o f the prostate. The main 
advantage o f HDR treatment is the considerable decrease in treatment time due to its 
high dose rate. The Ir-192 source dosimetry has been extensively studied [13] both 
experimentally and via Monte Carlo simulation. However, practical dose 
measurements at positions close to the source are difficult to obtain, due to the high 
dose gradients [137]. This makes the microSelectron-HDR an ideal model system for 
comparing the accuracy and precision o f 3-D dosimetry via Optical-CT with well- 
established data. In particular, the high-resolution capabilities of Optical-CT may 
offer improvements over other experimental techniques such as the ability to extract 
slice images anywhere within a 3-D dataset.
The microSelectron-HDR remote after-loading device for high dose-rate 
brachytherapy treatment is currently used at the RSCH. The single Ir-192 source 
(outer capsule diameter o f 0.9 mm in diameter and 4.50 mm in length) is attached to a 
flexible steel cable to enable treatment through catheters. The source consists o f a 
pure iridium metal core (density 22.42 g cm'^) within which the Ir-192 is uniformly 
distributed [138], which is welded to a 200 mm-long woven steel cable with diameter 
0.70 mm. The remaining cable length is approximately 1305 mm with cross-section 
diameter o f 0.90 mm. Figure 6.1 shows the microSelectron-HDR Ir-192 source (part 
V2, No. 105.002) designed and manufactured by Nucletron.
Stml Capsule
------4.5
" T).65>|r-192 core o r
Figure 6.1: Mechanical design of a microSelectron-HDR Ir-192 source 1138]
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6.1.1 Current Published Results
The microSelectron-HDR used in interstitial and intracavitary brachytherapy has been 
well documented both theoretically and experimentally. Nath et al. [20] measured the 
anisotropy function o f a Ir-192 source (Best Industries) in 1993 in a solid water 
phantom using LiF TLD dosimeters; the results were published in the AAPM TG-43 
[13]. Other authors used experimental methods such as ionization chambers [139], 
LiF TLD rods [140-142], diodes [141], MOSFETS [143], Monte Carlo calculations 
[138, 140, 141, 144-147] and radiochromic films [148, 149] to obtain the dose 
distribution.
There are different versions o f microSelectron-HDR, the classic/old design and the 
new design. The classic/old design has an Ir-192 core with size 0.6 x 3.5 mm while 
the new design is slightly larger at 0.65 x 3.6 mm. In this study, the new design was 
used.
Most published dosimetric results include measurements at distances 1 cm or more. 
Monte Carlo calculations and radiochromic films were able to provide dose 
distribution closer than 1 cm. For intravascular brachytherapy, the AAPM TG-60 
suggests dosimetric data should be evaluated for distance below 5 mm [137]. 
Distances less than 5 mm are difficult to measure practically due to the high dose 
gradients [137].
Figure 6.2: MicroSelectron-HDR remote after-loading system (left), with catheter connected to a 
channel for the delivery of source wire (right)
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M icroSlectron
HDR
2 0 0 7 M onte Carlo  
Film
M CNP  
GAF M D -55
N/A S u rek a  C S  [148]
Old 2 0 0 6 M onte Carlo M CNP 0 -3 6 0
0 .2 5 -5 cm
S u reka C S  [147]
Old 2 0 0 6 M O SFET  
M onte Carlo
M CNP N/A Zilio V [1 4 3 ]
Old 2 0 0 4 Film GAF HS 0 -1 8 0
1-5cm
S h arm a S  D [149]
Old 2 0 0 4 M onte Carlo M CNP N/A L ym peropoulou
[146]
Old 2 0 0 2 M onte Carlo In h o u se 0 -1 8 0  
0 .2 , 1cm
P ap a g ia n n is  P [145]
Old 2 0 0 2 Film GAF HS N/A P ierm attei A [150]
Old 1 9 9 8 TLD 
M onte Carlo
L iF T L D -100  
In h o u se
0 -1 8 0
3 -7cm
K araiskos P [140]
N ew 19 9 8 M onte Carlo M CPT 0 -1 8 0
0 .2 5 -5 cm
D ask a lov  G [138]
Old 19 9 7 Ion C h am b er M iniature N/A M ishra V [139]
Old 1 9 9 6 M onte Carlo E G S 4 /
P R E ST A
0 -3 6 0
3-7cm
R u sse ll KR [151]
Old 1 9 9 5 TLD, D iode  
M onte Carlo
L iF T L D -100 , 
P -T ype, M CPT
0 -2 0 0
1 .5 -5cm
Kirov A S  [141]
Old 1 9 9 5 M onte Carlo M CPT 0 -1 8 0
0 .2 5 -5 cm
W illiam son JF [144]
Old 1 9 9 4 TLD LiF 1 5 -90  
1 -10cm
M uller-Runkel [142]
Old 1 9 9 3 M onte Carlo M CPT N/A W illiam son JF [152]
B est
Industries
1 9 9 3 TLD LiF 0 -9 0
1-7cm
Nath R [20]
M icroSlectron
P D R
1 9 9 5
1 9 9 3
TLD, D iode  
M onte Carlo 
M onte Carlo
T L D -100, P- 
T ype, M CPT  
M CPT
0 -2 0 0  
1 5 -5cm
Kirov A S  [141] 
W illiam son JF [1521
G am m am ed
P D R
2001 G el MRI 0 -3 6 0
1-2cm
D e D e e n e  [87]
V ariS ource 2 0 0 2 M onte Carlo In h o u se 0 -1 8 0  
0 .2 , 1cm
P ap a g ia n n is  P [145]
1 9 9 9 M onte Carlo In h o u se 0 -1 8 0  
0 .2 5 -1 5cm
K araiskos P [153]
B uchler 2 0 0 2 M onte Carlo In h o u se 0 -1 8 0  
0 .2 , 1cm
P ap a g ia n n is  P [145]
A ngioR ad™ 2 0 0 2 M onte Carlo In h o u se N/A P ap a g ia n n is  P [145]
Varian HDR 2 0 0 0 M onte Carlo In h o u se 0 -1 8 0  
0 .2 5 -1 5cm
A n g e lo p o u lo s  A 
[154]
Table 6.1: Measurements and calculations conducted on different Ir-192 sources
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6.2 MCNP Monte Carlo simulation
6.2.1 MCNP Model of Ir-192 Source
This section investigates the dosimetric characteristics o f the Ir-192 HDR source 
using MCNP Monte Carlo simulation. A MCNP Monte Carlo simulation was 
conducted to simulate the equivalent setup o f the Ir-192 implant experiment. The 
source model was based on the MicroSelectron HDR (new design, Nucletron). The 
new design dimensions were derived from mechanical drawings published by 
Daskalov [138] originally supplied by the vendor [155]. For the calculation of 
anisotropy functions, tally cells were placed at 0° to 90° at 10° intervals for distance 1 
cm and 2 cm from the source centre. To obtain the dose profile at a particular slice, 
tally cells were placed along lines situated at 7 mm and 11 mm from the centre o f the 
Ir-192 source and perpendicular to the long axis o f the source; the locations o f the 
slice were specifically match those o f the film dosimetric experiment described in 
section 6.4. The MCNP input syntax file o f the Ir-192 HDR source model can be 
found in Appendix E.
6.2.2 Results and discussions
A total o f 250 million histories were calculated in fulfilment o f the requirement o f the 
ten statistical tests. The anisotropy functions were calculated based on the 
PRESAGE™ elemental composition with mass density o f 1.05g cm'^, which is 
slightly higher than that o f water (0.998 g cm'^). Figure 6.4 shows the comparison o f 
MCNP simulation in water and in PRESAGE'^'^ at 1 cm with 10 million histories, 
difference o f up to 1.5% was observed at 10° to 20°, and less than 0.5% difference for 
polar angles above 30°. It is concluded that Monte Carlo simulation in water and in 
PRESAGE™ yields similar results, and that simulation based on PRESAGE™ would 
provide a close estimate to that o f water.
The comparison o f anisotropy functions with other authors is shown in Figure 6.3. 
The comparison includes results taken from a selection o f previous authors who used 
the old/classic design and Daskalov [138] who had published the values o f the 
anisotropy functions for the new designed microSelectron HDR-192 source. The TG- 
43 recommended consensus by Nath [20] used an Ir-192 source manufactured by Best 
Industries and hence was excluded in the comparison. Table 6.2 shows the
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comparison at 1 cm and 2 cm from source centre. The average standard error o f the 
Monte Carlo simulation sample mean at 1 cm is 0.0036 (0.36%) and 0.006 (0.6%) at 2 
cm. At 1 cm from source centre, results from our MCNP Monte Carlo showed good 
agreement with Daskalov at all polar angles except at 0°; this indicates the correct 
source geometry in our Monte Carlo simulation. For the microSelectron HDR 
old/classic design, large differences o f up to 29% were observed between Karaiskos 
and Williamson’s results at 0° to 20°. The differences may be related to the geometry, 
material and physics library used in the different Monte Carlo codes adopted by the 
authors. For experimental results, the variation o f source geometry during source 
manufacturing process may also apply.
C om parison 1 cm
0° 10° 20°
MCNP 0 .603 0 .7 1 9 0 .843
Williamson 0.551 0 .6 8 3 0 .8 2 9
Karaiskos 0.711 0 .7 3 4 0 .8 4 4
D askalov 0.631 0 .7 2 7 0 .8 3 9
K araiskos vs. 
W illiamson 29.0% 7.5% 1.8%
MCNP vs. 
D askalov -4.4% -1.1% 0.4%
Com parison 2 cm
0° 10° 20°
0 .603 0 .7 2 5 0 .843
0 .576 0 .703 0 .833
0 .727 0 .749 0 .863
0 .645 0 .7 4 5 0 .846
26.2% 6.5% 3.6%
-5.5% -2.6% -0.3%
Table 6.2: Comparison of anisotropy functions at low polar angles for 1 cm and 2 cm
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Figure 6.3: Graph of Monte Carlo results vs. other publishers at 1 cm (left) and 2 cm (right)
o
oc
3u .>.a.2
0.9
MCNP (PRESAGE) 
MCNP (Water)
0.7
o■!2 0.6
< 0.5
0 20 40 60 80
Polar Angle (®)
Figure 6.4: Graph ofF(r,0) Monte Carlo results in Water and PRESAGE at 1cm
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6.3 Optical-CT Analysis
6.3.1 Experimental Procedures
A hole 2 mm in diameter and 2.5cm in depth was drilled in a 6cm-diameter, 6cm high 
cylindrical PRESAGE™ dosimeter, providing a channel to secure a source catheter. 
An Ir-192 cable-driven source was inserted via the prepared catheter and allowed to 
reside for a set amount o f time (see Figure 6.5). The previous review and simulations 
conducted as part o f this investigation suggest that an improved experimental 
determination o f the anisotropy function at low polar angles would be useful. 
Previous polymer gel dosimetry o f Ir-192 studies [87] have not been totally successful, 
due to oxygen contamination and other complications. The use o f PRESAGE™ was 
expected to eliminate these problems.
PRESAGE™ dosimeters (batch #181) were used in this experiment. The Ir-192 
source dwell position was 2 mm from the bottom o f the drilled channel. The dose rate 
recorded on 06/02/2007 14:14 was 4.29 cGy m^ h"' at a distance o f Im. The source 
activity at the time of irradiation was 153.3 GBq (4.14ci) and the dose rate was 1.692 
cGy m^ h '’ or 4.7cGy cm^ sec '. The total time of irradiation was 300 second, which 
translates to approximately 13.5 Gy at 1 cm from the source centre and 2.7 Gy at 2 cm 
(See Table 6.3). After 12 hours, to allow for any post-irradiation colour development 
effect [98], the dosimeter was scanned by our in-house Optical-CT scanner using the 
procedures described in section 5.3 .
Figure 6.5: Presage™ dosimeter with catheter in position (top left), flexi-catheter connected to 
delivery wire (top right), MicroSelectron-HDR remote after-loading system with Presage™ 
dosimeter (bottom left), irradiated Presage™ dosimeter showing colour changes (bottom right)
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h ( r , e )  = S,  \  - - F ( r , e )  g ( r )
(2D Formalism)
1 cm 2 cm
16920 16920 cG y h'^
A 0 .98 0 .98 cG y cm^ / U h
gr (C o n sen su s) 1 0 .814
1 1
G (r,6^)
0 .976 0 .244
161 .83 32 .93 Gy h '
15 /05 /2007 300  S e c s
1 Duration
D ays Hours S eco n d s Total Hours
00 00 300 0 .0 8 3 3
1 cm 161 .83 0 .0833 13.48
2 cm 3 2 .93 0 .0 8 3 3 2 .7 4
Table 6.3: Calculation of absorbed dose at 1 cm and 2 cm for Ir-192 HDR source
/  Hole
<  0 005
20 10 20
Figure 6.6: Photo of irradiated PRESAGE™ dosimeter side view inside scanning glass cell (top 
left) optical-CT projection image of irradiated PRESAGE™, total of 400 projections over 180° 
(top right); optical-CT single slice reconstruction, Pixel size: 0.25 m m \ slice thickness: 0.25 mm 
(bottom left); line profile across reconstructed image; central dip and artifact correspond to 
position of drilled hole (bottom right)
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6.3.2 Results and discussions
The anisotropy functions were calculated from the Optical-CT three-dimensional 
dataset by taking the mean pixel values o f the surrounding 6 pixels (0.8 mm). The 
average standard error o f the sample mean is o f the order 0.015 (1.5%) for polar 
angles 0° < 6^ <90° at 1 cm from centre o f source, and 0.019 (1.9%) at 2 cm. The 
comparison o f anisotropy functions obtained by Monte Carlo simulation and Optical- 
CT experiment with Daskalov [138] is shown in Figure 6.8. Results o f the classic/old 
design were not included in this comparison. The calculated and measured anisotropy 
functions were in good agreement with Daskalov especially at polar angles above 10°. 
As a suitable measure o f the success o f this study, the results o f Daskalov’s Monte 
Carlo study over the range 10° < ^ <80° was used to compare with the Optical-CT 
results, the mean value \Daskalov{6 ) -  OCT {9)\v^aiS 2.1% at 1 cm from source centre
and \DaskaJov{6 )~  MCNP{6 )\v^2iS 0.4%. The line profile taken at 7 mm from centre
o f source is shown in Figure 6.7, the systematic peaks may be due to the ring artifacts 
within the slice image. The attempt to extract the line profile at 11 mm was 
unsuccessful due to the noise associated with the image slice.
Optical-CT| 
MCNP !
3 -2 •1 0 1 2 3
Distance from Soure Centre (cm)
Figure 6.7: Optical-CT Slice at 7 mm from source centre with corresponding line profile
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Figure 6.8: Graph ofF(r,0J between Monte Carlo and Optical-CT results at 1 cm (top) and 2 cm
(bottom)
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6.4 Radiochromic Film Analysis
6.4.1 Experimental Procedures
A similar experiment was conducted at the same session with GAFCHROMIC® EBT 
films. A PRESAGE™ dosimeter was sliced in half lengthways, with a grooved 
channel machined on one half to secure a catheter during irradiation. An array o f three 
GAFCHROMIC® EBT films was sandwiched between the two halves o f PRESAGE™ 
dosimeter to record the dose distribution (see Figure 6.9). The Ir-192 source was 
inserted via the catheter using the MicroSelectron HDR remote afferloader. The 
CCTV in the control room was used to monitor the irradiation process. Slice profiles 
were also obtained by inserting EBT films at 7 mm and 11 mm below the source 
centre using a similar method described in section 5.6.3. GAFCHROMIC® EBT films 
(ISP Technologies, Lot no 35146-003A1) were used in this experiment. The Ir-192 
source dwelling position was 2 mm from the bottom of the drilled channel. The 
source activity at the time o f irradiation was 153.3 GBq (4.14 ci) and the dose rate 
was 161.83 Gy h '. The total time o f irradiation was 40 second, which translates to 1.8 
Gy at 1 cm and 0.4 Gy at 2 cm from the source centre. The films were scanned 12 
hours post-irradiation and calibrated to represent dose and the anisotropy functions 
were calculated using an in-house IDE program.
Top View Side View
PRESAGEDOSIMETER
Array of 
GAFCHROMIC* Films
3,0 cm
3.0 cm;
/Catheter
Channel
PRESAGE'”
DOSIMETER
4
GAFCHROMIC* . Films 
/  Array
6 cm Diameter 6 cm Diameter
Figure 6.9 Schematic diagram of GAFCHROMIC® EBT films sandwiched in PRESAGE^’'* 
dosimeter (top), photo of PRESAGE™ phantom with a secure plastic holder, connected to the 
MicroSelectron HDR system via a flexi-catheter (bottom)
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6.4.2 Results and discussions
The anisotropy functions are presented in Table 6.4 and a global comparison is shown 
in Figure 6. I I . The relative eiTor o f the sample mean at 1 cm from the centre o f the 
source across all polar angles ranged from 0.20% to 0.27% and at 2 cm from 0.22% to 
0.27%. Error bars to represent the absolute standard error would be o f the order o f (or 
smaller than) the size o f the plots symbols and so are omitted. At 1 cm from the 
source centre, the EBT film results were significantly different from the optical-CT 
and MCNP simulation results. This may be due to the lack o f response o f the EBT 
film to the high-dose rate o f delivery, though this is unlikely to be the case since the 
manufacturer claimed that the EBT film response is independent o f dose rate and 
there are no report published suggesting this is not the case. Therefore the source of 
the discrepancy is yet unknown at present.
The percentage standard deviation between results from this study and Daskalov from 
0° to 20° was up to 14.1% and below 2.6% for angles above 20°. At 2 cm, for angles 
above 10°, the EBT results were in good agreement with the Optical-CT and Monte 
Carlo results. The percentage standard deviation between our results and Daskalov 
from 0° to 20° was up to 11.8% and below 1.3% for angles above 20°.
Figure 6.10 shows the line profile eomparison o f EBT film, Optical-CT and MCNP 
Monte Carlo results at 7 mm and 11 mm from source centre. Results o f EBT film are 
in excellent agreement with MCNP Monte Carlo results at 7 mm, but appeared to be 
noisy at 11mm due to the relatively low signal with increased distance from source 
centre. The line profile o f Optical-CT at 11 mm could not be extracted from the image 
slice due to the low signal to noise.
13 0
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Authors Polar angle 0 (d egrees)0 10 20 30 40 50 60 70 80 90
EBT Film 0 .8 2 5 0 .859 0 .9 1 8 0 .9 5 5 0 .980 0 .992 0 .9 9 7 1.001 0 .998 1
MCNP 0 .6 0 3 0 .7 1 9 0 .8 4 3 0.911 0 .9 4 9 0 .973 0 .9 8 4 0 .9 9 6 0 .999 1
Optical-CT 0 .6 6 5 0 .7 3 7 0 .8 1 4 0 .9 3 5 0 .9 6 4 1.006 1.007 1.021 0 .995 1
D askalov 0.631 0 .7 2 7 0 .8 3 9 0 .902 0 .9 4 9 0 .965 0 .982 0 .9 9 7 1.000 1
% S D 13.0% 8.6% 6.5% 2.4% 2.1% 2.0% 1.9% 1.6% 1.0% 0.0%
Relative 
Error of EBT 
Film
0.2% 0.2% 0.3% 0.2% 0.2% 0.3% 0.2% 0.3% 0.3% 0.3%
Authors Polar angle  0 (d egrees)0 10 20 30 40 50 60 70 80 90
EBT Film 0.801 0 .7 9 6 0 .852 0 .9 1 4 0 .946 0 .968 0 .984 0 .9 9 9 1.007 1
MCNP 0.610 0 .7 2 5 0 .843 0 .9 0 3 0 .9 4 6 0 .972 0 .985 0 .998 0 .999 1
Optical-CT 0.701 0 .7 6 7 0 .8 4 0 0 .9 2 3 0 .9 7 3 0 .965 0 .999 0.991 0 .986 1
D askalov 0 .6 4 5 0 .7 4 5 0 .8 4 6 0 .907 0 .9 5 5 0 .9 6 5 0 .982 0 .9 9 8 1.000 1
% S D 10.6% 8.9% 5.1% 1.5% 1.3% 1.1% 1.8% 0.5% 0.8% 0.0%
Relative 
Error of EBT 
Film
0.2% 0.3% 0.3% 0.3% 0.2% 0.2% 0.3% 0.3% 0.3% 0.3%
Table 6.4; ¥(r, 0) between published and GAFCHROMIC® EBT film results at 1 cm and 2 cm
 Optical-CT
 EBT Film
 MCNP
0.4 -
■3 •1 1 3Distance from soure  centre (cm)
EBT Film 
 MCNP0.8
-3 •2 ■1 0 1 2 3Distance from source  centre(cm)
Figure 6.10: EBT Film slice at 7mm from source centre with corresponding line profile (left), 
EBT Film Slice at 11 mm with line profile (right)
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Figure 6.11: Graph of¥(r,9) between published and GAFCHROMIC® EBT film results at 1 cm
(top) and 2 cm (bottom)
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6.5 Conclusions
In this chapter, three different techniques, GAFCHROMIC® EBT films, Optical-CT 
with PRESAGE™ and MCNP Monte Carlo simulation have been used to determine 
the anisotropy functions o f a microSelectron-HDR Ir-192 source commonly used in 
HDR brachytherapy.
The accuracy o f the Monte Carlo simulations is highly dependent on the input data o f 
the source model, the effect o f source model description on the anisotropy functions 
was demonstrated in Section 5.1.3. In this study, the 3-D MCNP Monte Carlo 
simulations were based upon the AAPM TG-43 recommendations, manufacturer and 
previously published source geometry, photon energy spectrum and photon cross- 
sections. For experimental data, the anisotropy functions were calculated from a 3-D 
Optical-CT dataset and 2-D digitised image datasets o f GAFCHROMIC® EBT film. 
The calculated and measured anisotropy functions were in good agreement with 
Daskalov's results especially at polar angles above 10°. For polar angles in the range 
30° < i9 <80°, the percentage o f standard deviation between results from this study and 
other authors was below 2.6% at 1 cm from source centi'e and below 1.3 % at 2 cm. 
At 1 cm from the source centre, the EBT film results were significantly different from 
the results o f Optical-CT, MCNP simulation and Daskalov’s. This may be the result 
o f  lack o f response o f  the GAFCHROMIC® EBT film at high dose rate; though this is 
unlikely to be the case since the manufacturer claimed that if  sufficient time is 
allowed post-irradiation, the GAFCHROMIC® BBT film does not exhibit a dose rate 
dependence [57]. Other types o f film such as the GAFCHROMIC® HS [149, 156] and 
GAFCHROMIC® MD-55 [63, 148] were used by previous investigators which may 
be more suitable for high dose rate dosimetry due to the relatively dose-rate 
independent from the range o f 0.034 Gy miif* to 80 Gy min"'.
The results o f this study indicated an evident potential o f the utilisation of 
PRESAGE™ with Optical-CT as an accurate 3-D method o f dosimetry for 
characterizing the anisotropy functions for Ir-192 HDR source. On the contrary, 
results obtained with GAFCHROMIC® EBT films showed that this may not be the 
most suitable dosimeter for HDR brachytherapy dosimetry.
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Chapter 7 Study of the 1-125 Model 6733 EchoSeed™
The newly developed iodine 1-125 seeds Model 6733/6735 also known as 
EchoSeed™ was introduced at the end o f 2003 and are now commercially available. 
Similar to the successful Model 6711, the physical characteristics o f the 4.5 mm x 0.8 
mm EchoSeed™ consist o f 1-125 adsorbed on a silver-halide rod (i.e. surface 
distributed) and contained in a 0.05 mm thick titanium shell, with minimum and 
maximum source strength o f 10.99 MBq (0.30 mCi) and 24.90 MBq (0.68 mCi), and 
a laser welded semi-circled end design. The specifically designed grooves on the outer 
surface o f the titanium capsule allow enhanced visualization under ultrasound. Figure
7.1 shows the EchoSeed™. The dosimetric characteristics o f EchoSeed™ have 
previously been reported by two independent investigators, TLD measurements by 
Meigooni et al [27] and PTRAN Monte Carlo simulation by So wards et al [28] as 
recommended by the AAPM.
0.05 mm 
titanium1-125 adsorbed on silver rod
0.8 mm 0.5 mm
3.0 mm
4.5 mm
Figure 7.1: Model 6733 EchoSeed™
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7.1 Optical-CT Analysis
7.1.1 Experimental procedures
The PRESAGE™ solid dosimeter used in this experiment was taken from batch #181. 
An EchoSeed™ with air kerma strength o f 17.9 MBq (0.48 mCi) was vertically 
implanted into a 2.5 cm deep channel, and 3 mm off the centre o f the PRESAGE™ 
dosimeter in order to avoid effect o f the CT ring artifacts. The total absorbed dose at 
1 cm from the centre o f source after 3 weeks was approximately 1.7 Gy and 0.35 Gy 
at 2 cm (See Table 7.1). The EchoSeed™ was supplied at a lower air kerma strength 
than the OncoSeed™ primarily for its ultrasound imaging visualization properties. 
Ideally, the PRESAGE™ dosimeter should be irradiated to the minimum of 2 Gy; this 
was not possible due to the time restraint in this preliminary study.
D (r,0) = S , - A -  ■F{ r , 0 ) g ( r ) ^G{ro,0^) (2D Formalism)
1 cm 2 cm
0 .4 1 8 0 .418 cG y h’^
A 0 .98 0 .98 cG y cm^ / U h
gr (C o n sen su s) 1 0 .814
F ( r ,^ ) 1 1
G(/",^)
0 .976 0 .244
D ( r ,^ ) 0 .3 9 9 8 0 .0 8 1 4 cG y h""
In 2 5 /0 5 /2 0 0 7 14:25
Out 14 /06 /2007 16:45
1 Duration
D ays Hours Minutes
20 2 20 Total Hours
= 4 8 0  Hours 2 20 4 8 2 .3 3
1 cm 0 .3 9 8 8 4 82 .33 171.47
2 cm 0 .0 8 1 4 4 8 2 .3 3 34 .99
Table 7.1: Calculation of absorbed dose at 1 cm and 2 cm for 1-125 Model 6733 source
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7.1.2 Results and discussion
The dosimeter was scanned 12 hours post-irradiation by our in-house Optical-CT 
scanner to allow for any post-irradiation colour development effect. Projection images 
o f size 256 x 256 pixels were reconstructed to form a 3-D dataset with slice thickness 
o f 0.25 mm and image slice reconstruction at 0.25 mm^ per pixel. The anisotropy 
functions were calculated from the Optical-CT three-dimensional dataset by taking 
the pixel values o f the surrounding 0.8 mm using an in-house IDE program. The 
average standard error o f the sample mean for polar angles o f 0 to 90° is o f the order 
0.038 (3,8%) at 1 cm and 0.037 (3.7%) at 2 cm from the centre o f the source. The 
results are presented in Table 7.2 and Figure 7.2. At 1 cm, the anisotropy functions 
between Optical-CT and Sowards et al had high difference at polar angle o f 0° and 
differences o f less than 14% for angles above 10°. At 2 cm, the percentage 
differences between all authors are high at angles less than 10°; percentage standard 
error o f 11.2% was observed for Optical-CT, the differences may be due to the short 
irradiation time and the lack o f detectable optical density changes at 2 cm. Anisotropy 
functions published by Meigooni et al were only available for distances above 2 cm 
from centre o f source. Difference o f 22.3% was observed between Sowards and 
Meigooni at low polar angle.
Authors Polar an g le  0 (d egrees)0 10 20 30 40 50 60 70 80 90
Optical-CT 0 .470 0 .540 0 .8 1 3 0 .8 8 4 0 .9 7 4 0.981 0 .9 8 5 0 .9 3 6 1.071 1
Sow ards 0 .305 0 .5 0 7 0 .7 1 4 0 .848 0 .9 4 4 0 .9 9 9 1.029 1.038 1.026 1
Optical-CT
% Standard
Error
7.7% 7.6% 2.9% 1.7% 3.7% 3.5% 2.4% 3.6% 2.8% 2.8%
Optical-CT  
vs. Sow ards 53.9% 6.5% 13.9% 4.3% 3.1% -1.8% -4.3% -9.8% 4.4% 0.0%
Authors Polar angle  0 (d egrees)0 10 20 30 40 50 60 70 80 90
Optical-CT 0 .788 0 .8 8 0 0.851 0 .9 5 4 0 .9 8 9 0 .9 5 4 0 .9 7 5 0 .982 1.018 1
Sow ards 0 .3 8 4 0 .5 6 6 0 .7 3 7 0.851 0 .932 0 .9 8 4 1.016 1.031 1.035 1
M eigooni 0 .4 9 4 0 .6 2 5 0 .7 3 4 0.881 0 .8 9 5 0 .949 0 .9 9 5 1.015 1.011 1
Optical-CT
% Standard
Error
11.2% 4.3% 3.6% 2.0% 2.7% 2.6% 2.2% 2.4% 3.6% 3.3%
Optical-CT  
vs. Sow ards 105.1% 55.4% 15.5% 12.1% 6.1% -3.0% -4.0% -4.7% -1.6% 0.0%
Optical-CT  
vs. M eigooni 59.5% 40.7% 15.9% 8.3% 10.5% 0.5% -2.0% -3.2% 0.7% 0.0%
S ow ards vs. 
M eigooni -22.3% -9.4% 0.4% -3.4% 4.1% 3.7% 2.1% 1.6% 2.4% 0.0%
Table 7.2: Y(r,B) between published and Optical-CT results at 1 cm (Top) 2 cm (Bottom)
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Figure 7.2: Graph of¥(r,0) between published, Optical-CT and EBT film results at 1 cm (top), 2
cm (bottom)
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7.2 Radiochromic Film Analysis
7.2.1 Experimental procedures
The GAFCHROMIC® EBT films (ISP Technologies, Lot no 35146-003A1) 
experimental setup and the pre- and post scans were conducted in a similar manner to 
the experimental procedures in Section 5.6.3 with the 6711 OncoSeed™. An 
EchoSeed™ with air kerma strength o f 17.9 MBq (0.48 mCi) was implanted in the 
groove for 3 weeks. The total absorbed dose at 1 cm from the centre o f source was 
approximately 1.7Gy and approximately 0.35Gy at 2 cm. The GAFCHROMIC® EBT 
films were digitised at a resolution o f 300 dpi (118 pixel/cm), and equivalent pixel 
size o f 0.085mm. The films were calibrated to dose and the anisotropy functions were 
calculated using an in-house IDE program.
Top View Side View
PRESAGE"DOSIMETER
Array of 
GAFCHROMIC» Films
2.1 cm
3.9 cm
PRESAGE"'
DOSIMETER GAFCHROMIC* Films 
Array/
6 cm Diameter 6 cm Diameter
Figure 7.3: Schematic view of EchoSeed™ implanted inside a groove channel within a 
PRESAGE™ dosimeter (top), photo of PRESAGE™ phantom (bottom)
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7.2.2 Results and discussion
The anisotropy functions were calculated by taking the average pixel values o f the 
surrounding 0.8 mm. The standard error o f the sample mean at 2 cm from the centre 
o f the source is o f the order 0.002 (0.2%). Error bars to represent the standard error, 
would be o f the order o f (or smaller than) the size o f the plots symbols and so are 
omitted. The anisotropy functions obtained by the GAFCHROMIC® EBT film 
experiment with other published data are shown in Table 7.3 and Figure 7.2. The 
experimental results o f Meigooni et al were not available at 1 cm and ranged from 2 
cm to 7 cm. At 1 cm, the anisotropy results between the Optical-CT and EBT films 
are in good agreement for polar angles above 10°. At small angles, results published 
by Sowards are consistently lower than the Optical-CT and EBT films results; the 
differences may be related to the seed geometry and elemental composition used in 
Sowards ' Monte Carlo simulation. It is unclear fi'om the source o f literature [28] the 
method used in specifying the source geometry, particularly the groove features on the 
surface o f the EchoSeed™. At 2 cm, the EBT film results except for small polar 
angles (<I0°) are in good agreements (<4,2%) with measured data by Meigooni. 
Monte Carlo results from Sowards et al also compared well with Meigooni at polar 
angles 20° to 90° with noticeable large difference observed at small angles <10°.
Authors Polar an g le  6 (d eg rees)0 10 20 30 40 50 60 70 80 90
EBT Film 0 .527 0 .6 7 7 0.751 0 .8 4 4 0.911 0 .9 5 5 0 .9 9 4 0 .9 9 7 0 .998 1
Optical-CT 0 .470 0 .540 0 .8 1 3 0 .8 8 4 0 .9 7 4 0.981 0 .9 8 5 0 .9 3 6 1.071 1
Sow ards 0 .3 8 4 0 .5 6 6 0 .7 3 7 0.851 0 .9 3 2 0 .9 8 4 1 .016 1.031 1 .035 1
Optical-CT  
vs. EBT Film 12.2% -5.5% 2.4% -3.5% 0.5% -2.6% -4.4% -9.3% 5.6% 0.0%
EBT vs. 
Sow ards 37.3% 12.8% 11.2% 8.1% 2.7% 0.8% 0.2% -0.6% -1.2% 0.0%
Authors Polar angle  0 (d egrees)0 10 20 30 40 50 60 70 80 90
EBT Film 0 .527 0 .677 0.751 0 .8 4 4 0.911 0 .955 0 .9 9 4 0 .9 9 7 0 .998 1
Optical-CT 0 .788 0 .880 0.851 0 .9 5 4 0 .989 0 .9 5 4 0 .975 0 .982 1.018 1
M eigooni 0 .494 0 .6 2 5 0 .7 3 4 0.881 0 .8 9 5 0 .949 0 .995 1 .015 1.011 1
Sow ards 0 .3 8 4 0 .5 6 6 0 .7 3 7 0.851 0 .932 0 .9 8 4 1.016 1.031 1.035 1
Optical-CT  
vs. EBT Film 49.5% 30.0% 13.4% 13.0% 8.5% 0.0% -1.9% -1.5% 2.0% 0.0%
EBT vs. 
M eigooni 6.7% 8.3% 2.3% -4.2% 1.8% 0.6% -0.1% -1.8% -1.3% 0.0%
Sow ards vs. 
M eigooni -22.3% -9.4% 0.4% -3.4% 4.1% 3.7% 2.1% 1.6% 2.4% 0.0%
Table 7.3: ¥(r,9) of published and GAFCHROMIC® EBT film results at 1cm (Top) 2cm (Bottom)
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7.3 Conclusions
In this chapter, the anisotropy functions o f the newly developed iodine 1-125 seeds 
Model 6733 EchoSeed™ was successfully determined by two experimental methods; 
PRESAGE™ with Optical-CT and GAFCHROMIC® EBT film dosimetry. The 
anisotropy functions obtained by the two different methods were in good agreement 
with maximum difference o f up to 12% at small polar angles. At I cm from source 
centre, the anisotropy functions obtained by Optical-CT can be observed but with 
some fluctuation at 60° to 80°; this may be caused by the low signal to noise due to the 
short irradiation time with equivalent absorbed dose o f approximately 1.7 Gy. 
Sowards’ results at I cm are consistently lower than the Optical-CT and EBT films 
results. The source o f the discrepancies may be related to the source geometry and 
elemental composition used in the Monte Carlo simulation.
At 2 cm, the anisotropy results for Optical-CT were consistently higher than the 
GAFCHROMIC® EBT film and other published results. The difference again may be 
due to the result o f the short irradiation time (approximately 0.35 Gy); which is below 
the limit o f reliable measurement. The low signal to noise problem encountered in this 
experiment can be resolved by extending the duration time o f irradiation. The EBT 
film results matched well with Meigooni; and were in better agreement than Sowards’ 
results throughout the range o f polar angles investigated.
This is a pilot study o f the Model 6733 EchoSeed™, a Monte Carlo simulation was 
not conducted in time for this study due to the complicated model geometry with the 
additional groove features on the outer titanium shell.
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Chapter 8 Conclusions, Future work and Recommendations
This report summarises the dosimetric study o f the 1-125 Model 6711 OncoSeed™, 
Model 6733 EchoSeed™ and Ir-192 HDR brachytherapy sources involving Monte 
Carlo simulations and various innovative experimental methods. The anisotropy 
functions obtained through solid polymer dosimetry (PRESAGE™ with Optical-CT) 
are in good agreement with previously published results as described in Chapter 1 to 
Chapter 7, particularly when the PRESAGE™ dosimeter has good optical clarity, 
minimal surface and internal manufacturing artifacts and had been irradiated for 
sufficient time to provide an easily detectable signal by the Optical-CT system. 
GAFCHROMIC® EBT films and Monte Carlo results have provided complementaiy 
results for cross-comparison with Optical-CT results.
Monte Carlo simulations and film dosimetry are capable o f providing dose profiles, 
yet the user must specify the particular slices (via tally cells or location o f films) 
ahead o f the simulation or experiment. One would need to repeat the experiment in 
order to obtain information from other slices. The advantage o f using Optical-CT 
includes the ability to view and extract dose profiles o f any image slices within the 
3-D dataset, which in contrast to film dosinietiy, is practically more feasible in 
consideration o f the time and cost. Results presented in Section 5.8 showed line 
profiles o f Optical-CT data that had better agreement with Monte Carlo data than 
those o f EBT films. Combining the Optical-CT system with the new solid polymer 
dosimeter (PRESAGE™) had enabled the 3-D dosimetry o f low dose-rate 
brachytherapy sources that was not possible with previous experimental methods o f 
dosimetry. In conclusion, GAFCHROMIC® EBT film dosimetry had produced 
superior results over Optical-CT due to its high resolution, high sensitivity and 
stability during and after irradiation. Further improvement is needed for PRESAGE™ 
to become a common method o f dosimetry, including characteristics such as: higher 
sensitivity, better optical clarity and tissue equivalent properties. Suggestions for 
further work are summarised in the following sections.
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8.1 Method of Dosimetry
For the solid polymer dosimetric experiments conducted, the vertical implant 
technique was found to be the most suitable. The technique had enabled the successful 
determination o f anisotropy functions for various brachytherapy sources in our study 
as well as the 2D slice image analysis for all regions below the drilled channel. It 
involves a channel being drilled a few millimetres off the centre o f the dosimeter 
allowing a secure dwelling position for different brachytherapy sources. The 
properties o f PRESAGE™ had many practical advantages over other polymer gel 
systems including its rigid, easily machineable nature, stable during a prolonged 
irradiation period and insensitive to oxygen [71]. The use o f the auto-developing 
GAFCHROMIC® EBT films has provided in-phantom 2D results for verification with 
Optical-CT experiments and Monte Carlo simulations. The results from this study 
may be implemented further, particularly in the optimisation o f experimental 
protocols and Monte Carlo simulations with more accurate physical and dosimetric 
specifications. This can be achieved by following some form o f written experimental 
protocol with the ability o f updating it in future with more efficient experimental 
procedures. The Monte Carlo input file would also need to be updated to reflect the 
changes made in the equivalent experiment.
8.2 Optimum Irradiation Time
This report has demonstrated the successful determination o f the anisotropy functions 
by irradiating a PRESAGE™ dosimeter for a period o f time and scanning it with the 
Optical-CT system. Taking into account the low dose rate hence the longer irradiation 
time for I-125 brachytherapy seed sources; what is the optimum dose requirement for 
a successful determination o f the anisotropy functions by Optical-CT? From the 
experience gained from this study, the recommended minimum dose at I cm from the 
centre o f source should be between 2.5 to 3 Gy. This will provide adequate optical 
density signal for the calculation o f anisotropy functions for distance o f <1.5 cm. For 
Ir-192 HDR sources, for the determination o f anisotropy functions at <2 cm; the 
optimum dose is 10 Gy at 1 cm from centre o f source. User must calculate the 
duration o f irradiation according to the relevant source activity. Further development 
o f a higher sensitivity PRESAGE™ dosimeter would also shorten the time o f 
irradiation and provide adequate optical density change.
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8.3 Treatment Planning System
The potential outcome to this work will allow the validation o f the underpinning 
models and assumptions that are made by the planning software o f the manufacturer’s 
brachytherapy system. At present, there is no independent 3D verification system that 
the dose received by the patient is that which is prescribed by the clinician.
Due to the lack o f access to the hospital treatment planning system, the studies 
investigated herein were not possible to make a direct comparison with the hospital 
treatment planning data. This would be an area o f considerable interest for future 
investigations.
8.4 Other Applications
With the experience gained in this report, the next step would be to investigate the 
application o f solid polymer dosimetry with Optical-CT (CCD and Laser), 
GAFCFIROMIC® EBT film dosimetry, Monte Carlo simulation and other techniques 
(e.g. TLDs, doped glass fibres) in the dosimetry o f other newly developed 
brachytherapy sources. The different method o f dosimetry will complement the 
recommendation o f the AAPM for new low-energy photon-emitting sources (photon 
energies less than 50 keV) in which studies should include at least one experimental 
and one Monte Carlo [17]. The application o f PRESAGE™ with Optical-CT is not 
limited to photon dosimetiy; other areas o f interest currently under investigation in 
our centre include electron and proton therapy [157, 158].
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Appendix
A. International Prostate Symptom Score (IPSS)
international p rostate sym ptom  sc o r e  (IPSS)
Name: Date:
1
J  ^
i f 3 1 i l i s
incomplete emptying
Over the past montli, how often have you had a sensation o f 
not emptying your Madder completely after you finish 
iirinaiinB?
0 1 2 3 4 5
Frequency
Over tlte past month, how often have you had to urinate 
again less than two hours after you finished urinating?
0 1 2 3 4 5
Intermlttency
Over the past month, how often have you found you stopped 
and started again several times when y«i urinated?
0 1 2 3 4 5
Urgency
Over the last month, how difficult have you found it to 
postpone utination?
0 1 2 3 4 5
Weak stream
Over the past montlr. how often have you had a weak 
urinary stream?
0 1 2 3 4 5
Straining
Over the past month, how often have you had to push or 
strain to begin uràmtion?
0 1 2 3 4 5
i 1 1 1 II l i
Nocturia
Over the past month, many times did you most typically got 0 1 2 3 /\ 5up to urinate from the time you went to btxl until the time 
you got up in the morning?
Total IPSS score
Quality of life due to urinary symptoms ia 1 ilii 111
1 f  you were to spend the rest of your life will) your urinary 
condition the way it is now, how would you feel about that? 0 1 2 3 4 5 6
Tolal score; 0-7 Mildly sympumiaiic; 8-19 moderately synptoinatie; 20-35 severely symptomatic.
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B. Optical Density vs Dose for 6MV and 10MV
±zru_
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C. Line Source Approximation
In Figure 2.3 o f Chapter 2, the dose rate at point P due to a region o f a one 
dimensional source o f width dz, located at co-ordinate Z along the horizontal axis is
(D. 1)
The ML comes about because the radioactive material, which in Equ. ( 5 ) is all 
concentrated at a point and dispersed over a distance L.
-  {rsin of" + {rcos6— z f  
= — 2rZ cosO +Z^
(D .2 )
Thus, D a t P o c -  rT J-L2L IrZcosd-b Z^ (D .3 )
Substitute s = Z - rcosO and a= rsinO. The integral becomes
D az—I  k=-L2 s^ +a^ ds (D .4 )
This is the standard integral with solution — tan'^ —a a
Now replace Z, r, 6 to give
D  oc - 1Lrsind tan
rcos6 - Z  
rsinO
+ 1 .2
(D. 5)
Referring again to Fig. A, we see that
= ta^(90 -  e,) a .d  _ g jrsinO rsinO (D .6 )
Hence,
D  cc— =LrsinO Lrsind (D .7 )
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D  oc - 1LrsinO \ (9 o -e , ) - (9 o -e ) ] (D. 8)
rsinO
rcosO
► Z
Fig. A: Line source approximation
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Expanding (D. 7) we have
V
-1D  oc LrsinO
K , rsinO— - tan -------------2 ^ LrcosO-----2 j
\  r  \
K rsinO 
2 rcosO — L~2 )
(D. 9)
Now consider the limit 6^  -4- 0 s in O ^  0, cosO -^  1 and tan A6>-> AO
D  oc LrsinO
r 0 r 0
+  ■ (D. 10)
1 1
L L
2 2
1 L
L Ur -----4
.2 I '
Q.E.D
(D. 11)
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D. MCNP model of 6711 seed
Iodine Model 6711 Seed
c ++++++++++++++++-I +++++++++
c File Prepared by Philip Wai
c ++++++++++++++++++++■ 
c Cell Card
++ + ++C + + + + + + + + 4
1 1 -10.50 -I 6 -5
2
5
6
7 4 -4.54 -11 8
8 4 -4.54 -12 -9
111 5 -1.050 -111
121 5 -1.050 -121
131 5 -1.050 -131
141 5 -1.050 -141
151 5 -1.050 -151
211 5 -1.050 211 -212
221 5 -1.050 221 -222
231 5 -1.050 231 -232
241 5 -1.050 241 -242
251 5 -1.050 251 -252
311 5 -1.050 311 -312
321 5 -1.050 321 -322
331 5 -1.050 331 -332
341 5 -1.050 341 -342
351 5 -1.050 351 -352
411 5 -1.050 411 -412
421 5 -1.050 421 -422
431 5 -1.050 431 -432
441 5 -1.050 441 -442
451 5 -1.050 451 -452
511 5 -1.050 511 -512
521 5 -1.050 521 -522
531 5 -1.050 531 -532
541 5 -1.050 541 -542
551 5 -1.050 551 -552
611 5 -1.050 611 -612
621 5 -1.050 621 -622
631 5 -1.050 631 -632
641 5 -1.050 641 -642
651 5 -1.050 651 -652
711 5 -1.050 711 -712
721 5 -1.050 721 -722
731 5 -1.050 731 -732
741 5 -1.050 741 -742
751 5 -1.050 751 -752
811 5 -1.050 811 -812
821 5 -1.050 821 -822
imp:p=l $ Silver Rod
2 -4.93 1 -4 6 -5 imp :p= 1 $ 1-125 Coating Centre
3 -0.00120 -7 -8 9(4:5:-6) imp:p=l $ Air Gap
4 -4.54 7 -8 9 -10 imp:p=l $ Titanium Outer Shell
imp:p=l $ Titanium Right Tip 
imp:p=l $ Titanium Right Tip
, imp:p=l $ tally ring 1,00 
imp:p=l $ tally ring 2,00 
imp:p=l $ tally ring 3,00 
imp:p=l $ tally ring 4,00 
imp:p=l $ tally ring 5,00 
imp:p=l $ tally ring 1,10 
imp:p=l $ tally ring 2,10 
imp:p=l $ tally ring 3,10 
imp:p=l $ tally ring 4,10 
imp:p=l $ tally ring 5,10 
imp:p=l $ tally ring 1,20 
imp:p=l $ tally ring 2,20 
imp:p=l $ tally ring 3,20 
imp:p=l $ tally ring 4,20 
imp:p=l $ tally ring 5,20 
imp:p=l $ tally ring 1,30 
imp:p=l $ tally ring 2,30 
imp:p=l $ tally ring 3,30 
imp:p=l $ tally ring 4,30 
imp:p=l $ tally ring 5,30 
imp:p=l $ tally ring 1,40 
imp:p=l $ tally ring 2,40 
imp:p=l $ tally ring 3,40 
imp:p=l $ tally ring 4,40 
imp:p=l $ tally ring 5,40 
imp:p=l $ tally ring 1,50 
imp:p=l $ tally ring 2,50 
imp:p=l $ tally ring 3,50 
imp:p=l $ tally ring 4,50 
imp:p=l $ tally ring 5,50 
imp:p=l $ tally ring 1,60 
imp:p=l $ tally ring 2,60 
imp;p=l $ tally ring 3,60 
imp:p=l $ tally ring 4,60 
imp:p=l $ tally ring 5,60 
inip:p=l $ tally ring 1,70 
imp;p=l $ tally ring 2,70
159
A p p e n d ix
831 5 -1.050 831 -832 mp:p=
841 5 -1.050 841 -842 mp:p=
851 5 -1.050 851 -852 mp:p=
911 5 -1.050 911 -912 mp:p=
921 5 -1.050 921 -922 mp:p=
931 5 -1.050 931 -932 mp:p=
941 5 -1.050 941 -942 mp:p=
951 5 -1.050 951 -952 mp:p=
961 5 -1.050 961 -962 mp:p=
971 5 -1.050 971 -972 mp:p=
981 5 -1.050 981 -982 mp:p=
991 5 -1.050 991 -992 mp:p=
901 5 -1.050 901 -902 mp:p=
9 5 -1.050 -13 -14 15 16 - 17 18
$ tally ring 3,70
$ ta  
$ ta  
$ ta  
$ ta  
$ ta 
$ ta 
$ ta 
$ ta 
$ ta 
$ ta 
$ ta
ly ring 4,70 
ly ring 5,70 
ly ring 1,80 
ly ring 2,80 
ly ring 3,80 
ly ring 4,80 
ly ring 5,80 
ly ring 1,90 
ly ring 2,90 
ly ring 3,90 
ly ring 4,90
10 0
$ tally ring 5,90
(10 : (12 -9): (8 11))
#111 #121 #131 #141 #151
#211 #221 #231 #241 #251
#311 #321 #331 #341 #351
#411 #421 #431 #441 #451
#511 #521 #531 #541 #551
#611 #621 #631 #641 #651
#711 #721 #731 #741 #751
#811 #821 #831 #841 #851
#911 #921 #931 #941 #951
#961 #971 #981 #991 #901
imp:p=l $ Phantom 
13 :14 ;-15 : -16 : 17 : -18 imp:p=0 $ World Volume
c  + + + + + + + + + + + + + + + - H - + + + + + + + + + + + +  
c Surface Card
c +++++++++++++++++++++++++++++ 
1
4
5
6
7
8 
9
ex 0.0249 
ex 0.025 
px 0.15 
px -0.15 
ex 0.034 
px 0.175 
px -0.175
10 ex 0.04
11 SQ 400.0 625.0 625.0 0.0 0.0 0.0 -1.0 0.175 0.0 0.0 $ 5mm End Caps
12 SQ 400.0 625.0 625.0 0.0 0.0 0.0 -1,0 -0.175 0.0 0.0
13 py 15.0
14 px 15.0
15 py -15.0
16 px -15.0
17 pz 15.0
18 pz -15.0
111 rcc 0.950 0.0 0.0 0.1 0.0 0.0 0.05
121 rcc 1.950 0.0 0.0 0.1 0.0 0.0 0.05
131 rcc 2.950 0.0 0.0 0.1 0.0 0.0 0.05
141 rcc 3.950 0.0 0.0 0.1 0.0 0.0 0.05
Setting locations o f tally cells
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151 rcc 4.950 0.0 0.0 0.1 0.0 0.0 0.05
211 rcc 0.935 0.0 0.0 0.1 0.0 0.0 0.124
212 rcc 0.935 0.0 0.0 0.1 0.0 0.0 0.224
221 rcc 1.920 0.0 0.0 0.1 0.0 0.0 0.297
222 rcc 1.920 0.0 0.0 0.1 0.0 0.0 0,397
231 rcc 2.904 0,0 0.0 0.1 0.0 0.0 0.471
232 rcc 2.904 0.0 0.0 0.1 0.0 0,0 0.571
241 rcc 3.889 0.0 0,0 0.1 0.0 0.0 0,645
242 rcc 3.889 0.0 0.0 0,1 0.0 0.0 0.745
251 rcc 4.874 0.0 0.0 0,1 0.0 0.0 0.818
252 rcc 4.874 0.0 0.0 0.1 0,0 0.0 0.918
311 rcc 0.890 0.0 0.0 0.1 0.0 0,0 0.292
312 rcc 0.890 0.0 0.0 0.1 0.0 0,0 0.392
321 rcc 1.829 0.0 0.0 0.1 0.0 0.0 0.634
322 rcc 1.829 0,0 0.0 0.1 0,0 0.0 0.734
331 rcc 2,769 0.0 0.0 0.1 0.0 0.0 0.976
332 rcc 2.769 0.0 0.0 0.1 0.0 0.0 1.076
341 rcc 3.709 0.0 0.0 0.1 0.0 0.0 1.318
342 rcc 3.709 0.0 0.0 0.1 0.0 0.0 1,418
351 rcc 4.648 0.0 0.0 0.1 0.0 0.0 1.660
352 rcc 4.648 0.0 0.0 0.1 0.0 0.0 1.760
411 rcc 0.816 0.0 0,0 0.1 0.0 0.0 0.450
412 rcc 0.816 0.0 0.0 0.1 0.0 0.0 0.550
421 rcc 1.682 0.0 0.0 0.1 0.0 0.0 0.950
422 rcc 1.682 0.0 0.0 0.1 0.0 0.0 1.050
431 rcc 2.548 0.0 0.0 0.1 0.0 0,0 1,450
432 rcc 2.548 0.0 0.0 0.1 0.0 0.0 1.550
441 rcc 3.414 0.0 0.0 0.1 0.0 0.0 1.950
442 rcc 3.414 0,0 0.0 0.1 0,0 0.0 2.050
451 rcc 4.280 0,0 0.0 0.1 0,0 0.0 2,450
452 rcc 4.280 0.0 0.0 0.1 0,0 0.0 2.550
511 rcc 0.716 0.0 0.0 0.1 0.0 0,0 0.593
512 rcc 0.716 0,0 0.0 0.1 0.0 0,0 0,693
521 rcc 1.482 0,0 0.0 0.1 0.0 0.0 1,236
522 rcc 1.482 0.0 0.0 0.1 0.0 0.0 1,336
531 rcc 2.248 0.0 0,0 0.1 0.0 0.0 1,878
532 rcc 2.248 0.0 0,0 0.1 0,0 0.0 1,978
541 rcc 3.014 0.0 0.0 0.1 0.0 0.0 2.521
542 rcc 3,014 0.0 0.0 0.1 0.0 0.0 2.621
551 rcc 3.780 0.0 0.0 0.1 0.0 0.0 3.164
552 rcc 3.780 0.0 0.0 0.1 0.0 0.0 3.264
611 rcc 0.593 0.0 0.0 0.1 0.0 0.0 0.716
612 rcc 0.593 0.0 0.0 0.1 0,0 0.0 0.816
621 rcc 1.236 0.0 0.0 0.1 0.0 0.0 1.482
622 rcc 1.236 0.0 0.0 0.1 0.0 0,0 1.582
631 rcc 1.878 0.0 0.0 0.1 0.0 0.0 2.248
632 rcc 1.878 0.0 0,0 0.1 0.0 0.0 2.348
641 rcc 2.521 0.0 0.0 0.1 0.0 0.0 3.014
642 rcc 2.521 0.0 0.0 0.1 0,0 0.0 3.114
651 rcc 3.164 0.0 0.0 0.1 0.0 0.0 3.780
652 rcc 3.164 0.0 0.0 0.1 0.0 0.0 3.880
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711 rcc 0.450 0.0 0.0 0.1 0.0 0.0 0.816
712 rcc 0.450 0.0 0.0 0.1 0.0 0.0 0.916
721 rcc 0.950 0.0 0.0 0.1 0.0 0.0 1.682
722 rcc 0.950 0.0 0.0 0.1 0.0 0.0 L782
731 rcc 1.450 0.0 0.0 0.1 0.0 0.0 2.548
732 rcc 1.450 0.0 0.0 0.1 0.0 0.0 2.648
741 rcc 1.950 0.0 0.0 0.1 0.0 0.0 3.414
742 rcc 1.950 0.0 0.0 0.1 0.0 0.0 3.514
751 rcc 2.450 0.0 0.0 0.1 0.0 0.0 4.280
752 rcc 2.450 0.0 0.0 0.1 0.0 0.0 4.380
811 rcc 0.292 0.0 0.0 0.1 0.0 0.0 0.890
812 rcc 0.292 0.0 0.0 0.1 0.0 0.0 0.990
821 rcc 0.634 0.0 0.0 0.1 0.0 0.0 1.829
822 rcc 0.634 0.0 0.0 0.1 0.0 0.0 1.929
831 rcc 0.976 0.0 0.0 0.1 0.0 0.0 Z769
832 rcc 0.976 0.0 0.0 0.1 0.0 0.0 2.869
841 rcc 1.318 0.0 0.0 0.1 0.0 0.0 3.709
842 rcc 1.318 0.0 0.0 0.1 0.0 0.0 3.809
851 rcc 1.660 0.0 0.0 0.1 0.0 0.0 4.648
852 rcc 1.660 0.0 0.0 0.1 0.0 0.0 4.748
911 rcc 0.124 0.0 0.0 0.1 0.0 0.0 0.935
912 rcc 0.124 0.0 0.0 0.1 0.0 0.0 1.035
921 rcc 0.297 0.0 0.0 0.1 0.0 0.0 1.920
922 rcc 0.297 0.0 0.0 0.1 0.0 0.0 2.020
931 rcc 0.471 0.0 0.0 0.1 0.0 0.0 2.904
932 rcc 0.471 0.0 0.0 0.1 0.0 0.0 3.004
941 rcc 0.645 0.0 0.0 0.1 0.0 0.0 3.889
942 rcc 0.645 0.0 0.0 0.1 0.0 0.0 3.989
951 rcc 0.818 0.0 0.0 0.1 0.0 0.0 4.874
952 rcc 0.818 0.0 0.0 0.1 0.0 0.0 4.974
961 rcc -0.050 0.0 0.0 0.1 0.0 0.0 0.950
962 rcc -0.050 0.0 0.0 0.1 0.0 0.0 1.050
971 rcc -0.050 0.0 0.0 0.1 0.0 0.0 1.950
972 rcc -0.050 0.0 0.0 0.1 0.0 0.0 2.050
981 rcc -0.050 0.0 0.0 0.1 0.0 0.0 2.950
982 rcc -0.050 0.0 0.0 0.1 0.0 0.0 3.050
991 rcc -0.050 0.0 0.0 0.1 0.0 0.0 3.950
992 rcc -0.050 0.0 0.0 0.1 0.0 0.0 4.050
901 rcc -0.050 0.0 0.0 0.1 0.0 0.0 4.950
902
I !
rcc -0.050 0.0 0.0 0.1 0.0 0.0 5.050
C I i 
C Simulation for Photons
^  -1 1C I 1
mode p
C + + + + + + + + + + + + + + + + + + + + 4 - + +  
c Material Card 
c +++++++++++++++++++++++ 
m l 47000 1 $ Silver
m2 53000 1 $1-125
c material 3 is air (density is taken from ICRP-30. chemical
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c elements taken from ANSI/ANS-6.4.3-1991, "Gamma-Ray 
c Attenuation Coefficients and Buildup Factors for Engineering 
c Materials").
m3 1000 -0.000732 $ hydrogen 
6000 -0.000123 $ carbon 
7000 -0.750325 $ nitrogen 
8000 -0.236077 $ oxygen 
18000 -0.012743 $ argon 
m4 22000 1 $ Titanium
m5 6000 -0.6074 $ carbon $PRESAGE Composition
1000 -0.0892 $ hydrogen 
7000 -0.0446 $ nitrogen 
8000 -0.2172 $ oxygen 
17000 -0.0234 $ Chlorine 
35000 -0.0184 $ Bromine 
plib=03
c ++++++++++++++++++++++++++++++++ 
c Source Specification
C 4 —H —I—h + + + H —H —H + + + H —I—I—h + + 4 —I—I—I—hH—1~+4—I—h
sdef erg=d3 par=2 pos=0 0 0 axs=l 0 0 ext=dl rad=d2 
sil -0.15 0.15 
spl 0 1
si2 0.0249 0.025
sp2 -21 1
si3L  0.027202 0.027472 0.03098 0.03171 0.035492 $ Nuclear Data for 1-125 
sp3 0.406 0.757 0.202 0.0439 0.0668
c ++++++++++++++++++++++++++++++++ 
c Energy Deposition
c ++++++++++++++++++++++++++++++++ 
fl6:p 111 211 311 411 511 611 711 811 911 961
f26:p 121 221 321 421 521 621 721 821 921 971
f36:p 131 231 331 431 531 631 731 831 931 981
f46:p 141 241 341 441 541 641 741 841 941 991
f56:p 151 251 351 451 551 651 751 851 951 901
prdmp j -120
c ++++++++++++++++++++++++++++ 
c No o f Particles Events
lips 100000000 I
E. WICNP Model of lr-192 HDR MicroSelectron I
c Ir-192 MCNP Model
c ++++++++++++++++++++++++++++ 
c File Prepared by Philip Wai 
c ++++++++++++++++++++++ 
c Cell Card
c ++++++++++++++++++++++
1 2 -22.42 -1 6 -5 imp:p=l $ Ir-192 Rod New Source by Daskalov
5 3 -0.00120 -7 -8 9 (l:5:-6) imp:p=l $ Air Gap
6 4 -8.02 7 -8 9 -10 imp:p= 1 $ Stainless Steel Outer Shell
7 4 -8.02 -11 8 imp:p=l $ Stainless Steel End Cap
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ï
8 4 -8.02 -12 -9 imp:p=l $ Stainless Steel End Cap
111 6 -1.050 -111 imp:p=l $ tally ring 1,00
121 6 -1.050 -121 imp;p=l $ tally ring 2,00
211 6 -1.050 211 -212 mp:p=l $ tally ring 1,10
221 6 -1.050 221 -222 mp:p=l $ tally ring 2,10
311 6 -1.050 311 -312 mp:p=l $ tally ring 1,20
321 6 -1.050 321 -322 mp:p=l $ tally ring 2,20
411 6 -1.050 411 -412 mp:p=l $ tally ring 1,30
421 6 -1.050 421 -422 mp:p=l $ tally ring 2,30
511 6 -1.050 511 -512 mp:p=l $ tally ring 1,40
521 6 -1.050 521 -522 mp:p=l $ tally ring 2,40
611 6 -1.050 611 -612 mp:p=l $ tally ring 1,50
621 6 -1.050 621 -622 mp:p=l $ tally ring 2,50
711 6 -1.050 711 -712 mp:p=l $ tally ring 1,60
721 6 -1.050 721 -722 mp:p=l $ tally ring 2,60
811 6 -1.050 811 -812 mp:p=l $ tally ring 1,70
821 6 -1.050 821 -822 mp:p=l $ tally ring 2,70
911 6 -1.050 911 -912 mp:p==l $ tally ring 1,80
921 6 -1.050 921 -922 mp:p=l $ tally ring 2,80
961 6 -1.050 961 -962 mp:p=l $ tally ring 1,90
971 6 -1.050 971 -972 mp:p=l $ tally ring 2,90
9 6 -1.050 -13 - 14 15 $Cyl nder Presage Phantom
(10:1:12 -9): (8 11))
#111 #121 $#131 #141 #151
#211 #221 $#231 #241 #251
#311 #321 $#331 #341 #351
#411 #421 $#431 #441 #451
#511 #521 $#531 #541 #551
#611 #621 $#631 #641 #651
#711 #721 $#731 #741 #751
#811 #821 $#831 #841 #851
#911 #921 $#931 #941 #951
#961 #971 $#981 #991 #901
imp:p=l $ Phantom 
10 0 13 : 14 :-15 imp:p=0 $ World Volume
c +++++++++++++++++++++++++++++ 
c Surface Card
c +++++++++++++++++++++++++++++
I cx 0.0325
c 2 px 0.1499
c 3 px -0.1499
c 4 cx 0.0325
5 px 0.18
6 px -0.18
7 cx 0.035
8 px 0.18
9 px -0.18
10 cx 0.045
II SQ 2500.0 493.827 493.827 0.0 0.0 0.0 -1.0 0.18 0.0 0.0 $ 0.2mm End
Caps 0.45mm Thick
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12 SQ 2500.0 493.827 493.827 0.0 0.0 0.0 -1.0
13 cx 3.0 $ PRESAGE Diameter
14 px 3.5 $ PRESAGE Dosimeter Height
15 px -2.5 $ Distance to hole in cm
- 0 . 18  0 .0  0 .0
111 rcc 0.950 0.0 0.0 0.1 0.0 0.0 0.05
121 rcc 1.950 0.0 0.0 0.1 0.0 0.0 0.05
131 rcc 2.950 0.0 0.0 0.1 0.0 0.0 0.05
141 rcc 3.950 0.0 0.0 0.1 0.0 0.0 0.05
151 rcc 4.950 0.0 0.0 0.1 0.0 0.0 0.05
211 rcc 0.935 0.0 0.0 0.1 0.0 0.0 0.124
212 rcc 0.935 0.0 0.0 0.1 0.0 0.0 0.224
221 rcc 1.920 0.0 0.0 0.1 0.0 0.0 0.297
222 rcc 1.920 0.0 0.0 0.1 0.0 0.0 0.397
231 rcc 2.904 0.0 0.0 0.1 0.0 0.0 0.471
232 rcc 2.904 0.0 0.0 0.1 0.0 0.0 0.571
241 rcc 3.889 0.0 0.0 0.1 0.0 0.0 0.645
242 rcc 3.889 0.0 0.0 0.1 0.0 0.0 0.745
251 rcc 4.874 0.0 0.0 0.1 0.0 0.0 0.818
252 rcc 4.874 0.0 0.0 0.1 0.0 0.0 0.918
311 rcc 0.890 0.0 0.0 0.1 0.0 0.0 0.292
312 rcc 0.890 0.0 0.0 0.1 0.0 0.0 0.392
321 rcc 1.829 0.0 0.0 0.1 0.0 0.0 0.634
322 rcc 1.829 0.0 0.0 0.1 0.0 0.0 0.734
331 rcc 2.769 0.0 0.0 0.1 0.0 0.0 0.976
332 rcc 2.769 0.0 0.0 0.1 0.0 0.0 1.076
341 rcc 3.709 0.0 0.0 0.1 0.0 0.0 1.318
342 rcc 3.709 0.0 0.0 0.1 0.0 0.0 1.418
351 rcc 4.648 0.0 0.0 0.1 0.0 0.0 1.660
352 rcc 4.648 0.0 0.0 0.1 0.0 0.0 1.760
411 rcc 0.816 0.0 0.0 0.1 0.0 0.0 0.450
412 rcc 0.816 0.0 0.0 0.1 0.0 0.0 0.550
421 rcc 1.682 0.0 0.0 0.1 0.0 0.0 0.950
422 rcc 1.682 0.0 0.0 0.1 0.0 0.0 1.050
431 rcc 2.548 0.0 0.0 0.1 0.0 0.0 1.450
432 rcc 2.548 0.0 0.0 0.1 0.0 0.0 1,550
441 rcc 3.414 0.0 0.0 0.1 0.0 0.0 1.950
442 rcc 3.414 0.0 0.0 0.1 0.0 0.0 2.050
451 rcc 4.280 0.0 0.0 0.1 0.0 0.0 2.450
452 rcc 4.280 0.0 0.0 0.1 0.0 0.0 2.550
511 rcc 0.716 0.0 0.0 0.1 0.0 0.0 0.593
512 rcc 0.716 0.0 0.0 0.1 0.0 0.0 0.693
521 rcc 1.482 0.0 0.0 0.1 0.0 0.0 1.236
522 rcc 1.482 0.0 0.0 0.1 0.0 0.0 1.336
531 rcc 2.248 0.0 0.0 0.1 0.0 0.0 1.878
532 rcc 2.248 0.0 0.0 0.1 0.0 0.0 1.978
541 rcc 3.014 0.0 0.0 0.1 0.0 0.0 2.521
542 rcc 3.014 0.0 0.0 0.1 0.0 0.0 2.621
551 rcc 3.780 0.0 0.0 0.1 0.0 0.0 3.164
552 rcc 3.780 0.0 0.0 0.1 0.0 0.0 3.264
611 rcc 0.593 0.0 0.0 0.1 0.0 0.0 0.716
612 rcc 0.593 0.0 0.0 0.1 0.0 0.0 0.816
; Setting locations o f tally cells
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621 rcc 1.236 0.0 0.0 0.1 0.0 0.0 1.482
622 rcc 1.236 0.0 0.0 0.1 0.0 0.0 1.582
631 rcc 1.878 0.0 0.0 0.1 0.0 0.0 2.248
632 rcc 1.878 0.0 0.0 0.1 0.0 0.0 2.348
641 rcc 2.521 0.0 0.0 0.1 0.0 0.0 3.014
642 rcc 2.521 0.0 0.0 0.1 0.0 0.0 3.114
651 rcc 3.164 0.0 0.0 0.1 0.0 0.0 3.780
652 rcc 3.164 0.0 0.0 0.1 0.0 0.0 3.880
711 rcc 0.450 0.0 0.0 0.1 0.0 0.0 0.816
712 rcc 0.450 0.0 0.0 0.1 0.0 0.0 0.916
721 rcc 0.950 0.0 0.0 0.1 0.0 0.0 1.682
722 rcc 0.950 0.0 0.0 0.1 0.0 0.0 1.782
731 rcc 1.450 0.0 0.0 0.1 0.0 0.0 2.548
732 rcc 1.450 0.0 0.0 0.1 0.0 0.0 2.648
741 rcc 1.950 0.0 0.0 0.1 0.0 0.0 3.414
742 rcc 1.950 0.0 0.0 0.1 0.0 0.0 3.514
751 rcc 2.450 0.0 0.0 0.1 0.0 0.0 4.280
752 rcc 2.450 0.0 0.0 0.1 0.0 0.0 4.380
811 rcc 0.292 0.0 0.0 0.1 0.0 0.0 0.890
812 rcc 0.292 0.0 0.0 0.1 0.0 0.0 0.990
821 rcc 0.634 0.0 0.0 0.1 0.0 0.0 1.829
822 rcc 0.634 0.0 0.0 0.1 0.0 0.0 1.929
831 rcc 0.976 0.0 0.0 0.1 0.0 0.0 2.769
832 rcc 0.976 0.0 0.0 0.1 0.0 0.0 2.869
841 rcc 1.318 0.0 0.0 0.1 0.0 0.0 3.709
842 rcc 1.318 0.0 0.0 0.1 0.0 0.0 3.809
851 rcc 1.660 0.0 0.0 0.1 0.0 0.0 4.648
852 rcc 1.660 0.0 0.0 0.1 0.0 0.0 4.748
911 rcc 0.124 0.0 0.0 0.1 0.0 0.0 0.935
912 rcc 0.124 0,0 0.0 0.1 0.0 0.0 1.035
921 rcc 0.297 0.0 0.0 0.1 0.0 0.0 1.920
922 rcc 0.297 0.0 0.0 0.1 0.0 0.0 2.020
931 rcc 0.471 0.0 0.0 0.1 0.0 0.0 2.904
932 rcc 0.471 0.0 0.0 0.1 0.0 0.0 3.004
941 rcc 0.645 0.0 0.0 0.1 0.0 0.0 3.889
942 rcc 0.645 0.0 0.0 0.1 0.0 0.0 3.989
951 rcc 0.818 0.0 0.0 0.1 0.0 0.0 4.874
952 rcc 0.818 0.0 0.0 0.1 0.0 0.0 4.974
961 rcc -0.050 0.0 0.0 0.1 0.0 0.0 0.950
962 rcc -0.050 0.0 0.0 0.1 0.0 0.0 1.050
971 rcc -0.050 0.0 0.0 0.1 0.0 0.0 1.950
972 rcc -0.050 0.0 0.0 0.1 0.0 0.0 2.050
981 rcc -0.050 0.0 0.0 0.1 0.0 0.0 2.950
982 rcc -0.050 0.0 0.0 0.1 0.0 0.0 3.050
991 rcc -0.050 0.0 0.0 0.1 0,0 0.0 3.950
992 rcc -0.050 0.0 0,0 0.1 0.0 0.0 4.050
901 rcc -0.050 0.0 0.0 0.1 0.0 0.0 4.950
902 rcc -0.050 0.0 0.0 0.1 0.0 0.0 5.050
Simulation for Photons
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+ + + -H -+ + -H -t-+ -H -+ + + + + + + 4 -+
mode p
C  + + ‘4 - + + + + + + - t ~
c Material Card
C + '{“ t"{” l'+ + + + + + + + -{—{-+-1—h+ -|-+ + +
c m l 47000 1 $ Silver
c plib=03
m2 77000 -0.30 $ Ir-192
78000-0.70 $Pt-195
plib=03
c Material 3 is air (density is taken from ICRP-30. chemical 
c elements taken from ANSI/ANS-6.4.3-1991, "Gamma-Ray 
c Attenuation Coefficients and Buildup Factors for Engineering 
c Materials").
m3 1000 -0.000732 $ hydrogen 
6000 -0.000123 $ carbon 
7000 -0.750325 $ nitrogen 
8000 -0.236077 $ oxygen 
18000 -0.012743 $ argon 
plib=03
c Material 4 is Stainless Steel Shell - AISI316L Used by Daskalov 
m4 25000 -0.02 $ Manganese 
14000 -0.01 $ Silicon 
24000 -0.17 $ Chromium 
28000 -0.12$ Nickel 
26000 -0.68 $ Iron 
plib=03 
c Material 6 is PRESAGE
m6 6000 -0.6074 $ carbon $PRESAGE Composition 
1000 -0.0892 $ hydrogen 
7000 -0.0446 $ nitrogen 
8000 -0.2172 $ oxygen 
17000 -0.0234 $ Chlorine 
35000 -0.0184 $ Bromine 
plib=03
c
c ++++++++++++++++++++++++++++++++ 
c Source Specification
C + + + + H “+ + + + + + + + + + + + + + + + + + + + + + + + + + 4 -
sdef erg=d3 pai'=2 pos=0 0 0 axs=l 0 0 ext=dl rad=d2
sil -0.15 0.15
spl 0 1
si2 0.0249 0.025
sp2 -21 1
si3L  0.29 0.308 0.317 0.468 0.608 $ Nuclear Data for Ir-192 TG-43 in MeV 
sp3 0.291 0.298 0.831 0.476 0.133 $ No o f photons per decay
c +++++++++++++++++++++++++++-1-++++ 
c Energy Deposition
c ++++++++++++++++++++++++++++++++ 
fl6 :p  111 211 311 411 511 611 711 811 911 961
f26:p 121 221 321 421 521 621 721 821 921 971
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cf36:p 131 231 331 431 531 631 731 831 931 981
cf46:p 141 241 341 441 541 641 741 841 941 991
cf56:p 151 251 351 451 551 651 751 851 951 901
prdmp j -120
c +++++++++++++++++++-1-+++++++-}- 
c No o f Particles Events
c ++++++++++++++++++++++++++++ 
nps 250000000
F. IDL Calculation for Anisotropy Functions (Opticai-CT)
;Optical-CT Anisotropy Functions Analysis 
pro aniso
for i = 0.5,2,0.5 do begin ;Distance from centre in steps o f 0.5 cm 
for j = 0,90,10 do begin ; Degree from centre in steps o f 5 degree 
slicepos=ROUND((i*38.5)*cos(j*!DTOR)) 
radius=ROUND((i*38.5)*sinG*!DTOR))
H =117 ;Set X value o f source centre
K=133 ;Y value centre
cd,
"/export/home/moria/phradpg/phplpw/IDL/Scans/echoseed2/output256/" ;Reconstruc 
tion file location
SliceArray=read_idld('recon'+str(173-slicepos)+'.idld')
Count = 0 ;Reset Counter 
Dose = 0 ;Reset Dose 
SumDose = 0 ; Reset SumDose 
AvgDose = 0 ;Reset AvgDose 
PDose = 0 ;Reset PointDose 
PDose2 = 0 ;Reset PointDose Square 
SumDose2 = 0 ;Reset Sum o f PointDose Square 
FOR X = 0, 255 DO BEGIN ;Calculate Avg Dose o f slice 
FOR Y = 0, 255 DO BEGIN ; Input Slice Array size here 
C=(X-H)^2 
D=(Y-K)^2 
R2=radius'^2 
Err= FIX(C+D) - R2 
IF (ABS(Err) LT 10) THEN BEGIN 
Dose=SliceArray[X,Y]
Count = Count+1 
SumDose = SumDose + Dose 
AvgDose = SumDose/Count 
ENDIF 
ENDFOR 
ENDFOR
FOR X = 0, 255 DO BEGIN ^Calculate SD
FOR Y = 0, 255 DO BEGIN ;Input Calculate SD 
C=(X-H)^2 
D=(Y-K)^2 
R2=radius^2 
Err= FIX(C+D) - R2
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IF (ABS(Err) LT 10) THEN BEGIN 
PDose = Slice Array [X,Y]
PDose2 = (PDose - AvgDose)^2 
SumDose2 = SumDose2 + PDose2 
ENDIF 
ENDFOR 
ENDFOR
SD = SQRT(SumDose2 / Count)
SEM = SD / SQRT(Count) ; Standard Error o f the mean 
print, AvgDose, SEM ;print dose and standard error 
ENDFOR 
ENDFOR 
end
G. IDL Calculation for Anisotropy Functions (EBT Films)
;EBT Film Anisotropy Functions Analysis 
pro anisofilmhdrl Ibflip
cd, "/expoit/home/moria/phradpg/phplpw/IDL/Scans/HDR" ;Reconstruction file 
location
S lice Array=read_tiff('M 11 b_dot_flip.tif)
T=5 ^tolerance settings
for i = 0.5,2,0,0.5 do begin ;Distance from centre in steps o f 0.5 cm 
for j = 0,90,10 do begin ; Degree from centre in steps o f 5 degree 
slicepos=ROUND((i*l 18.1 l)*cosG*!DTOR)) 
radius=ROUND((i^l 18.1 l)*sin(j*!DTOR))
;print, iJ,slicepos,radius
;print, '--------------------------------  '
H=361 ;Set X value o f source centi e 
K=447 ;Y value centre
•jCount = 0 ;Reset Counter
Dose = 0 ;Reset Dose
SumDose = 0 ;Reset SumDose
AvgDose = 0 ;Reset AvgDose
X=H+radius
Y=slicepos+K
Z=H-radius
Dose=mean(SliceArray[X-(T/2):X+(T/2),Y- 
(T/2):Y+(T/2)])+mean(SliceArray[Z-(T/2):2+(T/2),Y-(T/2):Y+(T/2)]) ;calculate dose 
sdDose=(stddev(SliceArray[X“(T/2);X+(T/2),Y- 
(T/2):Y+(T/2)])+stddev(SliceArray[Z-(T/2):Z+(T/2),Y-(T/2):Y+(T/2)]))/2 
sderroi-sdDose/SQRT(T^2*2) 
print, AvgDose, sderror 
ENDFOR 
ENDFOR 
end
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